CA2578630A1 - Pyrimidinylimidazoles as tgf-beta inhibitors - Google Patents
Pyrimidinylimidazoles as tgf-beta inhibitors Download PDFInfo
- Publication number
- CA2578630A1 CA2578630A1 CA002578630A CA2578630A CA2578630A1 CA 2578630 A1 CA2578630 A1 CA 2578630A1 CA 002578630 A CA002578630 A CA 002578630A CA 2578630 A CA2578630 A CA 2578630A CA 2578630 A1 CA2578630 A1 CA 2578630A1
- Authority
- CA
- Canada
- Prior art keywords
- bicyclo
- pyrimidin
- imidazol
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003112 inhibitor Substances 0.000 title description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title description 2
- FKTSKGMJQQGFHN-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)pyrimidine Chemical class C1=CNC(C=2N=CC=CN=2)=N1 FKTSKGMJQQGFHN-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 165
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 39
- 230000003176 fibrotic effect Effects 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 18
- -1 hydroxy, amino, nitro, oxo, thioxo Chemical group 0.000 claims description 110
- 125000000217 alkyl group Chemical group 0.000 claims description 60
- 125000001072 heteroaryl group Chemical group 0.000 claims description 47
- 229910052739 hydrogen Inorganic materials 0.000 claims description 40
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 39
- 239000001257 hydrogen Substances 0.000 claims description 39
- 125000003118 aryl group Chemical group 0.000 claims description 37
- 210000004027 cell Anatomy 0.000 claims description 37
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 34
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 32
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 32
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 21
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 20
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 20
- 208000035475 disorder Diseases 0.000 claims description 20
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 19
- 125000003342 alkenyl group Chemical group 0.000 claims description 15
- 206010016654 Fibrosis Diseases 0.000 claims description 14
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 13
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 125000000304 alkynyl group Chemical group 0.000 claims description 13
- 210000002744 extracellular matrix Anatomy 0.000 claims description 13
- 230000004761 fibrosis Effects 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 230000019491 signal transduction Effects 0.000 claims description 13
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 12
- 125000004414 alkyl thio group Chemical group 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 230000037390 scarring Effects 0.000 claims description 11
- 125000004104 aryloxy group Chemical group 0.000 claims description 10
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 10
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 10
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 125000002252 acyl group Chemical group 0.000 claims description 9
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical group C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 claims description 9
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 9
- 125000005224 heteroarylcarbonylamino group Chemical group 0.000 claims description 9
- 125000004193 piperazinyl group Chemical group 0.000 claims description 9
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 206010020772 Hypertension Diseases 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 8
- 230000005855 radiation Effects 0.000 claims description 8
- 125000003435 aroyl group Chemical group 0.000 claims description 7
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 7
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 7
- 201000010260 leiomyoma Diseases 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- SHEAUYBYKARAME-UHFFFAOYSA-N methyl 1-[4-(6-methylpyridin-2-yl)-5-(2-methylsulfonylpyrimidin-4-yl)-1h-imidazol-2-yl]bicyclo[2.2.2]octane-4-carboxylate Chemical compound C1CC(C(=O)OC)(CC2)CCC12C(N1)=NC(C=2N=C(C)C=CC=2)=C1C1=CC=NC(S(C)(=O)=O)=N1 SHEAUYBYKARAME-UHFFFAOYSA-N 0.000 claims description 7
- 125000003386 piperidinyl group Chemical group 0.000 claims description 7
- GDAIFEPYRASGRM-UHFFFAOYSA-N 1-[5-(2-methylpyrimidin-4-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1h-imidazol-2-yl]bicyclo[2.2.2]octane-4-carboxylic acid Chemical compound CC1=NC=CC(C2=C(N=C(N2)C23CCC(CC2)(CC3)C(O)=O)C2=CN3N=CN=C3C=C2)=N1 GDAIFEPYRASGRM-UHFFFAOYSA-N 0.000 claims description 6
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 6
- 238000009825 accumulation Methods 0.000 claims description 6
- 206010069351 acute lung injury Diseases 0.000 claims description 6
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 6
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 6
- QRNGIZIVLZGQPW-UHFFFAOYSA-N methyl 1-[5-(2-methylpyrimidin-4-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1h-imidazol-2-yl]bicyclo[2.2.2]octane-4-carboxylate Chemical compound C1CC(C(=O)OC)(CC2)CCC12C(N1)=NC(C2=CN3N=CN=C3C=C2)=C1C1=CC=NC(C)=N1 QRNGIZIVLZGQPW-UHFFFAOYSA-N 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 230000002018 overexpression Effects 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 6
- DCSXVNBJFYIXIH-UHFFFAOYSA-N 1-[5-(2-methylpyrimidin-4-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1h-imidazol-2-yl]bicyclo[2.2.2]octane-4-carboxamide Chemical compound CC1=NC=CC(C2=C(N=C(N2)C23CCC(CC2)(CC3)C(N)=O)C2=CN3N=CN=C3C=C2)=N1 DCSXVNBJFYIXIH-UHFFFAOYSA-N 0.000 claims description 5
- BFTOGZFVFWSNJF-UHFFFAOYSA-N 1-[5-[2-(cyclopropylamino)pyrimidin-4-yl]-4-(6-methylpyridin-2-yl)-1h-imidazol-2-yl]bicyclo[2.2.2]octane-4-carboxamide Chemical compound CC1=CC=CC(C2=C(NC(=N2)C23CCC(CC2)(CC3)C(N)=O)C=2N=C(NC3CC3)N=CC=2)=N1 BFTOGZFVFWSNJF-UHFFFAOYSA-N 0.000 claims description 5
- GWJQEWCTGGIYQC-UHFFFAOYSA-N 1-[5-[2-(cyclopropylamino)pyrimidin-4-yl]-4-(6-methylpyridin-2-yl)-1h-imidazol-2-yl]bicyclo[2.2.2]octane-4-carboxylic acid Chemical compound CC1=CC=CC(C2=C(NC(=N2)C23CCC(CC2)(CC3)C(O)=O)C=2N=C(NC3CC3)N=CC=2)=N1 GWJQEWCTGGIYQC-UHFFFAOYSA-N 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 5
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 5
- 239000004202 carbamide Substances 0.000 claims description 5
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 201000002793 renal fibrosis Diseases 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- KPUSZZFAYGWAHZ-UHFFFAOYSA-N 3-azabicyclo[2.2.2]octane Chemical group C1CC2CCC1NC2 KPUSZZFAYGWAHZ-UHFFFAOYSA-N 0.000 claims description 4
- CONVAEXWACQJSA-UHFFFAOYSA-N 3-oxabicyclo[2.2.2]octane Chemical group C1CC2CCC1OC2 CONVAEXWACQJSA-UHFFFAOYSA-N 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010059245 Angiopathy Diseases 0.000 claims description 4
- 206010004664 Biliary fibrosis Diseases 0.000 claims description 4
- 208000016192 Demyelinating disease Diseases 0.000 claims description 4
- 206010012305 Demyelination Diseases 0.000 claims description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 4
- 208000007659 Fibroadenoma Diseases 0.000 claims description 4
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010039710 Scleroderma Diseases 0.000 claims description 4
- 125000005872 benzooxazolyl group Chemical group 0.000 claims description 4
- 125000005874 benzothiadiazolyl group Chemical group 0.000 claims description 4
- 210000003445 biliary tract Anatomy 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 230000009787 cardiac fibrosis Effects 0.000 claims description 4
- 230000002490 cerebral effect Effects 0.000 claims description 4
- 210000003679 cervix uteri Anatomy 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 206010016629 fibroma Diseases 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 210000003128 head Anatomy 0.000 claims description 4
- 230000002440 hepatic effect Effects 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 210000003739 neck Anatomy 0.000 claims description 4
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 4
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical group C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 230000029663 wound healing Effects 0.000 claims description 4
- REYSLEGAAKFCRQ-UHFFFAOYSA-N 1-[5-(2-aminopyrimidin-4-yl)-4-(6-methylpyridin-2-yl)-1h-imidazol-2-yl]bicyclo[2.2.2]octane-4-carboxylic acid Chemical compound CC1=CC=CC(C2=C(NC(=N2)C23CCC(CC2)(CC3)C(O)=O)C=2N=C(N)N=CC=2)=N1 REYSLEGAAKFCRQ-UHFFFAOYSA-N 0.000 claims description 3
- NHBUNMRREKYNKL-UHFFFAOYSA-N 1-[5-(2-cyclopropylpyrimidin-4-yl)-4-quinoxalin-6-yl-1h-imidazol-2-yl]bicyclo[2.2.2]octan-4-ol Chemical compound C1CC(O)(CC2)CCC12C(N1)=NC(C=2C=C3N=CC=NC3=CC=2)=C1C(N=1)=CC=NC=1C1CC1 NHBUNMRREKYNKL-UHFFFAOYSA-N 0.000 claims description 3
- KIZAXJYFDWLRFS-UHFFFAOYSA-N 1-[5-(2-methylpyrimidin-4-yl)-4-([1,2,4]triazolo[4,3-a]pyridin-6-yl)-1h-imidazol-2-yl]bicyclo[2.2.2]octan-4-ol Chemical compound CC1=NC=CC(C2=C(N=C(N2)C23CCC(O)(CC2)CC3)C2=CN3C=NN=C3C=C2)=N1 KIZAXJYFDWLRFS-UHFFFAOYSA-N 0.000 claims description 3
- VFTPRXRFTGGRMR-UHFFFAOYSA-N 1-[5-[2-(cyclopropylamino)pyrimidin-4-yl]-4-(6-methylpyridin-2-yl)-1h-imidazol-2-yl]-n-hydroxybicyclo[2.2.2]octane-4-carboxamide Chemical compound CC1=CC=CC(C2=C(NC(=N2)C23CCC(CC2)(CC3)C(=O)NO)C=2N=C(NC3CC3)N=CC=2)=N1 VFTPRXRFTGGRMR-UHFFFAOYSA-N 0.000 claims description 3
- GNHRGEPQRGPMCT-UHFFFAOYSA-N 1-[5-[2-(cyclopropylamino)pyrimidin-4-yl]-4-(6-methylpyridin-2-yl)-1h-imidazol-2-yl]-n-methoxybicyclo[2.2.2]octane-4-carboxamide Chemical compound C1CC(C(=O)NOC)(CC2)CCC12C(N1)=NC(C=2N=C(C)C=CC=2)=C1C(N=1)=CC=NC=1NC1CC1 GNHRGEPQRGPMCT-UHFFFAOYSA-N 0.000 claims description 3
- CJQNJRRDTPULTL-UHFFFAOYSA-N 3-azabicyclo[3.2.1]octane Chemical group C1C2CCC1CNC2 CJQNJRRDTPULTL-UHFFFAOYSA-N 0.000 claims description 3
- CVHYJFJDSMSYGH-UHFFFAOYSA-N 4-[5-(2-methylpyrimidin-4-yl)-4-quinoxalin-6-yl-1h-imidazol-2-yl]cyclohexan-1-ol Chemical compound CC1=NC=CC(C2=C(N=C(N2)C2CCC(O)CC2)C=2C=C3N=CC=NC3=CC=2)=N1 CVHYJFJDSMSYGH-UHFFFAOYSA-N 0.000 claims description 3
- AJJPZAKVXPEORK-UHFFFAOYSA-N 6-[2-tert-butyl-5-(2-cyclopropylpyrimidin-4-yl)-1h-imidazol-4-yl]quinoxaline Chemical compound N1C(C(C)(C)C)=NC(C=2C=C3N=CC=NC3=CC=2)=C1C(N=1)=CC=NC=1C1CC1 AJJPZAKVXPEORK-UHFFFAOYSA-N 0.000 claims description 3
- NVGAONDYQPIKIE-UHFFFAOYSA-N 6-[2-tert-butyl-5-[2-(trifluoromethyl)pyrimidin-4-yl]-1h-imidazol-4-yl]quinoxaline Chemical compound N1C(C(C)(C)C)=NC(C=2C=C3N=CC=NC3=CC=2)=C1C1=CC=NC(C(F)(F)F)=N1 NVGAONDYQPIKIE-UHFFFAOYSA-N 0.000 claims description 3
- COOYKNZJWSGUJD-UHFFFAOYSA-N 6-[5-(2-cyclopropylpyrimidin-4-yl)-2-(1-methylsulfonylpiperidin-4-yl)-1h-imidazol-4-yl]quinoxaline Chemical compound C1CN(S(=O)(=O)C)CCC1C1=NC(C=2C=C3N=CC=NC3=CC=2)=C(C=2N=C(N=CC=2)C2CC2)N1 COOYKNZJWSGUJD-UHFFFAOYSA-N 0.000 claims description 3
- DIOBLZDPEAWPAK-UHFFFAOYSA-N 6-[5-[2-(trifluoromethyl)pyrimidin-4-yl]-1h-imidazol-4-yl]quinoxaline Chemical compound FC(F)(F)C1=NC=CC(C2=C(N=CN2)C=2C=C3N=CC=NC3=CC=2)=N1 DIOBLZDPEAWPAK-UHFFFAOYSA-N 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 200000000007 Arterial disease Diseases 0.000 claims description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 3
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000002260 Keloid Diseases 0.000 claims description 3
- 206010023330 Keloid scar Diseases 0.000 claims description 3
- 208000004852 Lung Injury Diseases 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
- LPCWKMYWISGVSK-UHFFFAOYSA-N bicyclo[3.2.1]octane Chemical group C1C2CCC1CCC2 LPCWKMYWISGVSK-UHFFFAOYSA-N 0.000 claims description 3
- 208000018631 connective tissue disease Diseases 0.000 claims description 3
- 208000010706 fatty liver disease Diseases 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 210000001117 keloid Anatomy 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 231100000515 lung injury Toxicity 0.000 claims description 3
- BONOOAYCHZZVND-UHFFFAOYSA-N methyl 1-[5-[2-(cyclopropylamino)pyrimidin-4-yl]-4-(6-methylpyridin-2-yl)-1h-imidazol-2-yl]bicyclo[2.2.2]octane-4-carboxylate Chemical compound C1CC(C(=O)OC)(CC2)CCC12C(N1)=NC(C=2N=C(C)C=CC=2)=C1C(N=1)=CC=NC=1NC1CC1 BONOOAYCHZZVND-UHFFFAOYSA-N 0.000 claims description 3
- ORDRWSKGQYJUQB-UHFFFAOYSA-N n-[1-[5-[2-(cyclopropylamino)pyrimidin-4-yl]-4-(6-methylpyridin-2-yl)-1h-imidazol-2-yl]-4-bicyclo[2.2.2]octanyl]-2,2,2-trifluoroacetamide Chemical compound CC1=CC=CC(C2=C(NC(=N2)C23CCC(CC2)(CC3)NC(=O)C(F)(F)F)C=2N=C(NC3CC3)N=CC=2)=N1 ORDRWSKGQYJUQB-UHFFFAOYSA-N 0.000 claims description 3
- OSXUPRKKVSLTEZ-UHFFFAOYSA-N n-[1-[5-[2-(cyclopropylamino)pyrimidin-4-yl]-4-(6-methylpyridin-2-yl)-1h-imidazol-2-yl]-4-bicyclo[2.2.2]octanyl]acetamide Chemical compound C1CC(NC(=O)C)(CC2)CCC12C(N1)=NC(C=2N=C(C)C=CC=2)=C1C(N=1)=CC=NC=1NC1CC1 OSXUPRKKVSLTEZ-UHFFFAOYSA-N 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 claims description 3
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical group C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 3
- 208000020431 spinal cord injury Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- LZAPLGQNLFUTOU-UHFFFAOYSA-N 1-[4-quinoxalin-6-yl-5-[2-(trifluoromethyl)pyrimidin-4-yl]-1h-imidazol-2-yl]bicyclo[2.2.2]octan-4-ol Chemical compound C1CC(O)(CC2)CCC12C(N1)=NC(C=2C=C3N=CC=NC3=CC=2)=C1C1=CC=NC(C(F)(F)F)=N1 LZAPLGQNLFUTOU-UHFFFAOYSA-N 0.000 claims description 2
- IITIZYRMDPTJAP-UHFFFAOYSA-N 4-[4-(1,3-benzodioxol-5-yl)-5-(2-methylsulfanylpyrimidin-4-yl)-1h-imidazol-2-yl]benzamide Chemical compound CSC1=NC=CC(C2=C(N=C(N2)C=2C=CC(=CC=2)C(N)=O)C=2C=C3OCOC3=CC=2)=N1 IITIZYRMDPTJAP-UHFFFAOYSA-N 0.000 claims description 2
- PNFODLUWBLVNJD-UHFFFAOYSA-N 4-[4-(1,3-benzodioxol-5-yl)-5-(2-methylsulfanylpyrimidin-4-yl)-1h-imidazol-2-yl]benzonitrile Chemical compound CSC1=NC=CC(C2=C(N=C(N2)C=2C=CC(=CC=2)C#N)C=2C=C3OCOC3=CC=2)=N1 PNFODLUWBLVNJD-UHFFFAOYSA-N 0.000 claims description 2
- 150000001204 N-oxides Chemical class 0.000 claims description 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 2
- 125000006383 alkylpyridyl group Chemical group 0.000 claims description 2
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 2
- 125000005163 aryl sulfanyl group Chemical group 0.000 claims description 2
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- AYBAYRSDQLKGBA-UHFFFAOYSA-N benzyl 4-[5-(2-cyclopropylpyrimidin-4-yl)-4-quinoxalin-6-yl-1h-imidazol-2-yl]piperidine-1-carboxylate Chemical compound C1CC(C=2NC(=C(N=2)C=2C=C3N=CC=NC3=CC=2)C=2N=C(N=CC=2)C2CC2)CCN1C(=O)OCC1=CC=CC=C1 AYBAYRSDQLKGBA-UHFFFAOYSA-N 0.000 claims description 2
- HGVJKJTWVKWHNL-UHFFFAOYSA-N benzyl n-[1-[5-[2-(cyclopropylamino)pyrimidin-4-yl]-4-(6-methylpyridin-2-yl)-1h-imidazol-2-yl]-4-bicyclo[2.2.2]octanyl]carbamate Chemical compound CC1=CC=CC(C2=C(NC(=N2)C23CCC(CC2)(CC3)NC(=O)OCC=2C=CC=CC=2)C=2N=C(NC3CC3)N=CC=2)=N1 HGVJKJTWVKWHNL-UHFFFAOYSA-N 0.000 claims description 2
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 2
- 125000005171 cycloalkylsulfanyl group Chemical group 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 2
- 125000005419 heteroarylsulfonylamino group Chemical group 0.000 claims description 2
- JPUNLPDLHYEFHG-UHFFFAOYSA-N methyl 1-[4-(6-methylpyridin-2-yl)-5-(2-oxo-1h-pyrimidin-6-yl)-1h-imidazol-2-yl]bicyclo[2.2.2]octane-4-carboxylate Chemical compound C1CC(C(=O)OC)(CC2)CCC12C(N1)=NC(C=2N=C(C)C=CC=2)=C1C1=CC=NC(=O)N1 JPUNLPDLHYEFHG-UHFFFAOYSA-N 0.000 claims description 2
- VGUBUAAMYIJYSJ-UHFFFAOYSA-N methyl 1-[5-(2-methoxypyrimidin-4-yl)-4-(6-methylpyridin-2-yl)-1h-imidazol-2-yl]bicyclo[2.2.2]octane-4-carboxylate Chemical compound C1CC(C(=O)OC)(CC2)CCC12C(N1)=NC(C=2N=C(C)C=CC=2)=C1C1=CC=NC(OC)=N1 VGUBUAAMYIJYSJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 claims description 2
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 claims description 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- ZYTPHJMFJJGFAE-UHFFFAOYSA-N 1-[5-(2-methylpyrimidin-4-yl)-4-quinoxalin-6-yl-1h-imidazol-2-yl]bicyclo[2.2.2]octan-4-ol Chemical compound CC1=NC=CC(C2=C(N=C(N2)C23CCC(O)(CC2)CC3)C=2C=C3N=CC=NC3=CC=2)=N1 ZYTPHJMFJJGFAE-UHFFFAOYSA-N 0.000 claims 2
- IAJVXOFFUNWYCJ-UHFFFAOYSA-N [4-[5-(2-cyclopropylpyrimidin-4-yl)-4-quinoxalin-6-yl-1h-imidazol-2-yl]-1-bicyclo[2.2.2]octanyl]methanol Chemical compound C1CC(CO)(CC2)CCC12C(N1)=NC(C=2C=C3N=CC=NC3=CC=2)=C1C(N=1)=CC=NC=1C1CC1 IAJVXOFFUNWYCJ-UHFFFAOYSA-N 0.000 claims 2
- BDQSLLQVJGTDGH-UHFFFAOYSA-N n-[1-[5-[2-(cyclopropylamino)pyrimidin-4-yl]-4-(6-methylpyridin-2-yl)-1h-imidazol-2-yl]-4-bicyclo[2.2.2]octanyl]methanesulfonamide Chemical compound CC1=CC=CC(C2=C(NC(=N2)C23CCC(CC2)(CC3)NS(C)(=O)=O)C=2N=C(NC3CC3)N=CC=2)=N1 BDQSLLQVJGTDGH-UHFFFAOYSA-N 0.000 claims 2
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- FTKRHDBAUOEGGQ-UHFFFAOYSA-N benzyl 4-[4-quinoxalin-6-yl-5-[2-(trifluoromethyl)pyrimidin-4-yl]-1h-imidazol-2-yl]piperidine-1-carboxylate Chemical compound FC(F)(F)C1=NC=CC(C2=C(N=C(N2)C2CCN(CC2)C(=O)OCC=2C=CC=CC=2)C=2C=C3N=CC=NC3=CC=2)=N1 FTKRHDBAUOEGGQ-UHFFFAOYSA-N 0.000 claims 1
- 201000003149 breast fibroadenoma Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 abstract description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 108020003175 receptors Proteins 0.000 description 36
- 102000005962 receptors Human genes 0.000 description 36
- 239000000203 mixture Substances 0.000 description 33
- 108010059616 Activins Proteins 0.000 description 31
- 102000005606 Activins Human genes 0.000 description 31
- 239000000488 activin Substances 0.000 description 31
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 25
- 239000000243 solution Substances 0.000 description 22
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000002904 solvent Substances 0.000 description 12
- 229910001868 water Inorganic materials 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 8
- LNJMHEJAYSYZKK-UHFFFAOYSA-N 2-methylpyrimidine Chemical class CC1=NC=CC=N1 LNJMHEJAYSYZKK-UHFFFAOYSA-N 0.000 description 7
- 239000007821 HATU Substances 0.000 description 7
- 229910004373 HOAc Inorganic materials 0.000 description 7
- 125000005126 aryl alkyl carbonyl amino group Chemical group 0.000 description 7
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 125000005169 cycloalkylcarbonylamino group Chemical group 0.000 description 7
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 229910010062 TiCl3 Inorganic materials 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 125000004181 carboxyalkyl group Chemical group 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 125000004043 oxo group Chemical group O=* 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 125000003396 thiol group Chemical class [H]S* 0.000 description 5
- NWGPLYYBECWONP-UHFFFAOYSA-N (carbamoylamino) hydrogen sulfate Chemical compound NC(=O)NOS(O)(=O)=O NWGPLYYBECWONP-UHFFFAOYSA-N 0.000 description 4
- KSCSMSRUTOBTQN-UHFFFAOYSA-N 1-(2-methylpyrimidin-4-yl)-2-quinoxalin-6-ylethane-1,2-dione Chemical compound CC1=NC=CC(C(=O)C(=O)C=2C=C3N=CC=NC3=CC=2)=N1 KSCSMSRUTOBTQN-UHFFFAOYSA-N 0.000 description 4
- FFDAWZPULBEKKN-UHFFFAOYSA-N 2-hydroxyimino-1-(2-methylpyrimidin-4-yl)-2-([1,2,4]triazolo[1,5-a]pyridin-6-yl)ethanone Chemical compound CC1=NC=CC(C(=O)C(=NO)C2=CN3N=CN=C3C=C2)=N1 FFDAWZPULBEKKN-UHFFFAOYSA-N 0.000 description 4
- 239000005695 Ammonium acetate Substances 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 235000019257 ammonium acetate Nutrition 0.000 description 4
- 229940043376 ammonium acetate Drugs 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000006274 endogenous ligand Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- PCGCUEKRWRYZBD-UHFFFAOYSA-N methyl 1-[1-hydroxy-4-(6-methylpyridin-2-yl)-5-(2-methylsulfanylpyrimidin-4-yl)imidazol-2-yl]bicyclo[2.2.2]octane-4-carboxylate Chemical compound C1CC(C(=O)OC)(CC2)CCC12C(N1O)=NC(C=2N=C(C)C=CC=2)=C1C1=CC=NC(SC)=N1 PCGCUEKRWRYZBD-UHFFFAOYSA-N 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 235000010288 sodium nitrite Nutrition 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 4
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 4
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 206010006895 Cachexia Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 102400000401 Latency-associated peptide Human genes 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 3
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 3
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 3
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108091005682 Receptor kinases Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010046798 Uterine leiomyoma Diseases 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 230000035578 autophosphorylation Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- UOTOQJFVJGLVGK-UHFFFAOYSA-N bicyclo[2.2.2]octan-4-ol Chemical compound C1CC2CCC1(O)CC2 UOTOQJFVJGLVGK-UHFFFAOYSA-N 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- UFTIQYBZOCMAET-UHFFFAOYSA-N methyl 1-[1-hydroxy-4-(2-methylpyrimidin-4-yl)-5-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazol-2-yl]bicyclo[2.2.2]octane-4-carboxylate Chemical compound C1CC(C(=O)OC)(CC2)CCC12C(N(C=1C2=CN3N=CN=C3C=C2)O)=NC=1C1=CC=NC(C)=N1 UFTIQYBZOCMAET-UHFFFAOYSA-N 0.000 description 3
- SPXGZQOUUBLKGH-UHFFFAOYSA-N methyl 1-[4-(6-methylpyridin-2-yl)-5-(2-methylsulfanylpyrimidin-4-yl)-1h-imidazol-2-yl]bicyclo[2.2.2]octane-4-carboxylate Chemical compound C1CC(C(=O)OC)(CC2)CCC12C(N1)=NC(C=2N=C(C)C=CC=2)=C1C1=CC=NC(SC)=N1 SPXGZQOUUBLKGH-UHFFFAOYSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000651 myofibroblast Anatomy 0.000 description 3
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- HVLLSGMXQDNUAL-UHFFFAOYSA-N triphenyl phosphite Natural products C=1C=CC=CC=1OP(OC=1C=CC=CC=1)OC1=CC=CC=C1 HVLLSGMXQDNUAL-UHFFFAOYSA-N 0.000 description 3
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 101150101604 ACVR1B gene Proteins 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- IBCXZJCWDGCXQT-UHFFFAOYSA-N LY 364947 Chemical compound C=1C=NC2=CC=CC=C2C=1C1=CNN=C1C1=CC=CC=N1 IBCXZJCWDGCXQT-UHFFFAOYSA-N 0.000 description 2
- 101710128836 Large T antigen Proteins 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 2
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000868 anti-mullerian hormone Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- ULVSHNOGEVXRDR-UHFFFAOYSA-N 1,1-dimethoxypropan-2-one Chemical compound COC(OC)C(C)=O ULVSHNOGEVXRDR-UHFFFAOYSA-N 0.000 description 1
- LDZGWHKUCWHNNP-UHFFFAOYSA-N 1,2-di(pyrimidin-2-yl)ethane-1,2-dione Chemical compound N=1C=CC=NC=1C(=O)C(=O)C1=NC=CC=N1 LDZGWHKUCWHNNP-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- NMKSIMYBPSPWPI-UHFFFAOYSA-N 1-(2-methylpyrimidin-4-yl)-2-([1,2,4]triazolo[1,5-a]pyridin-6-yl)ethanone Chemical compound CC1=NC=CC(C(=O)CC2=CN3N=CN=C3C=C2)=N1 NMKSIMYBPSPWPI-UHFFFAOYSA-N 0.000 description 1
- BQALSZFABWQBLL-UHFFFAOYSA-N 1-(6-methylpyridin-2-yl)-2-(4-methylsulfanylpyrimidin-2-yl)ethanone Chemical compound CSC1=CC=NC(CC(=O)C=2N=C(C)C=CC=2)=N1 BQALSZFABWQBLL-UHFFFAOYSA-N 0.000 description 1
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- YBSYYLRYPMFRNL-UHFFFAOYSA-N 2,2-bis(methylsulfonyl)propane Chemical compound CS(=O)(=O)C(C)(C)S(C)(=O)=O YBSYYLRYPMFRNL-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- QGSPXSBNLPSTOA-UHFFFAOYSA-N 2-(2-methylpyrimidin-4-yl)-1-quinoxalin-6-ylethanone Chemical compound CC1=NC=CC(CC(=O)C=2C=C3N=CC=NC3=CC=2)=N1 QGSPXSBNLPSTOA-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- WDUVROQOWKIBDV-UHFFFAOYSA-N 2-hydroxyimino-1-(6-methylpyridin-2-yl)-2-(4-methylsulfanylpyrimidin-2-yl)ethanone Chemical compound CC1=CC=CC(=N1)C(C(=NO)C1=NC=CC(=N1)SC)=O WDUVROQOWKIBDV-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- DFZIBCAWOSFLFR-UHFFFAOYSA-N 4-(dimethylamino)-1,1-dimethoxybut-3-en-2-one Chemical compound COC(OC)C(=O)C=CN(C)C DFZIBCAWOSFLFR-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- FHELOQCALDEPNY-UHFFFAOYSA-N 4-hydroxybicyclo[2.2.2]octane-1-carbaldehyde Chemical compound C1CC2(C=O)CCC1(O)CC2 FHELOQCALDEPNY-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-UHFFFAOYSA-N 6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNCC(O)C(O)C(O)C(O)CO MBBZMMPHUWSWHV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- JAJIPIAHCFBEPI-UHFFFAOYSA-N 9,10-dioxoanthracene-1-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)O JAJIPIAHCFBEPI-UHFFFAOYSA-N 0.000 description 1
- PQJUJGAVDBINPI-UHFFFAOYSA-N 9H-thioxanthene Chemical compound C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 102100034111 Activin receptor type-1 Human genes 0.000 description 1
- 101710105225 Activin receptor type-1 Proteins 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 201000000054 Coronary Restenosis Diseases 0.000 description 1
- 206010056489 Coronary artery restenosis Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000020060 Increased inflammatory response Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
- 101800001155 Latency-associated peptide Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- 150000004259 N,P-acetals Chemical class 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010034665 Peritoneal fibrosis Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102000007614 Thrombospondin 1 Human genes 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 229910010061 TiC13 Inorganic materials 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 208000012346 Venoocclusive disease Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- ZXKINMCYCKHYFR-UHFFFAOYSA-N aminooxidanide Chemical compound [O-]N ZXKINMCYCKHYFR-UHFFFAOYSA-N 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012200 cell viability kit Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000017760 chronic graft versus host disease Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 108010011222 cyclo(Arg-Pro) Proteins 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 239000012351 deprotecting agent Substances 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- KUMNEOGIHFCNQW-UHFFFAOYSA-N diphenyl phosphite Chemical compound C=1C=CC=CC=1OP([O-])OC1=CC=CC=C1 KUMNEOGIHFCNQW-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 150000004665 fatty acids Chemical group 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 125000004967 formylalkyl group Chemical group 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009681 mesenchymal cell proliferation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- KNSYWHCOJRHWRP-UHFFFAOYSA-N methyl 1-formylbicyclo[2.2.2]octane-4-carboxylate Chemical compound C1CC2(C=O)CCC1(C(=O)OC)CC2 KNSYWHCOJRHWRP-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 125000005889 octahydrochromenyl group Chemical group 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000026341 positive regulation of angiogenesis Effects 0.000 description 1
- 230000030795 positive regulation of cellular component movement Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000722 protumoral effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- CCOXWRVWKFVFDG-UHFFFAOYSA-N pyrimidine-2-carbaldehyde Chemical class O=CC1=NC=CC=N1 CCOXWRVWKFVFDG-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229940032330 sulfuric acid Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compounds of formula (I) possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. The invention features a compound of the general formula (I) and uses thereof.
Description
PYRIMIDINYLIMIDAZOLES AS TGF-BETA INHIBITORS
[0001] This application claims priority to U.S. Serial No. 60/606,045, which was filed on August 31, 2004. The entire contents of the aforementioned application are incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0001] This application claims priority to U.S. Serial No. 60/606,045, which was filed on August 31, 2004. The entire contents of the aforementioned application are incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0002] TGFO (Transforming Growth Factor (3) is a member of a large family of dimeric polypeptide growth factors that includes, for example, activins, inhibins, bone morphogenetic proteins (BMPs), growth and differentiation factors (GDFs) and mullerian inhibiting substance (MIS). TGFO exists in three isoforms (TGFo1, TGF02, and TGF,(33) and is present in most cells, along with its receptors. Each isoform is expressed in both a tissue-specific and developmentally regulated fashion. Each TGFO isoform is synthesized as a precursor protein that is cleaved intracellularly into a C-terminal region (latency associated peptide (LAP)) and an N-terminal region known as mature or active TGF,6. LAP is typically non-covalently associated with mature TGFO prior to secretion from the cell. The LAP-TGF6 complex cannot bind to the TGFO receptors and is not biologically active. TGFO is generally released (and activated) from the complex by a variety of mechanisms including, for example, interaction with thrombospondin-1 or plasmin.
[0003] Following activation, TGFO binds at high affinity to the type II
receptor (TGFRRII), a constitutively active serine/threonine kinase. The ligand-bound type II
receptor phosphorylates the TGFO type I receptor (Alk 5) in a glycine/serine rich domain, which allows the type I
receptor to recruit and phosphorylate downstream signaling molecules, Smad2 or Smad3. See, e.g., Huse, M. et al.,lllol. Cell. 8: 671-682 (2001). Phosphorylated Smad2 or Smad3 can then complex with Smad4, and the entire hetero-Smad complex translocates to the nucleus and regulates transcription of various TGF(3-responsive genes. See, e.g., Massague, J. Ann. Rev .Biochein. Med. 67: 773 (1998).
receptor (TGFRRII), a constitutively active serine/threonine kinase. The ligand-bound type II
receptor phosphorylates the TGFO type I receptor (Alk 5) in a glycine/serine rich domain, which allows the type I
receptor to recruit and phosphorylate downstream signaling molecules, Smad2 or Smad3. See, e.g., Huse, M. et al.,lllol. Cell. 8: 671-682 (2001). Phosphorylated Smad2 or Smad3 can then complex with Smad4, and the entire hetero-Smad complex translocates to the nucleus and regulates transcription of various TGF(3-responsive genes. See, e.g., Massague, J. Ann. Rev .Biochein. Med. 67: 773 (1998).
[0004] Activins are also members of the TGFO superfamily, which are distinct from TGFO in that they are homo- or heterodimers of activin (3a or Ob. Activins signal in a manner similar to TGFO , that is, by binding to a constitutive serine-threonine receptor kinase, activin type II
receptor (ActRIIB), and activating a type I serine-threonine receptor, Alk 4, to phosphorylate Smad2 or Smad3. The consequent formation of a hetero-Smad complex with Smad4 also results in the activin-induced regulation of gene transcription.
receptor (ActRIIB), and activating a type I serine-threonine receptor, Alk 4, to phosphorylate Smad2 or Smad3. The consequent formation of a hetero-Smad complex with Smad4 also results in the activin-induced regulation of gene transcription.
[0005] Indeed, TGFO and related factors such as activin regulate a large array of cellular processes, e.g., cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, inflammatory cell recruitment, immunosuppression, wound healing, and extracellular matrix production. See, e.g., Massague, J. Ann.
Rev. .Cell. Biol. 6:
594-641 (1990); Roberts, A. B. and Sporn M. B. Peptide Growtlz Factors and Tlzeiz- Receptors, 95: 419-472 Berlin: Springer-Verlag (1990); Roberts, A. B. and Sporn M. B.
Growtlz Factors 8:1-9 (1993); and Alexandrow, M. G., Moses, H. L. Cancer Res. 55: 1452-1457 (1995).
Hyperactivity of TGFO signaling pathway underlies many human disorders (e.g., excess deposition of extracellular matrix, an abnormally high level of inflammatory responses, fibrotic disorders, and progressive cancers). Similarly, activin signaling and overexpression of activin is linked to pathological disorders that involve extracellular matrix accumulation and fibrosis (see, e.g., Matsuse, T. et al., Am. J. Respir. Cell Mol. Biol. 13: 17-24 (1995);
Inoue, S. et al., Biochem. Bioplzys. Res. Coznzn. 205: 441-448 (1994); Matsuse, T. et al, Am. J.
Pathol. 148: 707-713 (1996); De Bleser et al., Hepatology 26: 905-912 (1997); Pawlowski, J.E., et al., J. Clin.
Invest. 100: 639-648 (1997); Sugiyama, M. et al., Gastroenterology 114: 550-558 (1998); Munz, B. et al., EMBO J. 18: 5205-5215 (1999)), inflammatory responses (see, e.g., Rosendahl, A. et al., Am. J Repir. Cell Mol. Biol. 25: 60-68 (2001)), cachexia or wasting (see Matzuk, M. M. et al., Proc. Nat. Acad. Sci. USA 91: 8817-8821 (1994); Coerver, K.A. et al, Mol.
Endocrinol. 10:
534-543 (1996); Cipriano, S.C. et al. Endocz izzology 141: 2319-27 (2000)), diseases of or pathological responses in the central nervous system (see Logan, A. et al.
Eur. J. Neurosci. 11:
2367-2374 (1999); Logan, A. et al. Exp. Neui~ol. 159: 504-510 (1999); Masliah, E. et al., Neurochem. Int. 39: 393-400 (2001); De Groot, C. J. A. et al, J. Neuropathol.
Exp. Neurol. 58:
174-187 (1999), John, G. R. et al, Nat Med. 8: 1115-21 (2002)) and hypertension (see Dahly, A.
J. et al., Azn. J. Physiol. Regul. Izztegz . Comp. Physiol. 283: R757-67 (2002)). Studies have shown that TGFO and activin can act synergistically to induce extracellular matrix production (see, e.g., Sugiyama, M. et al., Gastroenterology 114: 550-558, (1998)). It is therefore desirable to develop modulators (e.g., antagonists) to members of the TGFO family to prevent and/or treat disorders involving this signaling pathway.
[0006] The invention is based on the discovery that compounds of formula (I) are unexpectedly potent antagonists of the TGFO family type I receptors, A1k5 and/or Alk 4.
Thus, compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGFO family signaling activity is desirable.
Rev. .Cell. Biol. 6:
594-641 (1990); Roberts, A. B. and Sporn M. B. Peptide Growtlz Factors and Tlzeiz- Receptors, 95: 419-472 Berlin: Springer-Verlag (1990); Roberts, A. B. and Sporn M. B.
Growtlz Factors 8:1-9 (1993); and Alexandrow, M. G., Moses, H. L. Cancer Res. 55: 1452-1457 (1995).
Hyperactivity of TGFO signaling pathway underlies many human disorders (e.g., excess deposition of extracellular matrix, an abnormally high level of inflammatory responses, fibrotic disorders, and progressive cancers). Similarly, activin signaling and overexpression of activin is linked to pathological disorders that involve extracellular matrix accumulation and fibrosis (see, e.g., Matsuse, T. et al., Am. J. Respir. Cell Mol. Biol. 13: 17-24 (1995);
Inoue, S. et al., Biochem. Bioplzys. Res. Coznzn. 205: 441-448 (1994); Matsuse, T. et al, Am. J.
Pathol. 148: 707-713 (1996); De Bleser et al., Hepatology 26: 905-912 (1997); Pawlowski, J.E., et al., J. Clin.
Invest. 100: 639-648 (1997); Sugiyama, M. et al., Gastroenterology 114: 550-558 (1998); Munz, B. et al., EMBO J. 18: 5205-5215 (1999)), inflammatory responses (see, e.g., Rosendahl, A. et al., Am. J Repir. Cell Mol. Biol. 25: 60-68 (2001)), cachexia or wasting (see Matzuk, M. M. et al., Proc. Nat. Acad. Sci. USA 91: 8817-8821 (1994); Coerver, K.A. et al, Mol.
Endocrinol. 10:
534-543 (1996); Cipriano, S.C. et al. Endocz izzology 141: 2319-27 (2000)), diseases of or pathological responses in the central nervous system (see Logan, A. et al.
Eur. J. Neurosci. 11:
2367-2374 (1999); Logan, A. et al. Exp. Neui~ol. 159: 504-510 (1999); Masliah, E. et al., Neurochem. Int. 39: 393-400 (2001); De Groot, C. J. A. et al, J. Neuropathol.
Exp. Neurol. 58:
174-187 (1999), John, G. R. et al, Nat Med. 8: 1115-21 (2002)) and hypertension (see Dahly, A.
J. et al., Azn. J. Physiol. Regul. Izztegz . Comp. Physiol. 283: R757-67 (2002)). Studies have shown that TGFO and activin can act synergistically to induce extracellular matrix production (see, e.g., Sugiyama, M. et al., Gastroenterology 114: 550-558, (1998)). It is therefore desirable to develop modulators (e.g., antagonists) to members of the TGFO family to prevent and/or treat disorders involving this signaling pathway.
[0006] The invention is based on the discovery that compounds of formula (I) are unexpectedly potent antagonists of the TGFO family type I receptors, A1k5 and/or Alk 4.
Thus, compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGFO family signaling activity is desirable.
[0007] In one aspect, a compound of the following formula:
(Ra)m N~ N
(:~--X-Y-R-A' R' where Rl can be heteroaryl.
(Ra)m N~ N
(:~--X-Y-R-A' R' where Rl can be heteroaryl.
[0008] Each Ra, independently, can be alkyl, alkenyl, alkynyl, alkoxy, acyl, halo, hydroxy, amino, nitro, oxo, thioxo, cyano, guanadino, amidino, carboxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkoxycarbonyl, alkylcarbonyloxy, urea, thiourea, sulfamoyl, sulfamide, carbamoyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfanyl, cycloalkylcarbonyl, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylsulfanyl, heterocycloalkylcarbonyl, aryl, aryloxy, arylsulfanyl, aroyl, heteroaryl, heteroaryloxy, heteroarylsulfanyl, or heteroaroyl.
[0009] X can be cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or a bond.
[0010] Y can be a bond, -C(O)-, -C(O)-O-, -O-C(O)-, -S(O)p O-, -O-S(O)P-, -C(O)-N(Rb)-, -N(Rb)-C(O)-, -O-C(O)-N(Rb)-, -N(Rb)-C(O)-0-, -C(O)-N(Rb)-0-, -O-N(Rb)-C(O)-, -O-S(O)P-N(Rb)-, -N(Rb)- S(O)P O-, -S(O)P N(Rb)-0-, -O-N(R)-S(O)p , -N(R)-C(O)-N(R )-, -N(Rt')-S(O)p N(R )-, -C(O)-N(Rb)-S(O)p , -S(O)p N(R)-C(O)-, -C(O)-N(R)-S(O)p-N(R )-, -C(O)-O-S(O)p N(Rb)-, -N(Rb)-S(O)P N(R )-C(O)-, -N(Rb)-S(O)p O-C(O)-, -S(O)p N(Rb)-, -N(Rb)-S(O)P ,-N(Rb)-, -S(O)P-, -0-, -S-, or -(C(Rb)(R ))q-. Each of Rb and Rc, independently, can be hydrogen, hydroxy, alkyl, alkoxy, amino, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroaralkyl. p can be 1 or 2, and q can be 1-4.
[0011] R2 can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, aralkyl, arylalkenyl, heterocycloalkyl, (heterocycloalkyl)alkyl, heterocycloalkenyl, (heterocycloalkenyl)alkyl, heteroaryl, heteroaralkyl, or (heteroaryl)alkenyl.
[0012] Each of A' and A2, independently, can be N or NRb. It is to be understood that when A' is NRb, A2 is N, and vice versa. The variable, m, can be 0, 1, 2, or 3. In other words, the pyrimidinyl ring can be unsubstituted or substituted with 1-3 Ra groups. Note that when mL-2, two adjacent Ra groups can join together to form a 4- to 8-membered optionally substituted cyclic moiety. That is, the pyrimidinyl ring can fuse with a cyclic moiety to form a moiety, that can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, heteroaryl, aryloxy, heteroaryloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylthio, sulfoxy, sulfamoyl, oxo, or carbamoyl.
[0013] Note also that if X is a bond, then Y is a bond; Rz is hydrogen or alkyl; m is 1, 2, or 3;
and at least one Ra is substituted at the 2-pyrimidinyl position (i.e., the position of the pyrimidinyl ring that is between the two nitrogen ring atoms).
and at least one Ra is substituted at the 2-pyrimidinyl position (i.e., the position of the pyrimidinyl ring that is between the two nitrogen ring atoms).
[0014] In an embodiment, X can be aryl or heteroaryl. For example, X can be an optionally substituted phenyl (e.g., alkyl or cyano). Y can be a bond, -N(R)-C(O)-, -N(R)-S(O)2-, -C(O)-, -C(O)-0-, -O-C(O)-, -C(O)-N(R)-, -S(O)P , -0-, -S(O)Z-N(Rb)-, - N(Rb)-, -N(Rb)-C(O)-0-, -N(R)-C(O)-N(Rc)-, -C(O)-N(R)-S(O)p N(R )-, or -C(O)-O-S(O)p N(R)-. R2 can be hydrogen, C1_6 alkyl, aryl, heteroaryl, aryl-Cl-4 alkyl, or heteroaryl-Cl.4 alkyl.
[0015] In an embodiment, X can be a 4- to 8-membered monocyclic cycloalkyl or heterocycloalkyl, or X can be a 4- to 8-membered bicyclic cycloalkyl or heterocycloalkyl. For example, X can be piperidinyl, piperazinyl, pyrrolidinyl, tetrahydrofuran, cyclohexyl, cyclopentyl, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2. 1 ]octane, 2-oxa-bicyclo[2.2.2]octane, 2-aza-bicyclo[2.2.2]octane, 3-aza-bicyclo[3.2. 1 ]octane, or 1 -aza-bicyclo [2.2.2] octane.
[0016] In an embodiment, X can be piperidinyl, piperazinyl, or pyrrolidinyl.
The piperdinyl, piperazinyl, or pyrrolidinyl can be bonded to Y via its nitrogen ring atom. Y
can be a bond, -C(0)0-, -C(O)-N(Rb)-, -S(0)2-, or -S(O)2-N(R)-, wherein Rb is hydrogen or C1-4 alkyl.
Alternatively, X can be cyclohexyl, cyclopentyl, or bicyclo[2.2.2]octane, and Y can be -N(Rb)-C(O)-, -N(R)-S(O)2-, -C(O)-, -C(O)-0-, -O-C(O)-, -C(O)-N(Rb)-, -S(O)p , -0-, -S(O)Z-N(Rb)-, - N(Rb)-, -N(R)-C(O)-0-, -C(O)-N(Rb)-0-, or -N(R)-C(O)-N(R )-.
The piperdinyl, piperazinyl, or pyrrolidinyl can be bonded to Y via its nitrogen ring atom. Y
can be a bond, -C(0)0-, -C(O)-N(Rb)-, -S(0)2-, or -S(O)2-N(R)-, wherein Rb is hydrogen or C1-4 alkyl.
Alternatively, X can be cyclohexyl, cyclopentyl, or bicyclo[2.2.2]octane, and Y can be -N(Rb)-C(O)-, -N(R)-S(O)2-, -C(O)-, -C(O)-0-, -O-C(O)-, -C(O)-N(Rb)-, -S(O)p , -0-, -S(O)Z-N(Rb)-, - N(Rb)-, -N(R)-C(O)-0-, -C(O)-N(Rb)-0-, or -N(R)-C(O)-N(R )-.
[0017] In an embodiment, Y can be -N(R)-C(O)-, -N(Rb)-S(O)2-, -C(O)-, -C(O)-0-, -O-C(O)-, -C(O)-N(R)-, -S(O)P , -0-, -S(O)2-N(R)-, - N(Rb)-, -N(R)-C(O)-0-, -C(O)-N(R)-0-, -N(R)-C(O)-N(R )-, -C(O)-N(R)-S(O)P N(R )-, or -C(O)-O-S(O)p-N(R)-.
[0018] In an embodiment, X and Y are each a bond; R2 can be hydrogen or C1_6 alkyl (e.g., C1-4 alkyl such as methyl or t-butyl); m can be 1 or 2 (e.g., m can be 1); at least one Ra is substituted at the 2-pyrimidinyl position and this Ra can be Cl-4 alkyl, C3_6 cycloalkyl, or amino (e.g, -CH3, -CF3, cyclopropyl, -NHZ, -NH-C1-4 alkyl, or -NH-cycloalkyl such as -NH-cyclopropyl).
[0019] In an embodiment, RZ can be hydrogen, C1_6 alkyl, aryl, heteroaryl, aryl-C1-4 alkyl, or heteroaryl-C1-4 alkyl. In an embodiment, RZ can be hydrogen, C1.4 alkyl, phenyl, pyridyl, imidazolyl, furanyl, thienyl, triazolyl, tetrazolyl, benzyl, phenylethyl, benzimidazolyl, benzothiazolyl, naphthylmethyl, naphthylethyl, or -CI_2 alkyl-pyridyl; each of which, independently, is optionally substituted with one or more substituents selected from the group consisting of fluoro, chloro, trifluoromethyl, methyl, ethyl, aminocarbonyl, alkylcarbonylamino, sulfamoyl, alkoxycarbonyl, and alkylcarbonyloxy.
[0020] In another embodiment, R'' can be hydrogen, methyl, ethyl, n-butyl, t-butyl, benzyl or pyridylmethyl. For example, R2 can be hydrogen, hydroxymethyl, or trifluoromethyl.
[0021] In an embodiment, R' can be benzo[1,3]dioxolyl, benzo[b]thiophenyl, benzo-oxadiazolyl, benzothiadiazolyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, 2-oxo-benzooxazolyl, pyridyl, pyrimidinyl, 2,3-dihydro-benzo[1,4]dioxyl, 2,3-dihydro-benzofuryl, 2,3-dihydro-benzo[b]thiophenyl, 3,4-dihydro-benzo[1,4]oxazinyl, 3-oxo-benzo[1,4]oxazinyl, 1,1-dioxo-2,3-dihydro- benzo[b]thiophenyl, [1,2,4]triazolo[1,5-a]pyridyl, [1,2,4]triazolo[4,3-a]pyridyl, quinolinyl, quinoxalinyl, quinazolinyl, isoquinolinyl, or cinnolinyl.
[0022] In an embodiment, m can be 0-2.
[0023] In an embodiment, Ra can be substituted at the 2-pyrimidinyl position.
[0024] In another embodiment, Ra can be C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, halo, amino, aminocarbonyl, or alkoxycarbonyl.
[0025] In an embodiment, Al can be N and A2 is NRb, or Al is NRb and A2 is N;
wherein Rb is hydrogen or C 1-4 alkyl.
wherein Rb is hydrogen or C 1-4 alkyl.
[0026] In an embodiment, m can be 0-2; Rl can be heteroaryl; R2 can be hydrogen, C1_6 alkyl, aryl, heteroaryl, -C1-4 alkyl-aryl, or -C1-4 alkyl-heteroaryl; X can be a 4-to 8-membered monocyclic or bicyclic cycloalkyl or heterocycloalkyl; and Y can be -N(R)-C(O)-, -N(R)-S(O)Z-, -C(O)-, -C(O)-O-, -O-C(O)-, -C(O)-N(R)-, -S(O)P , -0-, -S(O)2-N(R)-, -N(R)-, -N(R)-C(O)-0-, -N(Rb)-C(O)-N(Rc)-, -C(O)-N(R)-S(O)p N(Rc)-, or -C(O)-O-S(O)p N(Rb)-.
[0027] In an embodiment, m can be 0-2; Rl can be heteroaryl; RZ can be hydrogen, C1_6 alkyl, aryl, heteroaryl, -C1-4 alkyl-aryl, or -C1-4 alkyl-heteroaryl; X can be piperidinyl, piperazinyl, pyrrolidinyl, tetrahydrofuran, cyclohexyl, cyclopentyl, bicyclo[2.2. 1 ]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.1]octane, 2-oxa-bicyclo[2.2.2]octane, 2-aza-bicyclo[2.2.2]octane, 3-aza-bicyclo[3.2.1]octane, or 1 -aza-bicyclo[2.2.2] octane; and Y can be -N(Rb)-C(O)-, -N(R)-S(O)2-, -C(O)-, -C(O)-0-, -O-C(O)-, -C(O)-N(R)-, -S(O)p , -0-, -S(O)2-N(R)-, - N(R)-, -N(R)-C(O)-0-, -N(R)-C(O)-N(W)-, -C(O)-N(R)-S(O)P N(R )-, or -C(O)-O-S(O)p N(R)-.
[0028] In an embodiment, m can be 0-2; Rl can be heteroaryl; R2 can be hydrogen, C1.6 alkyl, aryl, heteroaryl, -C1-4 alkyl-aryl, or -C1-4 alkyl-heteroaryl; and -X-Y- can be ~-o-I I N
N-SOa N-C-O-, / SOz , or [0029] In an embodiment, Al can be N and A2 can be NH. Alternatively, Al can be NH and A2 can be N. RZ can be hydrogen, C1-4 alkyl, benzyl, or pyridylmethyl; m can be 1 and Ra can be substituted at the 2-pyrimidinyl position.
N-SOa N-C-O-, / SOz , or [0029] In an embodiment, Al can be N and A2 can be NH. Alternatively, Al can be NH and A2 can be N. RZ can be hydrogen, C1-4 alkyl, benzyl, or pyridylmethyl; m can be 1 and Ra can be substituted at the 2-pyrimidinyl position.
[0030] In an embodiment, m can be 0-2; Rl can be heteroaryl; R' can be hydrogen, C1_6 alkyl, aryl, heteroaryl, aryl-C1.4 alkyl, or heteroaryl-C1-4 alkyl; X can be cyclohexyl, cyclopentyl, or bicyclo[2.2.2]octane; and Y can be -N(Rb)-C(O)-, -N(R)-S(O)2-, -C(O)-, -C(O)-O-, -O-C(O)-, -C(O)-N(R)-, -S(O)P , -0-, -S(O)2-N(R)-, - N(Rb)-, -N(R)-C(O)-0-, -N(Rb)-C(O)-N(R )-, -C(O)-N(Rb)-S(O)p N(R )-, or -C(O)-O-S(O)p N(R)-. Each of Rb and R , independently, can be hydrogen or C1-4 alkyl. Al can be N and A2 can be NH, or alternatively, A' can be NH and A2 can be N. RZ can be hydrogen, CI-4 alkyl, benzyl, or pyridylmethyl; m can be 1 and Ra can be substituted at the 2-pyrimindyl position.
[0031] In an embodiment, X and Y can each be a bond; RZ can be hydrogen or C1-4 alkyl; m can be 1; Ra can be -CH3, -CF3, cyclopropyl, -NH2, -NH-C1-4 alkyl, or -NH-cycloalkyl; and Rl can be benzo[1,3]dioxolyl, benzo[b]thiophenyl, benzooxadiazolyl, benzothiadiazolyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, 2-oxo-benzooxazolyl, pyridyl, pyrimidinyl, 2,3-dihydro-benzo[1,4]dioxyl, 2,3-dihydro-benzofuryl, 2,3-dihydro-benzo[b]thiophenyl, 3,4-dihydro-benzo[1,4]oxazinyl, 3-oxo-benzo[1,4]oxazinyl, 1,1-dioxo-2,3-dihydro-benzo[b]thiophenyl, [1,2,4]triazolo[1,5-a]pyridyl, [1,2,4]triazolo[4,3-a]pyridyl, quinolinyl, quinoxalinyl, quinazolinyl, isoquinolinyl, or cinnolinyl.
[0032] The compound of formula (I) can be:
[0033] 4-[4-benzo[1,3]dioxol-5-yl-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-benzamide;
[0034] 4-[4-benzo[1,3]dioxol-5-yl-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-benzonitrile;
[0035] 4-[5-(2-methanesulfonyl-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester;
[0036] 4-[5-(2-methoxy-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester;
[0037] 4-[5-(2-hydroxy-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester;
[0038] 4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester;
[0039] 4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo [2.2.2] octane- 1 -carboxylic acid;
[0040] 4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid amide;
[0041] 4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo [2.2.2] octane- 1 -carboxylic acid hydroxyamide;
[0042] 4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-iH-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methoxy-amide;
[0043] 4-[5-(2-amino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid;
[0044] {4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-1-yl}-carbamic acid benzyl ester;
[0045] N-{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-l-yl}-acetamide;
[0046] N- {4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1 H-imidazol-2-yl] -bicyclo [2.2.2] oct-1-yl } -methane sulfonarnide;
[0047] N-{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-1-yl} -2,2,2-trifluoro-acetamide;
[0048] 4-[5-quinoxalin-6-yl-4-(2-trifluoromethyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octan-l-ol;
[0049] 4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-lH-imidazol-2-yl]-bicyclo[2.2.2]octan-l-ol;
[0050] 6-[2-tert-butyl-5-(2-cyclopropyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
(15686) [0051] 6-[5-(2-byclopropyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
(15686) [0051] 6-[5-(2-byclopropyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
[0052] {4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-lH-imidazol-2-yl]-bicyclo [2.2.2] o ct-1-yl } -methanol;
[0053] 6-[5-(2-trifluoromethyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
[0054] 6-[2-tert-butyl-5-(2-trifluoromethyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
[0055] 4-[5-quinoxalin-6-y1-4-(2-trifluoromethyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-piperidine-1-carboxylic acid benzyl ester;
[0056] 4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-lH-imidazol-2-yl]-piperidine-l-carboxylic acid benzyl ester;
[0057] 6-[5-(2-cyclopropyl-pyrimidin-4-yl)-2-(1-methanesulfonyl-piperidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
[0058] 4-[5-(2-methyl-pyrimidin-4-yl)-4-[1,2,4]triazolo[4,3-a]pyridin-6-yl-lH-imidazol-2-yl]-bicyclo[2.2.2]octan-1-ol;
[0059] 4-[4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo[1,5-a]pyridin-6-yl-lH-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid amide;
[0060] 4-[4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo[1,5-a]pyridin-6-yl-lH-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid;
[0061] 4-[4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo[1,5-a]pyridin-6-yl-lH-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester;
[0062] 4-[4-(2-methyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-lH-imidazol-2-yl]-cyclohexanol; or [0063] 4-[4-(2-methyl-pyrimidin-4-yl)-5 -quinoxalin-6-y1-1 H-imidazol-2-yl] -bicyclo [2.2.2] octan-1-ol.
[0064] In another aspect, a pharmaceutical composition includes a compound of formula (I) and a pharmaceutically acceptable carrier.
[0065] In another aspect, a method of inhibiting the TGF,6 signaling pathway in a subject includes administering to said subject an effective amount of a compound of formula (I).
[0066] In another aspect, a method of inhibiting the TGF,6 type I receptor in a cell, includes contacting said cell with an effective amount of a compound of formula (I).
[0067] In another aspect, a method of reducing the accumulation of excess extracellular matrix induced by TGF,6 in a subject includes administering to said subject an effective amount of a compound of formula (I).
[0068] In another aspect, a method of treating or preventing fibrotic condition in a subject includes administering to said subject an effective amount of a compound of formula (I). The fibrotic condition can be, for example, scleroderma, lupus nephritis, connective tissue disease, wound healing, surgical scarring, spinal cord injury, CNS scarring, acute lung injury, pulmonary fibrosis (such as idiopathic pulmonary fibrosis), chronic obstructive pulmonary disease, adult respiratory distress syndrome, drug-induced lung injury, glomerulonephritis, diabetic nephropathy, hypertension-induced nephropathy, alimentary track or gastrointestinal fibrosis, renal fibrosis, hepatic or biliary fibrosis (such as liver cirrhosis, primary biliary cirrhosis, fatty liver disease, primary sclerosing cholangitis), restenosis, cardiac fibrosis, opthalmic scarring, fibrosclerosis, fibrotic cancers, fibroids, fibroma, fibroadenomas, fibrosarcomas, transplant arteriopathy, or keloid. The fibrotic condition can be idiopathic in nature, genetically linked, or induced by radiation.
[0069] In another aspect, a method of inhibiting growth or metastasis of tumor cells and/or cancers in a subject includes administering to said subject an effective amount of a compound of formula (I).
[0070] In another aspect, a method of treating a disease or disorder mediated by an overexpression of TGF,6 includes administering to a subject in need of such treatment an effective amount of a compound of formula (I). The disease or disorder can be, for example, demyelination of neurons in multiple sclerosis, Alzheimer's disease, cerebral angiopathy, squamous cell carcinomas, multiple myeloma, melanoma, glioma, glioblastomas, leukemia, sarcomas, leiomyomas, mesothelioma, or carcinomas of the lung, breast, ovary, cervix, liver, biliary tract, gastrointestinal tract, pancreas, prostate, and head and neck.
[0071] An N-oxide derivative or a pharmaceutically acceptable salt of each of the compounds of formula (I) is also within the scope of this invention. For example, a nitrogen ring atom of the imidazole core ring or a nitrogen-containing heterocyclyl substituent can form an oxide in the presence of a suitable oxidizing agent such as m-chloroperbenzoic acid or H202.
[0072] A compound of formula (I) that is acidic in nature (e.g., having a carboxyl or phenolic hydroxyl group) can form a pharmaceutically acceptable salt such as a sodium, potassium, calcium, or gold salt. Also within the scope of the invention are salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, and N-methylglycamine. A compound of formula (I) can be treated with an acid to form acid addition salts. Examples of such acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, methanesulfonic acid, phosphoric acid, p-bromophenyl-sulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, oxalic acid, malonic acid, salicylic acid, malic acid, fumaric acid, ascorbic acid, maleic acid, acetic acid, and other mineral and organic acids well known to those skilled in the art. The acid addition salts can be prepared by treating a compound of formula (I) in its free base form with a sufficient amount of an acid (e.g., hydrochloric acid) to produce an acid addition salt (e.g., a hydrochloride salt). The acid addition salt can be converted back to its free base fotm by treating the salt with a suitable dilute aqueous basic solution (e.g., sodium hydroxide, sodium bicarbonate, potassium carbonate, or ammonia).
Compounds of formula (1) can also be, e.g., in a form of achiral compounds, racemic mixtures, optically active compounds, pure diastereomers, or a mixture of diastereomers.
Compounds of formula (1) can also be, e.g., in a form of achiral compounds, racemic mixtures, optically active compounds, pure diastereomers, or a mixture of diastereomers.
[0073] Compounds of formula (I) exhibit surprisingly high affinity to the TGF,6 family type I
receptors, Alk 5 and/or Alk 4, e.g., with ICSo and K; values of less than 10 M under conditions as described below in Examples 34 and 36, respectively. Some compounds of formula (I) exhibit IC50 and K; values of less than 1 [tM (such as below 50 nM).
receptors, Alk 5 and/or Alk 4, e.g., with ICSo and K; values of less than 10 M under conditions as described below in Examples 34 and 36, respectively. Some compounds of formula (I) exhibit IC50 and K; values of less than 1 [tM (such as below 50 nM).
[0074] Compounds of formula (I) can also be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and include those that increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism, and/or alter rate of excretion.
Examples of these modifications include, but are not limited to, esterification with polyethylene glycols, derivatization with pivolates or fatty acid substituents, conversion to carbamates, hydroxylation of aromatic rings, and heteroatom-substitution in aromatic rings.
Examples of these modifications include, but are not limited to, esterification with polyethylene glycols, derivatization with pivolates or fatty acid substituents, conversion to carbamates, hydroxylation of aromatic rings, and heteroatom-substitution in aromatic rings.
[0075] The present invention also features a pharmaceutical composition comprising a compound of formula (I) (or a combination of two or more compounds of formula (I)) and at least one pharmaceutically acceptable carrier. Also included in the present invention is a medicament composition including any of the compounds of formula (I), alone or in a combination, together with a suitable excipient.
[0076] The invention also features a method of inhibiting the TGF(3 family type I receptors, Alk and/or Alk 4 (e.g., with an IC50 value of less than 10 M; such as, less than 1 M; and for example, less than 5 nM) in a cell, including the step of contacting the cell with an effective amount of one or more compounds of formula (I). Also within the scope of the invention is a method of inihibiting the TGF,(3 and/or activin signaling pathway in a cell or in a subject (e.g., a mammal such as a human), including the step of contacting the cell with or administering to the subject an effective amount of one or more of the compounds of formula (I).
[0077] Also within the scope of the present invention is a method of treating a subject or preventing a subject from suffering a condition characterized by or resulted from an elevated level of TGFO and/or activin activity. The method includes the step of administering to the subject an effective amount of one or more of a compound of formula (I). The conditions include an accumulation of excess extracellular matrix; a fibrotic condition (which can be induced by drug or radiation), e.g., scleroderma, lupus nephritis, connective tissue disease, wound healing, surgical scarring, spinal cord injury, CNS scarring, acute lung injury, pulmonary fibrosis (such as idiopathic pulmonary fibrosis and radiation-induced pulmonary fibrosis), chronic obstructive pulmonary disease, adult respiratory distress syndrome, acute lung injury, drug-induced lung injury, glomerulonephritis, diabetic nephropathy, hypertension-induced nephropathy, alimentary track or gastrointestinal fibrosis, renal fibrosis, hepatic or biliary fibrosis, liver cirrhosis, primary biliary cirrhosis, cirrhosis due to fatty liver disease (alcoholic and nonalcoholic steatosis), primary sclerosing cholangitis, restenosis, cardiac fibrosis, opthalmic scarring, fibrosclerosis, fibrotic cancers, fibroids, fibroma, fibroadenomas, fibrosarcomas, transplant arteriopathy, and keloid); TGF(.3-induced growth or metastasis of tumor/cancer cells; and carcinomas (e.g, squamous cell carcinomas, multiple myeloma, melanoma, glioma, glioblastomas, leukemia, sarcomas, leiomyomas, mesothelioma, and carcinomas of the lung, breast, ovary, cervix, liver, biliary tract, gastrointestinal tract, pancreas, prostate, and head and neck); and other conditions such as cachexia, hypertension, ankylosing spondylitis, demyelination in multiple sclerosis, cerebral angiopathy and Alzheimer's disease.
[0078] As used herein, an "alkyl" group refers to a saturated aliphatic hydrocarbon group containing 1-8 (e.g., 1-6 or 1-4) carbon atoms. An alkyl group can be straight or branched.
Examples of an alkyl group include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-heptyl, and 2-ethylhexyl.
An alkyl group can be optionally substituted with one or more substituents such as alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, amino, nitro, carboxy, cyano, halo, hydroxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, cycloalkyl-alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, heterocycloalkyl-carbonylamino, heterocycloalkyl-alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, urea, thiourea, sulfamoyl, sulfamide, alkoxycarbonyl, or alkylcarbonyloxy.
Examples of an alkyl group include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-heptyl, and 2-ethylhexyl.
An alkyl group can be optionally substituted with one or more substituents such as alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, amino, nitro, carboxy, cyano, halo, hydroxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, cycloalkyl-alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, heterocycloalkyl-carbonylamino, heterocycloalkyl-alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, urea, thiourea, sulfamoyl, sulfamide, alkoxycarbonyl, or alkylcarbonyloxy.
[0079] As used herein, an "alkenyl" group refers to an aliphatic carbon group that contains 2-8 (e.g., 2-6 or 2-4) carbon atoms and at least one double bond. Like an alkyl group, an alkenyl group can be straight or branched. Examples of an alkenyl group include, but are not limited to, allyl, isoprenyl, 2-butenyl, and 2-hexenyl. An alkenyl group can be optionally substituted with one or more substituents such as alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, amino, nitro, carboxy, cyano, halo, hydroxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, cycloalkyl-alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, heterocycloalkyl-carbonylamino, heterocycloalkyl-alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, urea, thiourea, sulfamoyl, sulfamide, alkoxycarbonyl, or alkylcarbonyloxy.
[0080] As used herein, an "alkynyl" group refers to an aliphatic carbon group that contains 2-8 (e.g., 2-6 or 2-4) carbon atoms and has at least one triple bond. An alkynyl group can be straight or branched. Examples of an alkynyl group include, but are not limited to, propargyl and butynyl. An alkynyl group can be optionally substituted with one or more substituents such as alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, amino, nitro, carboxy, cyano, halo, hydroxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, cycloalkyl-alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, heterocycloalkyl-carbonylamino, heterocycloalkyl-alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, urea, thiourea, sulfamoyl, sulfamide, alkoxycarbonyl, or alkylcarbonyloxy.
[0081] As used herein, an "amino" group refers to NRxRY wherein each of Rx and RY is independently hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, aryl, aralkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, heteroaryl, or heteroaralkyl. When the term "amino"
is not the terminal group (e.g., alkylcarbonylamino), it is represented by -NRx-. Rx has the same meaning as defined above.
is not the terminal group (e.g., alkylcarbonylamino), it is represented by -NRx-. Rx has the same meaning as defined above.
[0082] As used herein, an "aryl" group refers to phenyl, naphthyl, or a benzofused group having 2 to 3 rings. For example, a benzofused group includes phenyl fused with one or two C4_8 carbocyclic moieties, e.g., 1, 2, 3, 4-tetrahydronaphthyl, indanyl, or fluorenyl. An aryl is optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkyl)alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkyl)alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.
[0083] As used herein, an "aralkyl" group refers to an alkyl group (e.g., a C1-4 alkyl group) that is substituted with an aryl group. Both "alkyl" and "aryl" have been defined above. An example of an aralkyl group is benzyl.
[0084] As used herein, a "cycloalkyl" group refers to an aliphatic carbocyclic ring of 3-10 (e.g., 4-8) carbon atoms. Examples of cycloalkyl groups include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, norbornyl, cubyl, octahydro-indenyl, decahydro-naphthyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, and bicyclo[3.2.3]nonyl. A
"cycloalkenyl" group, as used herein, refers to a non-aromatic carbocyclic ring of 3-10 (e.g., 4-8) carbon atoms having one or more double bond. Examples of cycloalkenyl groups include cyclopentenyl, 1,4-cyclohexa-di-enyl, cycloheptenyl, cyclooctenyl, hexahydro-indenyl, octahydro-naphthyl, bicyclo[2.2.2]octenyl, and bicyclo[3.3.1]nonenyl. A
cycloalkyl or cycloalkenyl group can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkyl)alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkyl)alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.
"cycloalkenyl" group, as used herein, refers to a non-aromatic carbocyclic ring of 3-10 (e.g., 4-8) carbon atoms having one or more double bond. Examples of cycloalkenyl groups include cyclopentenyl, 1,4-cyclohexa-di-enyl, cycloheptenyl, cyclooctenyl, hexahydro-indenyl, octahydro-naphthyl, bicyclo[2.2.2]octenyl, and bicyclo[3.3.1]nonenyl. A
cycloalkyl or cycloalkenyl group can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkyl)alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkyl)alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.
[0085] As used herein, a "heterocycloalkyl" group refers to a 3- to 10-membered (e.g., 4- to 8-membered) saturated ring structure, in which one or more of the ring atoms is a heteroatom, e.g., N, 0, or S. Examples of a heterocycloalkyl group include piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrofuryl, dioxolanyl, oxazolidinyl, isooxazolidinyl, morpholinyl, octahydro-benzofuryl, octahydro-chromenyl, octahydro-thiochromenyl, octahydro-indolyl, octahydro-pyrindinyl, decahydro-quinolinyl, octahydro-benzo[b]thiophenyl, 2-oxa-bicyclo[2.2.2]octyl, 1-aza-bicyclo[2.2.2]octyl, 3-aza-bicyclo[3.2.1]octyl, anad 2,6-dioxa-tricyclo[3.3.1.03'7]nonyl. A "heterocycloalkenyl" group, as used herein, refers to a 3- to 10-membered (e.g., 4- to 8-membered) non-aromatic ring structure having one or more double bonds, and wherein one or more of the ring atoms is a heteroatom, e.g., N, 0, or S. A
heterocycloalkyl or heterocycloalkenyl group can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkyl)alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkyl)alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.
heterocycloalkyl or heterocycloalkenyl group can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkyl)alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkyl)alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.
[0086] A "heteroaryl" group, as used herein, refers to a monocyclic, bicyclic, or tricyclic ring structure having 5 to 15 ring atoms wherein one or more of the ring atoms is a heteroatom, e.g., N, 0, or S and wherein one ore more rings of the bicyclic or tricyclic ring structure is aromatic.
Some examples of heteroaryl are pyridyl, furyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, indolyl, tetrazolyl, benzofuryl, benzthiazolyl, xanthene, thioxanthene, phenothiazine, dihydroindole, and benzo[1,3]dioxole. A heteroaryl is optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkyl)alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkyl)alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl. A
"heteroaralkyl" group, as used herein, refers to an alkyl group (e.g., a C1.4 alkyl group) that is substituted with a heteroaryl group. Both "alkyl" and "heteroaryl" have been defined above.
Some examples of heteroaryl are pyridyl, furyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, indolyl, tetrazolyl, benzofuryl, benzthiazolyl, xanthene, thioxanthene, phenothiazine, dihydroindole, and benzo[1,3]dioxole. A heteroaryl is optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkyl)alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkyl)alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl. A
"heteroaralkyl" group, as used herein, refers to an alkyl group (e.g., a C1.4 alkyl group) that is substituted with a heteroaryl group. Both "alkyl" and "heteroaryl" have been defined above.
[0087] As used herein, "cyclic moiety" includes cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, or heteroaryl, each of which has been defined previously.
[0088] As used herein, an "acyl" group refers to a formyl group or alkyl-C(=0)-where "alkyl"
has been defined previously. Acetyl and pivaloyl are examples of acyl groups.
has been defined previously. Acetyl and pivaloyl are examples of acyl groups.
[0089] As used herein, a "carbamoyl" group refers to a group having the structure -O-CO-NR"RY or -NR"-CO-O-RZ wherein R" and R'' have been defined above and W can be alkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroaralkyl.
[0090] As used herein, a "carboxy" and a "sulfo" group refer to -COOH and -SO3H, respectively.
[0091] As used herein, an "alkoxy" group refers to an alkyl-0- group where "alkyl" has been defined previously.
[0092] As used herein, a "sulfoxy" group refers to -O-SO-Rx or -SO-O-Rx, where Rx has been defined above.
[0093] As used herein, a"halogen" or "halo" group refers to fluorine, chlorine, bromine or iodine.
[0094] As used herein, a"sulfamoyP' group refers to the structure -S(O)2-NR"Ry or -NR" -S(O)2-RZ wherein R", R}", and RZ have been defined above.
[0095] As used herein, a "sulfamide" group refers to the structure -NRx -S(O)Z-NRYRZ wherein Rx, RY, and RZ have been defined above.
[0096] As used herein, a "urea" group refers to the structure -NRx-CO-NRYRZ
and a "thiourea"
group refers to the structure -NRx-CS-NRYRz. Rx, RY, and RZ have been defined above.
and a "thiourea"
group refers to the structure -NRx-CS-NRYRz. Rx, RY, and RZ have been defined above.
[0097] As used herein, an effective amount is defined as the amount required to confer a therapeutic effect on the treated patient, and is typically determined based on age, surface area, weight, and condition of the patient. The interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich et al., Cancer Chemot.laer. Rep., 50: 219 (1966). Body surface area may be approximately determined from height and weight of the patient. See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardsley, New York, 537 (1970). As used herein, "patient" refers to a mammal, including a human.
[0098] An antagonist, as used herein, is a molecule that binds to the receptor without activating the receptor. It competes with the endogenous ligand(s) or substrate(s) for binding site(s) on the receptor and, thus inhibits the ability of the receptor to transduce an intracellular signal in response to endogenous ligand binding.
[0099] As compounds of formula (I) are antagonists of TGFO receptor type I(AlkS) and/or acfivin receptor type I(Alk4), these compounds are useful in inhibiting the consequences of TGFO and/or activin signal transduction such as the production of extracellular matrix (e.g., collagen and fibronectin), the differentiation of stromal cells to myofibroblasts, and the stimulation of and migration of inflammatory cells. Thus, compounds of formula (I) inhibit pathological inflammatory and fibrotic responses and possess the therapeutic utility of treating and/or preventing disorders or diseases for which reduction of TGFO and/or activin activity is desirable (e.g., various types of fibrosis or progressive cancers). In addition, the compounds of formula (I) are useful for studying and researching the role of TGFO receptor type I(AlkS) and/or activin receptor type I(Alk4), such as their role in cellular processes, for example, signal transduction, production of extracellular matrix, the differentiation of stromal cells to myofibroblasts, and the stimulation of and migration of inflammatory cells.
[0100] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
[0101] Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
DETAILED DESCRIPTION OF THE INVENTION
DETAILED DESCRIPTION OF THE INVENTION
[0102] In general, the invention features compounds of formula (I), which exhibit surprisingly high affinitiy for the TGFO family type I receptors, Alk 5 and/or Alk 4.
Synthesis of the Compounds of formula (I) [0103] Compounds of formula (I) may be prepared by a number of known methods from commercially available or known starting materials. In one method, compounds of formula (I) are prepared according to Schemes 1a, lb, or 1c below. Specifically, in Scheme la, optionally substituted 2-methylpyrimidine (II) is deprotonated by LDA before reacting with Rl-substituted carboxylic acid methoxy-methyl-amide (V) to form an Rl-(6-methylpyrimidinyl)-ketone (III).
R' has been defined above. The methoxy-methyl-amide can be prepared by reacting a corresponding acid chloride (i.e., R'-CO-Cl) with N, O-dimethylhydroxylamine hydrochloride.
The Rl-(6-methylpyrimidinyl)-ketone (III) can then be treated with sodium nitrite in acetic acid to afford an a-keto-oxime (IV), which can undergo further reaction with an appropriate substituted (and optionally protected) aldehyde (VI) in the presence of ammonium acetate to yield a compound of formula (I).
Scheme la (Ra r Ra~
1. LDA R1~- m Na 2. Rl ~N, OCHg 0 NN HOAc (II) O
(V) (III) 1. NHqOAc OII
NOH a HxX-Y-R2 R1 I ~R 1 ( al N
R I m (VI) \R /m ~ ~X-Y-R2 y 0 NN 2. TiCl3, MeOH or H
P(OMe)3 or P(OEt)3 NN
(IV) (I) [0104] In another method, the above-described compounds of formula (I) can be prepared according to Scheme lb below. Specifically, 1,1-dimethoxy-propan-2-one can first react with dimethoxymethyl-dimethyl-amine at an elevated temperature to produce the intermediate 4-dimethylamino-1,1-dimethoxy-but-3-en-2-one, which can then react with an Ra-substituted amidine to form an Ra-substituted pyrimidine-2-carbaldehyde (IIa). This carbaldehyde (Ila) can then reacted with aniline and diphenyl phosphite to form a resulting N,P-acetal, which can further couple with an Rl-substituted aldehyde to produced an (Rl-methyl)-pyrimidinyl-ketone (IIIa). See, e.g., Journet et al., Tetrahedron Lett. 39:1717-1720 (1998).
Treatment of the (Rl-methyl)-pyrimidinyl-ketone (Illa) with sodium nitrite in acetic acid produces an a-keto-oxime (IVa), which can undergo reaction with an appropriate substituted (and optionally protected) aldehyde (VI) to yield a compound of formula (I) as described in Scheme la above.
Scheme lb NH
O NYO neat, 80 C RaK NH HBr/H2O
+ i RaN ~
~O o/n IOI O~
O1- ~OPh R' P~OPh 1. Rl-CHO
CHO PhNH2 I~ NH Cs2CO3 O
N N N N b (Ph0)2P(O)H 2. HCI
Ra Ra Ra (Ila) (Illa) 1. NH4OAc R N, 0 /
OH H X-Y-R2 R' N
NaNOZ
I ~ O (VI) ~ }--X-Y-R2 HOAc/THF/HaO NYN H
2. TiCl3, MeOH or N N
Ra P(OMe)3 or P(OEt)3 I (I) (IVa) Ra [0 . 105] In another method, the above-described compounds of formula (I) can be prepared according to Scheme 1c below. Specifically, an (Rl-methyl)-pyrimidinyl-ketone (IIIa) (described above) can be oxidized to form a pyrimidinyl-diketone (IVb), which can undergo reaction with an appropriate substituted (and optionally protected) aldehyde (VI) to yield a compound of formula (I) as described above.
Scheme lc N ) N 0 (Ra)m ~'N Rt NBS/DMSO (Ra)m ' t N R
O O
(Illa) (IVb) 1. NHqOAc OII
HxX-Y-R ~
z (Ra)n~~ N N
(VI) ~}--X-Y-Rz 2. TiCl3, MeOH or R1 N
P(OMe)3 or P(OEt)3 H
(I) [0106] If compound (VI) is in its protected form, appropriate deprotecting agents can be applied to the resulting compound after the coupling reaction of compound (IV) or (IVa) and compound (VI) to yield a compound of formula (I). See, e.g., T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, Inc., New York (198 1), for suitable protecting groups.
[0107] Alternatively, a compound of formula (I) can be prepared by reacting intermediate (IV) or (IVa) with an aldehyde (VII) to yield a further intermediate (VIII), which can then react with compound (IX) to yield a compound of formula (I). Note that moieties Y' and Y"
are precursors of moiety Y. See Scheme 2 below. In addition, desired substitutions at Ra can be obtained by selecting, for example, the appropriate compound (IIa) intermediate.
Scheme 2 N~N 0 (IV) (Ra)m NOH 1. NH4OAc or 0 x N
H X-Y' (Ra ~~--~ Y' (IVa) (Ra)m \ N NOH (VII) 14 H
R 2. TiCl3, MeOH N,,,~,,N
O
or (VIII) N
(IVb) (Ra)m ~
R1 Y"~ R2 0 (IX) (Ra m R I N~X-Y-R2 , \ H
N,,~,,, N
(I) [0108] In some embodiments, moiety X in compound (VII) is a nitrogen-containing heterocycloalkyl (e.g., piperidine). The nitrogen ring atom can be protected by a nitrogen protecting group (e.g., Cbz, Boc, or FMOC) before coupling to compound (IV) or (IVa) and deprotected afterwards (see first step of Scheme 3) to yield compound (VIIIa).
This compound can further react with various compounds (IX) to produce a compound of formula (I). See second steps of Scheme 3 below. It should be noted that compound (VIII) or compound (VIIIa) can be a compound of formula (I) as well.
Scheme 3 N~N 0 (IV) (Ra)m \ I ' 1. NH40Ac R
or -~
1 H N-Cbz )i_3 a Ri \\~~ N o_i N ~ NOH (yll) ( \ Deprotection (using R \m Y ~~-( N-Cbz ~-(h ~ s agents,e.g.,H2, Pd/C
(IVa) (Ra)m ~ \Y N
R' 2. TiCl3, MeOH NvN H ortiBr/HOAc) O
or (VIII) \
(lVb) (Ra)m N O R' O R2SO2CI (IX) (Ra \ R~~~ N) o-~
I DIEA /\ ~ N-SO~RZ
( \ H 1-3 N,,~,, N
(I) RaOCOCI (IX) (R R' N ) o-~ O
aJ,~ Y -l( NaHCO3 \~ ~ \ N O-Rz r' \YI H )i-3 N,,,N
(I) R' N
(Ra 1 \~N
1-3 H NH R2NC0 (IX) ~R R1 N )o-t ,,O'R
1~
N \ 2 N~N DIEA H t 3 H z (Villa) N,,~,,N
(I) R2COCI (IX) or (R
RZ al N ) o-~ 0 ' \ N-~
COH (IX), DIEA or I 1-3 R2 R2COOH (IX), N~ N H
coupling agent, e.g., ~
HATU (I) R' RZCHO (IX) (Ra 1 N ) o-i NaB(OAc)3H /\ I ~N~ z ~H/13 R
N,,,, N
(I) [0109] Similarly, when moiety X in compound (VII) is a cycloalkyl (e.g., cyclopentyl, cyclohexyl, or bicyclo[2.2.2]octane), it can be further functionalized to form a compound of formula (I) as depicted in Schemes 4, 5a, 5b, and 5c below.
Scheme 4 N'- N 0 (IV) (Ra)m 1 R 1. NH4OAc NOH
t N o-, NHCbz 0 NHCbz r ~ RI
or ~ )o-t (R'~m )1-3 H Deprotection (using N__'_N NOH H (VII) N ),., (IVa) (Ra)m-\ I NvN agents,e.g.,H2,Pd/C
RI 2. TiC13, MeOH (VIII) orHBr/HOAc) or /Ra Rt N o-~ NHSO2R2 N\ 0 R~SO2CI (IX) ai (IVb) (~''a)m ' / t DIEA H )~'3 - II R N N
O
(I) R2OCOCI (IX) ~ Ra m R1 N o-~ oN--~ 2 O-R
NaHCO3 N )1-a ~
N,,:,, N
(I) R' Ra N a-, NH2 RI I..I~O
m ~\ I N ),a R2NCO (IX) (Ra lm I N a~ N NR2 H DIEA /\ \ H~ H
NI~/ N (I
(Villa) N,,'~,, N
(I) R2COCI (IX) or Rt N 0-1 N40 R2COH (IX), DIEA or ~ R Rz R COOH (IX), coupling ~iV H )1-3 agent, e.g., HATU N,,Z~,- IN
(I) R2CHO (IX) (Ra Rt N o-~ N-\NaB(OAc)3H ~ 0-1 R~
II~H )7-3 NvN
(I) Scheme 5a N~N 0 (IV) (Ra)m \ YR1 NOH 1. NH4OAc or 0 H~COOMe R1 N
N~N NOH (VII) ( lRa ~ 'Z~~COOMe (A) (IVa) (Ra)m -\ ~ \ \ H
R1 2. TiCl3, MeOH N~N
or (I) \
(IVb) (RB)m N O R1 O rRa,1 R1 N j~COOH
\ m\ ~~(' \~-Deprotection \ ~/
(using reagents, N ~ N H
e.g., LiOH) (I) (can be further modified according to Scheme 5b below) N~ R
(IV) (Ra)m i 1 NOH 1. NH4OAc or 0 H-1-&OH
Ra R1 (VII) ~ J N
N N NOH m\ ~OH
(B) (IVa) (Ra)m 1 \ N
R 2. TiCi3, MeOH NI~N H
or (I) N \ 0 (IVb) (Ra)m ' N~ ~Rl 0 (RaR1 N
NH(Rb)SOzCI \\ N~~OSOaNH(Rb) II
N~N H
(I) Scheme 5b ~ Ra) Rt N~ /~\ (Ra ~ Rt N 0 \ ?-E'\~-COOH RZOH m m ~
(~) \ H \\ H OR2 N:~, N
(I) (~) ( R a ~ R ~ t N ~ (Ra ~ Rt N 0 )---~~-COOH RZNHa m (2) \ \ H ~~// fl \\ H~ NHRz N~N NvN
(~) (I) a Rt /~ / a R
3 ~R\ll\>__--CooH m RzSOaNH(Rb) lR ~ t N
~// N NHSOZR2 N~N EDC,DMAP \ ~H
N~N
(I) (i) (Ra \ Rt N
~'COOH 1. HATU, NH3 (Ra ) Rt N' ~--~
H 2. 2reducing agents ~I I ~%~-(~~~/ -~.
(4) NvN (e.g., BH3=THF) I \ H NHz N,,N
(i) (~) (can be further modified according to Scheme 5c below) (Ra / Ri N/~ Rt \m\~ ~~-f' \~-COOH diohenvlohosohorvlazide (Ra ~ N~
14 ~/ DIEA, benzyl alcohol, toluene \\ ~ H NH O
(5) N~ vN H
N~N O~-(I) (~) H2, Pd/C or (Ra ) Rt N~ /~\
l \rIm }-(~\k NHa HBr/HOAc \ H ~-/
NvN
(I) (can be further modified according to Scheme 5c below) (Ra ) R' NBH3=THF (Ra ~ R' N OH 2 COOH R SO,CI
DIEA, THF
(s \\ ) H THF \ H
NvN NvN
(1) (1) (Ra ~ R~ (R ) ~ N
\ N NaCN a R
m I ~
( ~O-~oR2 DMF \ N CN
N~N H O ~ N,,,, N H
aN3 LiCI / NHaCI HCI / H2O
(Ra ) R~ N
\~ \ r 1 (Ra ~ R1 N
H
'N \NCOOH
NN HN-N (I) /Ra ' R~ N (Ra ) R~' N /~ Trifluoroactic ' I\ ~~--( \~-COOH HATU, NH3 \ \ ~)- (~~CONH2 anhydride (7) N ~/ DMF ~\ H"N ~// Pyridine, THF
N,,,, N H N,,:~,, N
(1) (1) a R~
( R m\ ~ N C N NaN3 (Ra ~m R1 I N N-N
\H LiCl / NH4CI \~ NN N
N~iN N ~ N H H
Scheme 5c /~ ooNHSO2R2 RZSOZCI (IX) (Ra ) R~ N
DIEA ~~--f\i}-F~
H
N,,,,N
(I) O
R2OCOCI (IX) (Ra ) Ri N' N4 a m O
NaHCO3 ~ H
NN
(1) (Ra ) R' N NHa O
I N~ ~o R2NCO (IX) (Ra ) F''1 N N~ 2 r~ H DIEA \\ H-R
N~N r % H
(~) N,,Z~,, N
(~) R2COCI (IX) or Rt HO
R2COH (IX), DIEA or (Ra ~m I N~a R2 R2COOH (IX), coup ing N
agent, e.g., HATU H
NN (') R2CHO (IX) (Ra ) NN- \ z m R
NaB(OAc)3H N
~ H
N,,::~, N
(~) [01101 As is well known to a skilled person in chemistry, desired substitutions can be placed on the pyrimidinyl ring in the last steps of the synthesis. See Scheme 6 below, for example.
Scheme 6 sl~ O, S%O HN14~
N)IIN N'I" N NJ\\N H
N H202, NaWO4HZO / HZN-a / N
~} -X-Y-R2 ~ --X-Y-Rz , X-Y-R Z
R~ N HZSO4, MeOH R' N Reflux R' N
(I) (I) (I) [0111] Compounds of formula (I) wherein Rb is not hydrogen can be prepared by known methods. For example, compounds of formula (I) wherein Al is N and A2 is NH
(or vice versa) can be treated with R1(e.g., alkyl iodide) and CsCO3 to produce a compound of formula (I) wherein Rb is alkyl. See, e.g., Liverton, et al., J. Med. Chem., 42: 2180-2190 (1999).
[0112] As will be obvious to a skilled person in the art, some starting materials and intermediates may need to be protected before undergoing synthetic steps as described above.
For suitable protecting groups, see, e.g., T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, Inc., New York (1981).
Uses of Compounds of formula (I) [0113] As discussed above, hyperactivity of the TGFO family signaling pathways can result in excess deposition of extracellular matrix and increased inflammatory responses, which can then lead to fibrosis in tissues and organs (e.g., lung, kidney, and liver) and ultimately result in organ failure. See, e.g., Border, W.A. and Ruoslahti E. J. Clin. Invest. 90: 1-7 (1992) and Border, W.A. and Noble, N.A. N. Engl. J. Med. 331: 1286-1292 (1994). Studies have been shown that the expression of TGFO and/or activin mRNA and the level of TGFO and/or activin are increased in patients suffering from various fibrotic disorders, e.g., fibrotic kidney diseases, alcohol-induced and autoimmune hepatic fibrosis, myelofibrosis, bleomycin-induced pulmonary fibrosis, and idiopathic pulmonary fibrosis. Elevated TGF(3 and/or activin is has also been demonstrated in cachexia, demyelination of neurons in multiple sclerosis, Alzheimer's disease, cerebral angiopathy and hypertension.
[0114] Compounds of formula (I), which are antagonists of the TGFO family type I receptors Alk 5 and/or Alk 4, and inhibit TGFO and/or activin signaling pathway, are therefore useful for treating and/or preventing fibrotic disorders or diseases mediated by an increased level of TGFO
and/or activin activity. As used herein, a compound inhibits the TGFO family signaling pathway when it binds (e.g., with an IC50 value of less than 10 M; such as, less than 1 M; and for example, less than 5 nM) to a receptor of the pathway (e.g., Alk 5 and/or Alk 4), thereby competing with the endogenous ligand(s) or substrate(s) for binding site(s) on the receptor and reducing the ability of the receptor to transduce an intracellular signal in response to the endogenous ligand or substrate binding. The aforementioned disorders or diseases include any condition (a) marked by the presence of an abnormally high level of TGFO
and/or activin; and/or (b) an excess accumulation of extracellular matrix; and/or (c) an increased number and synthetic activity of myofibroblasts. These disorders or diseases include, but are not limited to, fibrotic conditions such as scleroderma, glomerulonephritis, diabetic nephropathy, lupus nephritis, hypertension-induced nephropathy, ocular or comeal scarring, alimentary track or gastrointestinal fibrosis, renal fibrosis, hepatic or biliary fibrosis, acute lung injury, pulmonary fibrosis (such as idiopathic pulmonary fibrosis and radiation-induced pulmonary fibrosis), post-infarction cardiac fibrosis, fibrosclerosis, fibrotic cancers, fibroids, fibroma, fibroadenomas, and fibrosarcomas. Other fibrotic conditions for which preventive treatment with compounds of formula (I) can have therapeutic utility include radiation-induced fibrosis, chemotherapy-induced fibrosis, and surgically-induced scarring including surgical adhesions, laminectomy, and coronary restenosis.
[0115] Increased TGFO activity is also found to manifest in patients with progressive cancers.
Studies have shown that in many cancers, the tumor cells, stromal cells, and/or other cells within a tumor generally overexpress TGF,6. This leads to stimulation of angiogenesis and cell motility, suppression of the immune system, and/or increased interaction of tumor cells with the extracellular matrix. See, e.g., Hojo, M. et al., Nature 397: 530-534 (1999) and Lammerts E. et al., Int. J. Cancer 102: 453-462 (2002). As a result, the tumors grow more readily, become more invasive and metastasize to distant organs. See, e.g., Maehara, Y. et al., J. Clin. Oncol.
17: 607-614 (1999) and Picon, A. et al., Cancet Epidemiol. Bi markers Prev.
7: 497-504 (1998).
Thus, compounds of formula (I), which are antagonists of the TGFO type I
receptor and inhibit TGFO signaling pathways, are also useful for treating and/or preventing various cancers which overexpress TGFO or benefit from TGFO's above-mentioned pro-tumor activities.
Such cancers include carcinomas of the lung, breast, liver, biliary tract, gastrointestinal tract, head and neck, pancreas, prostate, cervix as well as multiple myeloma, melanoma, glioma, and glioblastomas.
[0116] Importantly, it should be pointed out that because of the chronic, and in some cases localized, nature of disorders or diseases mediated by overexpression of TGFO
and/or activin (e.g., fibrosis or cancers), small molecule treatments (such as treatment disclosed in the present invention) are favored for long-term treatment.
[0117] Not only are compounds of formula (I) useful in treating disorders or diseases mediated by high levels of TGFO and/or activin activity, these compounds can also be used to prevent the same disorders or diseases. It is known that polymorphisms leading to increased TGFO and/or activin production have been associated with fibrosis and hypertension.
Indeed, high serum TGFO levels are correlated with the development of fibrosis in patients with breast cancer who have received radiation therapy, chronic graft-versus-host-disease, idiopathic interstitial pneumonitis, veno-occlusive disease in transplant recipients, and peritoneal fibrosis in patients undergoing continuous ambulatory peritoneal dialysis. Thus, the levels of TGFO
and/or activin in serum and of TGFO and/or activin mRNA in tissue can be measured and used as diagnostic or prognostic markers for disorders or diseases mediated by overexpression of TGFO and/or activin, and polymorphisms in the gene for TGFO that determine the production of TGFO and/or activin can also be used in predicting susceptibility to disorders or diseases. See, e.g., Blobe, G.C. et al., N. Engl. J. Med. 342(18): 1350-1358 (2000); Matsuse, T. et al., Am. J. Respir. Cell Mol. Biol. 13: 17-24 (1995); Inoue, S. et al., Biochem. Biophys. Res. Comm.
205: 441-448 (1994); Matsuse, T. et al, Am. J Pathol. 148: 707-713 (1996); De Bleser et al., Hepatology 26:
905-912 (1997); Pawlowski, J.E., et al., J Clin. Invest. 100: 639-648 (1997);
and Sugiyama, M.
et al., Gastroenterology 114: 550-558 (1998).
ADMINISTRATION OF COMPOUNDS OF FORMULA (I) [0118] As defined above, an effective amount is the amount required to confer a therapeutic effect on the treated patient. For a compound of formula (I), an effective amount can range, for example, from about 1 mg/kg to about 150 mg/kg (e.g., from about 1 mg/kg to about 100 mg/kg). Effective doses will also vary, as recognized by those skilled in the art, dependant on route of administration, excipient usage, and the possibility of co-usage with other therapeutic treatments including use of other therapeutic agents and/or radiation therapy.
[0119] Compounds of formula (I) can be administered in any manner suitable for the administration of pharmaceutical compounds, including, but not limited to, pills, tablets, capsules, aerosols, suppositories, liquid formulations for ingestion or injection or for use as eye or ear drops, dietary supplements, and topical preparations. The pharmaceutically acceptable compositions include aqueous solutions of the active agent, in an isotonic saline, 5% glucose or other well-known pharmaceutically acceptable excipient. Solubilizing agents such as cyclodextrins, or other solubilizing agents well-known to those familiar with the art, can be utilized as pharmaceutical excipients for delivery of the therapeutic compounds. As to route of administration, the compositions can be administered orally, intranasally, transdermally, intradermally, vaginally, intraaurally, intraocularly, buccally, rectally, transmucosally, or via inhalation, implantation (e.g., surgically), or intravenous administration.
The compositions can be administered to an animal (e.g., a mammal such as a human, non-human primate, horse, dog, cow, pig, sheep, goat, cat, mouse, rat, guinea pig, rabbit, hamster, gerbil, or ferret, or a bird, or a reptile, such as a lizard).
[0120] Optionally, compounds of formula (I) can be administered in conjunction with one or more other agents that inhibit the TGF(3 signaling pathway or treat the corresponding pathological disorders (e.g., fibrosis or progressive cancers) by way of a different mechanism of action. Examples of these agents include angiotensin converting enzyme inhibitors, nonsteroid and steroid anti-inflammatory agents, immunotherapeutics, chemotherapeutics, as well as agents that antagonize ligand binding or activation of the TGFO receptors, e.g., anti-TGFO, anti-TGF,(3 receptor antibodies, or antagonists of the TGFO type II receptors. Compounds of formula (I) can also be administered in conjunction with other treatments, e.g., radiation.
The invention will be iurther described in the following examples, which do not limit the scope of the invention described in the claims.
Example 1 4-[1-Hydroxy-4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo [1,5-a] pyridin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester Synthesis of the title compound is described in parts (a)-(b) below.
(a) 1-(2-Methyl-pyrimidin-4-yl)-2-[1,2,4]triazolo[1,5-a]pyridin-6-yl-ethane-1,2-dione 2-oxime (IVa) [0121] Sodium nitrite (1.03 g, 15 mmol) was added to a solution of 1-(2-methyl-pyrimidin-4-yl)-2-[1,2,4]triazolo[1,5-a]pyridin-6-yl-ethanone (prepared according to Scheme lb above) (2.5 g, 10 mmol) in a nzixture of HOAc/THF/HZO (6:4:1, 55 mL). The mixture was stirred at 0 C
for 1 hour and then room temperature for 1 hour. Solvent was removed under reduced pressure.
Residue was dissolved in water and NaOH (3N) was added until the pH was greater than 8. The aqueous solution was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated to give 1.8 g (64%) of the title compound as a yellow foam.
(b) 4-[1-Hydroxy-4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo[1,5-a]pyridin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester [0122] 4-Formyl-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester (0.170 g, 1.0 mmol) was added to a solution of 1-(2-methyl-pyrimidin-4-yl)-2-[1,2,4]triazolo[1,5-a]pyridin-6-yl-ethane-1,2-dione 2-oxime (0.282 g, 1 mmol) and ammonium acetate (1.54 g, 20 mmol) in acetic acid (5 mL). The mixture was refluxed for 3 hours. Solvent was removed under reduced pressure. The reaction mixture was then quenched with an ammonia/ice mixture. The aqueous solution was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated to give 0.400g (87%) of the title compound as a yellow solid.
Example 2 4-[4-(2-Methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo [1,5-a] pyridin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester [0123] Triethylphosphite (0.343 uL, 2.0 mmol) was added to a solution of 4-[1-hydroxy-4-(2-methyl-pyrimidin-4-yl)-5-[ 1,2,4]triazolo[ 1,5-a]pyridin-6-yl-1 H-irnidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester (0.40 g, 0.87 mmol; see Example 1 above) in DMF (10 mL). The mixture was heated at 110 C for 18 hours. The solvent was removed.
The residue was portioned between ethyl acetate and brine. The organic layer was dried over sodium sulfate, filtered, and concentrated to give a yellow oil. HPLC
purification gave 0.30 g (77%) of the title compound as a yellow oil. 1H NMR (300 MHz, Methanol-d4) S
9.32 (s, 1H), 8.69 (d, 1H, J = 5.7 Hz), 8.58 (s, 1H), 7.93 (m, 2H), 7.74 (d, 1H, J = 5.7 Hz), 3.68 (s, 3H), 2.65 (s, 3H), 2.15 (m, 6H), 1.99 (m, 6H). MS (ES+) m/z (M+l) 444.24.
Example 3 4-[4-(2-Methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo [1,5-a]pyridin-6-yl-lH-imidazol-2-yl]-bicyclo [2.2.2] octane-l-carboxylic acid [0124] Lithium hydroxide monohydrate (0.046 g, 1.12 mmol) was added to a solution of 4-[4-(2-methyl-pyrimidin-4-yl)-5-[ 1,2,4]triazolo[ 1,5-a]pyridin-6-yl-1 H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester (0.25 g, 0.56 mmol) in a mixture of THF/MeOH/H20 (2/1/1, 4 mL). The mixture was stirred for 3 hours, and the solvent was removed. The residue was diluted with water (30 mL). Citric acid was added to the solution to make the pH lower than 7. The aqueous solution was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated to give 0.180 g (75%) of the title compound as a yellow solid. 1H NMR (300 MHz, Methanol-d4) 6 9.29 (s, 1H), 8.65 (d, 1H, J= 5.4 Hz), 8.54 (s, 1H), 7.91 (m, 2H), 7.67 (d, 1H, J = 5.7 Hz), 2.64 (s, 3H), 2.14 (m, 6H), 2.00 (m, 6H). MS (ES+) m/z (M+1) 430.28.
Example 4 4-[4-(2-Methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo [1,5-a]pyridin-6-yl-lH-imidazol-2-yl]-bicyclo [2.2.2] octane-l-carboxylic acid amide [0125] HATU (0.265 g, 0.70 mmol) was added to a solution of 4-[4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo[1,5-a]pyridin-6-yl-lH-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid (0.150 g, 0.35 mmol) and potassium carbonate (0.1242 g, 1.75 mmol) in DMF (5 mL). The mixture was stirred for 10 minutes. NH3 was bubbled into the reaction mixture for 10 minutes.
The mixture was stirre for an additional2 hours. The mixture was filtered, and DMF was removed under reduced pressure. The residue was dissolved in DMSO and the DMSO
solution was filtered. HPLC purification of the DMSO solution gave 0.040 g (27%) of the title compound as a yellow solid. 1H NMR (300 MHz, Methanol-d4) S 9.30 (s, 1H), 8.67 (d, 1H, J
6.0 Hz), 8.56 (s, 1H), 7.92 (m, 2H), 7.69 (d, 1H, J = 6.0 Hz), 2.65 (s, 3H), 2.15 (m, 6H), 1.99 (m, 6H). MS (ES+) m/z (M+1) 429.25.
Example 5 4-[4-(2-Methyl-pyrimidin-4-y1)-5-quinoxalin-6-yl-lH-imidazol-2-yl]-bicyclo [2.2.2] octan-l-ol Synthesis of the title compound is described in parts (a)-(b) below.
(a) 1-(2-Methyl-pyrimidin-4-yl)-2-quinoxalin-6-yl-ethane-1,2-dione (IVb) [0126] To a solution of 2-(2-methyl-pyrimidin-4-yl)-1-quinoxalin-6-yl-ethanone (0.500 g, 1.9 mmol; prepared according to Scheme lb above)) in DMSO (5 mL) was added NBS
(0.337 g, 1.9 mmol) and then stirred at room temperature for 3 days. The mixture was partitioned between ether and water. Ether was washed with brine, dried over sodium sulfate, filtered and concentrated to give 0.200 g (38%) of 1-(2-methyl-pyrimidin-4-yl)-2-quinoxalin-6-yl-ethane-1,2-dione as a yellow solid.
(b) 4-[4-(2-Methyl-pyrimidin-4-y1)-5-quinoxalin-6-y1-1H-imidazol-2-y1]-bicyclo[2.2.2]octan-1-ol [0127] 4-Hydroxy-bicyclo [2.2.2] octane- 1 -carbaldehyde (0.130 g, 0.86 mmol) was added to a solution of 1-(2-methyl-pyrimidin-4-yl)-2-quinoxalin-6-yl-ethane-l,2-dione (0.200 g, 0.72 mmol) and ammonium acetate (0.554 g, 7.2 mmol) in acetic acid (10 mL). The mixture was reflux for 3 hours. Solvent was removed under reduced pressure. Reaction mixture was then quenched with ammonia/ice mixture. The aqueous solution was extracted with ethyl acetate.
Ethyl acetate was washed with brine, dried over sodium sulfate, filtered, and concentrated.
HPLC purification eluting with acetonitrile:water gave 0.06 g (20%) of the title compound as a yellow solid. 1H NMR (300 MHz, Methanol-d4) S 8.99 (m, 2H), 8.63 (d, 1H, J=
5.8 Hz), 8.43 (d, 1H, J = 1.8 Hz), 8.25 (d, 1H, J = 8.7 Hz), 8.03 (m, 1H), 7.47 (d, 1H, J =
5.7 Hz), 2.30 (m, 6H), 1.87 (m, 6H). MS (ES) m/z (M+l) 413.28.
Example 6 4-[1-Hydroxy-4-(6-methyl-pyridin-2-yl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester Synthesis of the title compound is described in parts (a)-(b) below.
(a) 1-(6-Methyl-pyridin-2-y1)-2-(4-methylsulfanyl-pyrimidin-2-y1)-ethane-1,2-dione 2-oxime (IV) [0128] Sodium nitrite (0.479 g, 6.9 mmol) was added to a solution of 1-(6-methyl-pyridin-2-yl)-2-(4-methylsulfanyl-pyrimidin-2-yl)-ethanone (1.2 g, 4.6 mmol; prepared according to Scheme 1 above) in a mixture of HOAc/THF/H20 (6:4:1, 35 mL). The mixture was stirred at 0 C for 1 hour and then at room temperature for another hour. Solvent was removed under reduced pressure. Residue was dissolved in water, to which NaOH (3N) was added until pH was larger than 8. The aqueous solution was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated to give 1.3 g (98%) of the title oxime as a yellow foam.
(b) 4-[1-Hydroxy-4-(6-methyl-pyridin-2-yl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester [0129] 4-Formyl-bicyclo[2.2.2]octane-l-earboxylic acid methyl ester (0.72 g, 2.5 mmol) was added to a solution of 1-(6-methyl-pyridin-2-yl)-2-(4-methylsulfanyl-pyrimidin-2-yl)-ethane-1,2-dione 2-oxime (0.6 g, 2.1 mmol) and ammonium acetate (3.1 g, 40 mmol) in acetic acid (30 mL). The mixture was reflux for 2 hours. Solvent was removed under reduced pressure.
Reaction mixture was then quenched with ammonia/ice mixture. The aqueous solution was extracted with ethyl acetate. Ethyl acetate was washed with brine, dried over sodium sulfate, filtered, and concentrated to 0.9 g (92%) of the title methyl ester as a yellow solid.
Example 7 4-[4-(6-Methyl-pyridin-2-yl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester [0130] Trimethylphosphite (1.0 mL, 9.7 mmol) was added to a solution of 4-[1-hydroxy-4-(6-methyl-pyridin-2-yl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester (0.9 g, 1.93 mmol; see Example 6 above) in DMF (10 mL). The mixture was stirred at 110 C for 18 hours. Solvent was removed to give a yellow oil. Column chromatography eluting with ethyl acetate:hexanes (50:50) gave 0.8 g (97%) of the title compound as a yellow solid. 1H NMR (300 MHz, DMSO-d6) S
12.25 (s, 1H), 8.51 (m, 1H), 7.71 (m, 2H), 7.59 (d, 1H, J= 6.0 Hz), 7.22 (t, 1H, J = 3.0 Hz), 3.61 (s, 3H), 3.29 (s, 3H), 2.11 (s, 3H), 1.98 (m, 6H), 1.83 (m, 6H). MS (ES+) m/z (M+l) 450.15.
Example 8 4-[5-(2-Methanesulfonyl-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1 H-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester [0131] Hydrogen peroxide (0.19 mL,6.68 mmol), 4N H2S04 (0.06 mL), and NaWO4HZO
(10 mg) were added to a solution of 4-[4-(6-methyl-pyridin-2-yl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester (0.60 g, 1.34 mmol;
see Example 7 above) in methonal (20 mL). The mixture was stirred at 50 C for 10 hours. The mixture was then quenched with water and stirred for 30 minutes. Saturated Na2SZO3 aqueous solution was added to neutralize the excess hydrogen peroxide. The aqueous solution was extracted with ethyl acetate. Ethyl acetate was washed with brine, dried over sodium sulfate, filtered, and concentrated. Column chromatography eluting with ethyl acetate gave 0.5 g (91%) of the title compound as a yellow solid. 1H NMR (300 MHz, Methanol-d4) 8 8.98 (m, 1H), 8.43 (m, 1H), 8.22 (m, 1H), 8.09 (m, 1H), 7.84 (m, 1H), 3.68 (s, 3H), 3.26 (s, 3H), 2.86 (s, 3H), 2.11 (m, 6h), 1.99 (m, 6H). MS (ES+) m/z (M+1) 482.02.
Example 9 4-[5-(2-Methanesulfonyl-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl] -bicyclo[2.2.2]octane-l-carboxylic acid methyl ester [0132] 4-[5-(2-Methanesulfonyl-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester (0.30 g, 0.62 mmol; see Example 8 above) was dissolved in cyclopropylamine (10 mL) and the mixture was placed in a sealed tube. The mixture was heated at 80 C for 18 hours. Solvent was removed to give 0.285 g (99%) of the title compound as a yellow solid. 1H NMR (300 MHz, Acetone-d6) 6 8.56 (m, 1H), 8.49 (m, 1H), 8.24 (m, 1H), 7.65 (m, 2H), 3.63 (s, 3H), 2.87 (m, 1H), 2.61 (s, 3H), 2.05 (m, 6H), 1.91 (m, 6H), 0.75 (m, 2H), 0.64 (m, 2H). MS (ES+) m/z (M+1) 459.17.
Example 10 4-[5-(2-Cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl] -bicyclo [2.2.2] octane-l-carboxylic acid [0133] Lithium hydroxide monohydrate (0.10 g, 2.44 mmol) was added to 4-[5-(2-Cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)- l H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester (0.28 g, 0.61 mmol) in a mixture of THF/MeOH/HZO (2/1/1, 5 mL). The mixture was stirred for 3 h. Solvent was removed.
Residue was diluted with water (30 mL). Citric acid was added to the solution to make the pH
lower than 7. The aqueous solution was extracted with ethyl acetate. Ethyl acetate was washed with brine, dried over sodium sulfate, filtered and concentrated to give 0.27 g (99%) of the title compound as a yellow solid. 'H NMR (300 MHz, Methanol-d4) 8 8.50 (m, 1H), 8.29 (m, 2H), 7.66 (m, 1H), 7.30 (m, 1H), 2.75 (m, 1H), 2.65 (s, 3H), 2.07 (m, 6H), 1.97 (m, 6H), 0.86 (m, 2H), 0.62 (m, 2H). MS (ES+) m/z (M+l) 445.10.
Example 11 4-[5-(2-Cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo [2.2.2] octane-l-carboxylic acid amide [0134] HATU (0.17 g, 0.45 mmol) was added to a solution of 4-[5-(2-Cyclopropylamino-pyrimidin-4-yl) -4-(6-methyl-pyridin-2-yl)-1 H-imidazol-2-yl] -bicyclo [2.2.2]
octanc-l-c arboxylic acid (0.10 g, 0.225 mmol; see Example 10 above) and potassium carbonate (0.155 g, 1.13 mmol) in anhydrous DMF (5 mL). The mixture was stirred for 30 minutes. Ammonia was bubbled through the mixture for 10 minutes. The mixture was continued to stir for 2 hours. The mixture was then filtered and concentrated. HPLC purification eluting with acetonitrile:water gave 0.070 g (70%) of the title compound as a yellow solid. 1H NMR (300 MHz, Methanol-d4) S
8.50 (d, 1H, J = 5.7 Hz), 8.30 (m, 2H), 7.67 (m, 1H), 7.32 (d, 1H, J= 5.7 Hz), 2.75 (m, 1H), 2.65 (s, 3H), 2.08 (m, 6H), 1.95 (m, 6H), 0.84 (m, 2H), 0.61 (m, 2H). MS (ES+) m/z (M+l) 444.21.
[0135] The compounds listed in the following Table were prepared in an analogous manner to those described in the methods and examples above.
Example Chemical Name 1H-NMR MS Method (ES+) m/z (M+l ) Ex. 12 4-[4-(2-Methyl-pyrimidin-4-yl)- (300 MHz, Methanol-d4) d 9.00 5-quinoxalin-6-yl-lH-imidazol- (m, 2H), 8.62 (d, 1H, J = 5.4 Hz), 2-yl]-cyclohexanol 8.46 (d, 1H, J = 1.2 Hz), 8.28 (d, 1H, J = 8.7 Hz), 8.06 (m, 1H), 387.1 Ex. 1 7.37 (m, 1H), 3.68 (m, 1H), 3.31 (m, 1H), 2.66 (s, 3H), 2.22 (m, 2H), 1.92 (m, 4H), 1.51 (m, 2H) Ex. 13 4-[5-Quinoxalin-6-yl-4-(2- (300 MHz, Methanol-d4) d 8.97 trifluoromethyl-pyrimidin-4-yl)- (m, 2H), 8.87 (d, 1H, J= 6.0 Hz), 1 H-imidazol-2-yl]- 8.37 (d, 1H, J = 3.0 Hz), 8.20 (d, bicyclo[2.2.2]octan-l-ol 1H, J = 9.0 Hz), 8.06 (m, 1H), 467.35 Ex. 5 7.86 (d, 1H, J = 6.0 Hz), 2.26 (m, 6H), 1.85 (m, 6H) Ex. 14 4-[4-(2-Cyclopropyl-pyrimidin- (300 MHz, Methanol-d4) d 8.99 4-yl)-5-quinoxalin-6-yl-1H- (m, 2H), 8.58 (d, 1H, J= 6.0 Hz), imidazol-2-yl]- 8.34 (d, 1H, J = 3.0 Hz), 8.25 (d, bicyclo[2.2.2]octan-l-ol 1H, J = 9.0 Hz), 7.98 (m, 1H), 439.41 Ex. 5 7.59 (d, 1H, J= 6.0 Hz), 2.25 (m, 6H), 2.14 (m, 1H), 1.85 (m, 6H), 0.94 (m, 2H), 0.76 (m, 2H) Ex. 15 6-[2-tert-Butyl-5-(2- (300 MHz, Methanol-d4) d 9.00 cyclopropyl-pyrimidin-4-yl)- (m, 2H), 8.60 (d, 1H, J = 6.0 Hz), 3H-imidazol-4-yl]-quinoxaline 8.38 (d, 1H, J = 3.0 Hz), 8.26 (d, 1H, J = 9.0 Hz), 8.00 (m, 1H), 371.35 Ex. 5 7.59 (d, 1H, J = 6.0 Hz), 2.14 (m, 1H), 1.61 (s, 9H), 0.94 (m, 2H), 0.77 (m, 2H) Ex. 16 6-[5-(2-Cyclopropyl-pyrimidin- (300 MHz, Methanol-d4) d 9.00 4-yl)-3H-imidazol-4-yl]- (m, 2H), 8.80 (s, 1H), 8.58 (d, 1H, quinoxaline J = 6.0 Hz), 8.39 (d, 1H, J = 1.5 Hz), 8.28 (d, 1H, J = 9.0 Hz), 8.05 315.18 Ex. 5 (m, 1 H), 7.5 3 (d, 1 H, J= 6.0 Hz), 2.19 (m, 1H), 1.01 (m, 2H), 0.93 (m, 2H) Ex. 17 {4-[4-(2-Cyclopropyl- (300 MHz, Methanol-d4) d 9.00 pyrimidin-4-yl)-5-quinoxalin-6- (m, 2H), 8.58 (d, 1H, J= 3.0 Hz), yl-lH-imidazol-2-yl]- 8.35 (d, 1H, J = 3.0 Hz), 8.25 (d, bicyclo[2.2.2]oct-1-yl}- 1H, J = 9.0 Hz), 7.99 (m, 1H), 453.4 Ex. 5 methanol 7.49 (d, 1H, J = 6.0 Hz), 3.59 (s, 2H), 2.13 (m, 6H), 1.69 (m, 1 H), 1.64 (m, 6H), 0.95 (m, 2H), 0.79 (m, 2H) Ex. 18 6-[5-(2-Trifluoromethyl- (300 MHz, Methanol-d4) d 8.97 pyrimidin-4-yl)-3H-imidazol-4- (m, 2H), 8.88 (d, 1H, J = 6.0 Hz), yl]-quinoxaline 8.61 (s, 1H), 8.42 (d, 1H, J= 1.5 343.15 Ex. 5 Hz), 8.23 (d, 1 H, J = 9.0 Hz), 8.13 (m, 1 H), 7.88 (d, 1 H, J = 6.0Hz), 2.65 (s, 3H) Ex. 19 6-[2-tert-Butyl-5-(2- (300 MHz, Methanol-d4) d 8.99 trifluoromethyl-pyrimidin-4-yl)- (m, 2H), 8.91 (d, 1H, J = 6.0 Hz), 3H-imidazol-4-yl]-quinoxaline 8.42 (d, 1H, J = 3.0 Hz), 8.24 (d, 399.3 Ex. 5 1H, J =9.0 Hz), 8.06 (m, 1H), 7.84 (d, 1H, J = 6.0 Hz), 1.58 (s, 9H) Ex. 20 4-[5-Quinoxalin-6-yl-4-(2- (300 MHz, Methanol-d4) d 8.98 trifluoromethyl-pyrimidin-4-yl)- (m, 2H), 8.86 (d, 1H, J = 6.0 Hz), 1H-imidazol-2-yl]-piperidine-l- 8.44 (d, 1H, J = 1.5 Hz), 8.26 (d, carboxylic acid benzyl ester 1H, J = 9.0 Hz), 8.06 (d, 1H, J = 560.26 Ex. 5 1.5 Hz), 7.84 (d, 1H, J = 6.0 Hz), 7.35 (m, 5H), 5.13 (s, 2H), 4.37 (m, 1 H), 4.05 (m, 1 H), 3.33 (m, 1H), 3.00 (m, 2H), 2.13 (m, 4H) Ex. 21 4-[4-(2-Cyclopropyl-pyrimidin- (300 MHz, Methanol-d4) d 8.81 4-yl)-5-quinoxalin-6-yl-1H- (m, 2H), 8.45 (d, 1H, J = 6.0 Hz), imidazol-2-yl]-piperidine-l- 8.25 (d, 1H, J = 1.5 Hz), 8.11 (d, carboxylic acid benzyl ester 1H, J = 9.0 Hz), 7.83 (d, 1H, J =
9.0 Hz), 7.56 (d, 1H, J= 6.0 Hz), 532.38 Ex. 5 7.20 (m, 5H), 4.96 (s, 2H), 4.19 (m, 2H), 3.3 8(m, 1H), 2.82 (m, 2H), 1.91 (m, 5H), 0.92 (m, 2H), 0.79 (m, 2H) Ex. 22 6-[5-(2-Cyclopropyl-pyrimidin- (300 MHz, Methanol-d4) d 8.99 4-yl)-2-(1-methanesulfonyl- (s, 2H), 8.57 (d, 1H, J = 5.7 Hz), piperidin-4-yl)-3H-imidazol-4- 8.37 (d, 1H, J = 1.8 Hz), 8.26 (d, yl]-quinoxaline 1H, J = 8.7 Hz), 8.03 (dd, 1H, J =
2.1 Hz, 8.7 Hz), 7.58 (d, 1H, J = 476.47 Ex. 5 5.7 Hz), 3.93 (m, 2H), 3.21 (m, 3H), 2.65 (s, 31-1), 2.10 (m, 5H), 0.98 (m, 2H), 0.86 (m, 2H) Ex. 23 4-[5-(2-Methyl-pyrimidin-4-yl)- (300 MHz, Methanol-d4) d 9.28 4-[1,2,4]triazolo[4,3-a]pyridin- (d, 1H, J = 3.0 Hz), 8.65 (d, 1H, J
6-yl-lH-imidazol-2-yl]- = 6.0 Hz), 8.54 (s, 1H), 7.92 (m, 402.46 Ex. 5 bicyclo[2.2.2]octan-l-ol 2H), 7.65 (d, 1H, J = 6.0 Hz), 2.65 (s, 3H), 2.23 (m, 6H), 1.84 (m, 6H) Ex. 24 4-[5-(2-Methoxy-pyrimidin-4- (300 MHz, Methanol-d4) 8 8.85 yl)-4-(6-methyl-pyridin-2-yl)- (d, 1H, J = 5.1 Hz), 8.61 (m, 111), 1H-imidazol-2-yl]- 8.44 (t, 1H, J = 8.1 Hz), 7.89 (m, bicyclo[2.2.2]octane-l- 1H), 7.77 (d, 1H, J = 7.5 Hz), 4.18 434.05 Ex.
carboxylic acid methyl ester (s, 3H), 3.68 (s, 3H), 3.03 (s, 3H), 9&10 2.10 (m, 6H), 1.98 (m, 6H) Ex. 25 4-[5-(2-Hydroxy-pyrimidin-4- (300 MHz, Methanol-d4) 6 8.21 yl)-4-(6-methyl-pyridin-2-yl)- (m, 3H), 7.55 (m, 1H), 7.37 (m, 1H-imidazol-2-yl]- 1H), 3.58 (s, 3H), 2.90 (s, 3H), 420.16 Ex.
bicyclo[2.2.2]octane-l- 2.00 (m, 6H), 1.87 (m, 6H) 9&10 carboxylic acid methyl ester Ex. 26 4-[5-(2-cyclopropylamino- (300 MHz, Acetone-d6) 5 8.56 (m, pyrimidin-4-yl)-4-(6-methyl- 1H), 8.49 (m, 1H), 8.24 (m, 1H), pyridin-2-yl)-1H-imidazol-2- 7.65 (m, 2H), 3.63 (s, 3H), 2.87 yl]-bicyclo[2.2.2]octane-l- (m, 1H), 2.61 (s, 3H), 2.05 (m, 459.17 Ex.
carboxylic acid methyl ester 6H), 1.91 (m, 6H), 0.75 (m, 2H), 9&10 0.64 (m, 2H).
Ex. 27 4-[5-(2-cyclopropylamino- (300 MHz, Methanol-d4) 6 8.49 pyrimidin-4-yl)-4-(6-methyl- (m, 1H), 8.30 (m, 2H), 7.66 (m, pyridin-2-yl)-1H-imidazol-2- 1H), 7.32 (m, 1H), 2.74 (m, 1H), 460.19 Ex.
yl]-bicyclo[2.2.2]octane-1- 2.65 (s, 3H), 2.07 (m, 6H), 1.93 9&10 carboxylic acid hydroxyamide (m, 6H), 0.85 (m, 2H), 0.61 (m, 2H).
Ex. 28 4-[5-(2-cyclopropylamino- (300 MHz, Methanol-d4) b 8.49 pyrimidin-4-yl)-4-(6-methyl- (m, 1H), 8.30 (m, 2H), 7.67 (m, pyridin-2-yl)-1H-imidazol-2- 1H), 7.31 (m, 1H), 3.67 (s, 3H), yl]-bicyclo[2.2.2]octane-l- 2.75 (m, 1H), 2.65 (s, 3H), 2.06 474.21 Ex.
carboxylic acid methoxy-amide (m, 6H), 1.92 (m, 6H), 0.84 (m, 9&10 2H), 0.62 (m, 2H).
Ex. 29 4-[5-(2-amino-pyrimidin-4-yl)- (300 MHz, Methanol-d4) 6 8.50 4-(6-methyl-pyridin-2-yl)-1H- (d, 1H, J = 5.4 Hz), 8.42 (d, 1H, J
imidazol-2-yl]- = 8.1 Hz), 8.34 (t, 1H, J= 7.8 Hz), bicyclo[2.2.2]octane- 1 - 7.68 (d, 1H, J = 7.5 Hz), 7.30 (d, 405.11 Ex.
carboxylic acid 1H, J = 5.4 Hz), 2.90 (s, 3H), 2.08 9&10 (m, 6H), 1.98 (m, 6H).
Ex. 30 {4-[5-(2-Cyclopropylamino- (300 MHz, Methanol-d4) 6 8.14 pyrimidin-4-yl)-4-(6-methyl- (m, 1H), 7.73 (m, 2H), 7.31 (m, pyridin-2-yl)-1H-imidazol-2- 5H), 7.06 (m, 1H), 6.70 (m, 1H), yl]-bicyclo[2.2.2]oct-1-yl}- 5.02 (s, 2H), 2.60 (m, 1H), 2.54 (s, 550.15 Ex.
carbamic acid benzyl ester 3H), 2.10 (m, 6H), 2.00 (m, 6H), 9&10 0.79 (m, 2H), 0.45 (m, 2H) Ex. 31 N-{4-[5-(2-cyclopropylamino- (300 MHz, Methanol-d4) S 8.47 pyrimidin-4-yl)-4-(6-methyl- (m, 1H), 8.29 (m, 2H), 7.69 (m, pyridin-2-yl)-1H-imidazol-2- 1H), 7.35 (m, 1H), 2.80 (s, 3H), 458.24 Ex.
yl]-bicyclo[2.2.2]oct-1-yl}- 2.65 (s, 3H), 2.10 (m, 12H), 1.36 9&10 acetamide (m, 1H), 0.85 (m, 2H), 0.62 (m, 2H).
Ex. 32 N-{4-[5-(2-cyclopropylamino- (300 MHz, Methanol-d4) 8 8.50 pyrimidin-4-yl)-4-(6-methyl- (m, 1H), 8.30 (m, 1H), 7.65 (m, pyridin-2-yl)-1H-imidazol-2- 1H), 7.49 (m, 1H), 7.29 (m, 1H), yl]-bicyclo[2.2.2]oct-1-yl}- 2.80 (s, 3H), 2.65 (s, 3H), 2.26 (m, 494.20 Ex.
methanesulfonamide 1H), 2.10 (m, 12H), 0.84 (m, 2H), 9&10 0.61 (m, 2H).
.. .... ..... ..
Ex. 33 N-{4-[5-(2-cyclopropylamino- (300 MHz, Methanol-d4) b 8.52 pyrimidin-4-yl)-4-(6-methyl- (d, 1H, J = 5.4 Hz), 8.31 (m, 1H), pyridin-2-yl)-1H-imidazol-2- 7.66 (m, 111), 7.49 (m, 1H), 7.30 yl]-bicyclo[2.2.2]oct-l-yl}- (d, 111, J = 5.4 Hz), 2.65 (s, 3H), 512.08 Ex.
2,2,2-trifluoro-acetamide 2.26 (m, 1H), 2.15 (m, 12H), 0.84 9&10 (m, 2H), 0.60 (m, 2H).
[0136] The TGF,6 inhibitory activity of compounds of formula (I) can be assessed by methods described in the following examples.
Example 34 Cell-Free Assay for Evaluating Inhibition of Autophosphorylation of TGF# Type I
Receptor [0137] The serine-threonine kinase activity of TGF(.i type I receptor was measured as the autophosphorylation activity of the cytoplasmic domain of the receptor containing an N-terminal poly histidine, TEV cleavage site-tag, e.g., His-TGF,l3RI. The His-tagged receptor cytoplasmic kinase domains were purified from infected insect cell cultures using the Gibco-BRL FastBac HTb baculovirus expression system.
[0138] To a 96-well Nickel FlashPlate (NEN Life Science, Perkin Elmer) was added 20 L of 1.25 Ci 33P-ATP/25 M ATP in assay buffer (50 mM Hepes, 60 mM NaCl, 1 mM
MgC12, 2 mM DTT, 5 mM MnC12, 2% glycerol, and 0.015% Brij 35). 10 L of each test compound of formula (I) prepared in 5% DMSO solution were added to the FlashPlate. The assay was then initiated with the addition of 20 L of assay buffer containing 12.5 pmol of His-TGFORI to each well. Plates were incubated for 30 minutes at room temperature and the reactions were then terminated by a single rinse with TBS. Radiation from each well of the plates was read on a TopCount (Packard). Total binding (no inhibition) was defined as counts measured in the presence of DMSO solution containing no test compound and non-specific binding was defined as counts measured in the presence of EDTA or no-kinase control.
[0139] Alternatively, the reaction performed using the above reagents and incubation conditions but in a microcentrifuge tube was analyzed by separation on a 4-20% SDS-PAGE
gel and the incorporation of radiolabel into the 40 kDa His-TGF[3RI SDS-PAGE band was quantitated on a Storm Phosphoimager (Molecular Dynamics).
[0140] Compounds of formula (I) typically exhibited IC5o values of less than 10 M; some exhibited IC50 values of less than 1 M; and some even exhibited IC50 values of less than 50 nM.
Example 35 Cell-Free Assay for Evaluating Inhibition of Activin Type I Receptor Kinase Activity [0141] Inhibition of the Activin type I receptor (Alk 4) kinase autophosphorylation activity by test compounds of formula (I) can be determined in a similar manner to that described above in Example 34 except that a similarly His-tagged form of Alk 4 (His-Alk 4) is used in place of the His-TGFRRI.
Example 36 TGF# Type I Receptor Ligand Displacement FlashPlate Assay [0142] 50 nM of tritiated 4-(3-pyridin-2-yl-lH-pyrazol-4-yl)-quinoline (custom-ordered from PerkinElmer Life Science, Inc., Boston, MA) in assay buffer (50 mM Hepes, 60 mM NaC12, 1 mM MgC12, 5 mM MnC12, 2 mM 1,4-dithiothreitol (DTT), 2% Brij 35; pH 7.5) was premixed with a test compound of formula (I) in 1% DMSO solution in a v-bottom plate.
Control wells containing either DMSO without any test compound or control compound in DMSO
were used.
To initiate the assay, His-TGFO Type I receptor in the same assay buffer (Hepes, NaC12, MgC12, MnC12, DTT, and 30% Brij added fresh) was added to a nickel coated FlashPlate (PE, NEN
catalog number: SMP 107), while the control wells contained only buffer (i.e., no His-TGF,(i Type I receptor). The premixed solution of tritiated 4-(3-pyridin-2-yl-lH-pyrazol-4-yl)-quinoline and test compound of formula (I) was then added to the wells. The wells were aspirated after an hour at room temperature and radioactivity in wells (emitted from the tritiated compound) was measured using TopCount (PerkinElmer Lifesciences, Inc., Boston MA).
Compounds of formula (I) typically exhibited Ki values of less than 10 M;
some exhibited Ki values of less than 1 M; and some even exhibited Ki values of less than 50 nM.
Example 37 Assay for Evaluating Cellular Inhibition of TGF# Signaling and Cytotoxicity [0143] Biological activity of the compounds of formula (I) was determined by measuring their ability to inhibit TGF(3-induced PAI-Luciferase reporter activity in HepG2 cells.
[0144] HepG2 cells were stably transfected with the PAI-luciferase reporter grown in DMEM
medium containing 10% FBS, penicillin (100 U/mL), streptomycin (100 g/mL), L-glutamine (2 mM), sodium pyruvate (1 mM), and non-essential amino acids (lx). The transfected cells were then plated at a concentration of 2.5 x 104 cells/well in 96 well plates and starved for 3-6 hours in media with 0.5% FBS at 37 C in a 5% COZ incubator. The cells were then stimulated with 2.5 ng/mL TGF(3ligand in the starvation media containing 1% DMSO either in the presence or absence of a test compound of formula (I) and incubated as described above for 24 hours. The media was washed out the following day and the luciferase reporter activity was detected using the LucLite Luciferase Reporter Gene Assay kit (Packard, cat.
no. 6016911) as recommended. The plates were read on a Wallac Microbeta plate reader, the reading of which was used to determine the IC50 values of compounds of formula (I) for inhibiting TGFO-induced PAI-Luciferase reporter activity in HepG2 cells. Compounds of formula (I) typically exhibited IC50 values of less 10 M.
[0145] Cytotoxicity was determined using the same cell culture conditions as described above.
Specifically, cell viability was determined after overnight incubation with the CytoLite cell viability kit (Packard, cat. no. 6016901). Compounds of formula (I) typically exhibited LD25 values greater than 10 M.
Example 38 Assay for Evaluating Inhibition of TGFO Type I Receptor Kinase Activity in Cells [0146] The cellular inhibition of activin signaling activity by the test compounds of formula (I) is determined in a similar manner as described above in Example 37 except that 100 ng/mL of activin is added to serum starved cells in place of the 2.5 ng/mL TGF(.3.
Example 39 Assay for TGFO-Induced Collagen Expression Preparation of Iinmortalized Collagen Promotor-Green Fluorescent Protein Cells [0147] Fibroblasts are derived from the skin of adult transgenic mice expressing Green Fluorescent Protein (GFP) under the control of the collagen 1A1 promoter (see Krempen, K. et al., Gene Exp. 8: 151-163 (1999)). Cells are immortalized with a temperature sensitive large T
antigen that is in an active stage at 33 C. Cells are expanded at 33 C and then transferred to 37 C at which temperature the large T antigen becomes inactive (see Xu, S. et al., Exp. Cell Res.
220: 407-414 (1995)). Over the course of about 4 days and one split, the cells cease proliferating. Cells are then frozen in aliquots sufficient for a single 96 well plate.
Assay of TGFO-induced Collagen-GFP Expression [0148] Cells are thawed, plated in complete DMEM (contains non-essential amino acids, 1mM
sodium pyruvate and 2mM L-glutamine) with 10 % fetal calf serum, and then incubated for overnight at 37 C, 5% CO2. The cells are trypsinized in the following day and transferred into 96 well format with 30,000 cells per well in 50 L complete DMEM containing 2 % fetal calf serum, but without phenol red. The cells are incubated at 37 C for 3 to 4 hours to allow them to adhere to the plate. Solutions containing a test compound of formula (I) are then added to wells with no TGFO (in triplicates), as well as wells with 1 ng/mL TGFO (in triplicates). DMSO is also added to all of the wells at a final concentration of 0.1%. GFP
fluorescence emission at 530 nm following excitation at 485 nm is measured at 48 hours after the addition of solutions containing a test compound on a CytoFluor microplate reader (PerSeptive Biosystems). The data are then expressed as the ratio of TGF(3-induced to non-induced for each test sample.
OTHER EMBODIMENTS
[0149] It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims.
Other aspects, advantages, and modifications are within the scope of the following claims.
Synthesis of the Compounds of formula (I) [0103] Compounds of formula (I) may be prepared by a number of known methods from commercially available or known starting materials. In one method, compounds of formula (I) are prepared according to Schemes 1a, lb, or 1c below. Specifically, in Scheme la, optionally substituted 2-methylpyrimidine (II) is deprotonated by LDA before reacting with Rl-substituted carboxylic acid methoxy-methyl-amide (V) to form an Rl-(6-methylpyrimidinyl)-ketone (III).
R' has been defined above. The methoxy-methyl-amide can be prepared by reacting a corresponding acid chloride (i.e., R'-CO-Cl) with N, O-dimethylhydroxylamine hydrochloride.
The Rl-(6-methylpyrimidinyl)-ketone (III) can then be treated with sodium nitrite in acetic acid to afford an a-keto-oxime (IV), which can undergo further reaction with an appropriate substituted (and optionally protected) aldehyde (VI) in the presence of ammonium acetate to yield a compound of formula (I).
Scheme la (Ra r Ra~
1. LDA R1~- m Na 2. Rl ~N, OCHg 0 NN HOAc (II) O
(V) (III) 1. NHqOAc OII
NOH a HxX-Y-R2 R1 I ~R 1 ( al N
R I m (VI) \R /m ~ ~X-Y-R2 y 0 NN 2. TiCl3, MeOH or H
P(OMe)3 or P(OEt)3 NN
(IV) (I) [0104] In another method, the above-described compounds of formula (I) can be prepared according to Scheme lb below. Specifically, 1,1-dimethoxy-propan-2-one can first react with dimethoxymethyl-dimethyl-amine at an elevated temperature to produce the intermediate 4-dimethylamino-1,1-dimethoxy-but-3-en-2-one, which can then react with an Ra-substituted amidine to form an Ra-substituted pyrimidine-2-carbaldehyde (IIa). This carbaldehyde (Ila) can then reacted with aniline and diphenyl phosphite to form a resulting N,P-acetal, which can further couple with an Rl-substituted aldehyde to produced an (Rl-methyl)-pyrimidinyl-ketone (IIIa). See, e.g., Journet et al., Tetrahedron Lett. 39:1717-1720 (1998).
Treatment of the (Rl-methyl)-pyrimidinyl-ketone (Illa) with sodium nitrite in acetic acid produces an a-keto-oxime (IVa), which can undergo reaction with an appropriate substituted (and optionally protected) aldehyde (VI) to yield a compound of formula (I) as described in Scheme la above.
Scheme lb NH
O NYO neat, 80 C RaK NH HBr/H2O
+ i RaN ~
~O o/n IOI O~
O1- ~OPh R' P~OPh 1. Rl-CHO
CHO PhNH2 I~ NH Cs2CO3 O
N N N N b (Ph0)2P(O)H 2. HCI
Ra Ra Ra (Ila) (Illa) 1. NH4OAc R N, 0 /
OH H X-Y-R2 R' N
NaNOZ
I ~ O (VI) ~ }--X-Y-R2 HOAc/THF/HaO NYN H
2. TiCl3, MeOH or N N
Ra P(OMe)3 or P(OEt)3 I (I) (IVa) Ra [0 . 105] In another method, the above-described compounds of formula (I) can be prepared according to Scheme 1c below. Specifically, an (Rl-methyl)-pyrimidinyl-ketone (IIIa) (described above) can be oxidized to form a pyrimidinyl-diketone (IVb), which can undergo reaction with an appropriate substituted (and optionally protected) aldehyde (VI) to yield a compound of formula (I) as described above.
Scheme lc N ) N 0 (Ra)m ~'N Rt NBS/DMSO (Ra)m ' t N R
O O
(Illa) (IVb) 1. NHqOAc OII
HxX-Y-R ~
z (Ra)n~~ N N
(VI) ~}--X-Y-Rz 2. TiCl3, MeOH or R1 N
P(OMe)3 or P(OEt)3 H
(I) [0106] If compound (VI) is in its protected form, appropriate deprotecting agents can be applied to the resulting compound after the coupling reaction of compound (IV) or (IVa) and compound (VI) to yield a compound of formula (I). See, e.g., T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, Inc., New York (198 1), for suitable protecting groups.
[0107] Alternatively, a compound of formula (I) can be prepared by reacting intermediate (IV) or (IVa) with an aldehyde (VII) to yield a further intermediate (VIII), which can then react with compound (IX) to yield a compound of formula (I). Note that moieties Y' and Y"
are precursors of moiety Y. See Scheme 2 below. In addition, desired substitutions at Ra can be obtained by selecting, for example, the appropriate compound (IIa) intermediate.
Scheme 2 N~N 0 (IV) (Ra)m NOH 1. NH4OAc or 0 x N
H X-Y' (Ra ~~--~ Y' (IVa) (Ra)m \ N NOH (VII) 14 H
R 2. TiCl3, MeOH N,,,~,,N
O
or (VIII) N
(IVb) (Ra)m ~
R1 Y"~ R2 0 (IX) (Ra m R I N~X-Y-R2 , \ H
N,,~,,, N
(I) [0108] In some embodiments, moiety X in compound (VII) is a nitrogen-containing heterocycloalkyl (e.g., piperidine). The nitrogen ring atom can be protected by a nitrogen protecting group (e.g., Cbz, Boc, or FMOC) before coupling to compound (IV) or (IVa) and deprotected afterwards (see first step of Scheme 3) to yield compound (VIIIa).
This compound can further react with various compounds (IX) to produce a compound of formula (I). See second steps of Scheme 3 below. It should be noted that compound (VIII) or compound (VIIIa) can be a compound of formula (I) as well.
Scheme 3 N~N 0 (IV) (Ra)m \ I ' 1. NH40Ac R
or -~
1 H N-Cbz )i_3 a Ri \\~~ N o_i N ~ NOH (yll) ( \ Deprotection (using R \m Y ~~-( N-Cbz ~-(h ~ s agents,e.g.,H2, Pd/C
(IVa) (Ra)m ~ \Y N
R' 2. TiCl3, MeOH NvN H ortiBr/HOAc) O
or (VIII) \
(lVb) (Ra)m N O R' O R2SO2CI (IX) (Ra \ R~~~ N) o-~
I DIEA /\ ~ N-SO~RZ
( \ H 1-3 N,,~,, N
(I) RaOCOCI (IX) (R R' N ) o-~ O
aJ,~ Y -l( NaHCO3 \~ ~ \ N O-Rz r' \YI H )i-3 N,,,N
(I) R' N
(Ra 1 \~N
1-3 H NH R2NC0 (IX) ~R R1 N )o-t ,,O'R
1~
N \ 2 N~N DIEA H t 3 H z (Villa) N,,~,,N
(I) R2COCI (IX) or (R
RZ al N ) o-~ 0 ' \ N-~
COH (IX), DIEA or I 1-3 R2 R2COOH (IX), N~ N H
coupling agent, e.g., ~
HATU (I) R' RZCHO (IX) (Ra 1 N ) o-i NaB(OAc)3H /\ I ~N~ z ~H/13 R
N,,,, N
(I) [0109] Similarly, when moiety X in compound (VII) is a cycloalkyl (e.g., cyclopentyl, cyclohexyl, or bicyclo[2.2.2]octane), it can be further functionalized to form a compound of formula (I) as depicted in Schemes 4, 5a, 5b, and 5c below.
Scheme 4 N'- N 0 (IV) (Ra)m 1 R 1. NH4OAc NOH
t N o-, NHCbz 0 NHCbz r ~ RI
or ~ )o-t (R'~m )1-3 H Deprotection (using N__'_N NOH H (VII) N ),., (IVa) (Ra)m-\ I NvN agents,e.g.,H2,Pd/C
RI 2. TiC13, MeOH (VIII) orHBr/HOAc) or /Ra Rt N o-~ NHSO2R2 N\ 0 R~SO2CI (IX) ai (IVb) (~''a)m ' / t DIEA H )~'3 - II R N N
O
(I) R2OCOCI (IX) ~ Ra m R1 N o-~ oN--~ 2 O-R
NaHCO3 N )1-a ~
N,,:,, N
(I) R' Ra N a-, NH2 RI I..I~O
m ~\ I N ),a R2NCO (IX) (Ra lm I N a~ N NR2 H DIEA /\ \ H~ H
NI~/ N (I
(Villa) N,,'~,, N
(I) R2COCI (IX) or Rt N 0-1 N40 R2COH (IX), DIEA or ~ R Rz R COOH (IX), coupling ~iV H )1-3 agent, e.g., HATU N,,Z~,- IN
(I) R2CHO (IX) (Ra Rt N o-~ N-\NaB(OAc)3H ~ 0-1 R~
II~H )7-3 NvN
(I) Scheme 5a N~N 0 (IV) (Ra)m \ YR1 NOH 1. NH4OAc or 0 H~COOMe R1 N
N~N NOH (VII) ( lRa ~ 'Z~~COOMe (A) (IVa) (Ra)m -\ ~ \ \ H
R1 2. TiCl3, MeOH N~N
or (I) \
(IVb) (RB)m N O R1 O rRa,1 R1 N j~COOH
\ m\ ~~(' \~-Deprotection \ ~/
(using reagents, N ~ N H
e.g., LiOH) (I) (can be further modified according to Scheme 5b below) N~ R
(IV) (Ra)m i 1 NOH 1. NH4OAc or 0 H-1-&OH
Ra R1 (VII) ~ J N
N N NOH m\ ~OH
(B) (IVa) (Ra)m 1 \ N
R 2. TiCi3, MeOH NI~N H
or (I) N \ 0 (IVb) (Ra)m ' N~ ~Rl 0 (RaR1 N
NH(Rb)SOzCI \\ N~~OSOaNH(Rb) II
N~N H
(I) Scheme 5b ~ Ra) Rt N~ /~\ (Ra ~ Rt N 0 \ ?-E'\~-COOH RZOH m m ~
(~) \ H \\ H OR2 N:~, N
(I) (~) ( R a ~ R ~ t N ~ (Ra ~ Rt N 0 )---~~-COOH RZNHa m (2) \ \ H ~~// fl \\ H~ NHRz N~N NvN
(~) (I) a Rt /~ / a R
3 ~R\ll\>__--CooH m RzSOaNH(Rb) lR ~ t N
~// N NHSOZR2 N~N EDC,DMAP \ ~H
N~N
(I) (i) (Ra \ Rt N
~'COOH 1. HATU, NH3 (Ra ) Rt N' ~--~
H 2. 2reducing agents ~I I ~%~-(~~~/ -~.
(4) NvN (e.g., BH3=THF) I \ H NHz N,,N
(i) (~) (can be further modified according to Scheme 5c below) (Ra / Ri N/~ Rt \m\~ ~~-f' \~-COOH diohenvlohosohorvlazide (Ra ~ N~
14 ~/ DIEA, benzyl alcohol, toluene \\ ~ H NH O
(5) N~ vN H
N~N O~-(I) (~) H2, Pd/C or (Ra ) Rt N~ /~\
l \rIm }-(~\k NHa HBr/HOAc \ H ~-/
NvN
(I) (can be further modified according to Scheme 5c below) (Ra ) R' NBH3=THF (Ra ~ R' N OH 2 COOH R SO,CI
DIEA, THF
(s \\ ) H THF \ H
NvN NvN
(1) (1) (Ra ~ R~ (R ) ~ N
\ N NaCN a R
m I ~
( ~O-~oR2 DMF \ N CN
N~N H O ~ N,,,, N H
aN3 LiCI / NHaCI HCI / H2O
(Ra ) R~ N
\~ \ r 1 (Ra ~ R1 N
H
'N \NCOOH
NN HN-N (I) /Ra ' R~ N (Ra ) R~' N /~ Trifluoroactic ' I\ ~~--( \~-COOH HATU, NH3 \ \ ~)- (~~CONH2 anhydride (7) N ~/ DMF ~\ H"N ~// Pyridine, THF
N,,,, N H N,,:~,, N
(1) (1) a R~
( R m\ ~ N C N NaN3 (Ra ~m R1 I N N-N
\H LiCl / NH4CI \~ NN N
N~iN N ~ N H H
Scheme 5c /~ ooNHSO2R2 RZSOZCI (IX) (Ra ) R~ N
DIEA ~~--f\i}-F~
H
N,,,,N
(I) O
R2OCOCI (IX) (Ra ) Ri N' N4 a m O
NaHCO3 ~ H
NN
(1) (Ra ) R' N NHa O
I N~ ~o R2NCO (IX) (Ra ) F''1 N N~ 2 r~ H DIEA \\ H-R
N~N r % H
(~) N,,Z~,, N
(~) R2COCI (IX) or Rt HO
R2COH (IX), DIEA or (Ra ~m I N~a R2 R2COOH (IX), coup ing N
agent, e.g., HATU H
NN (') R2CHO (IX) (Ra ) NN- \ z m R
NaB(OAc)3H N
~ H
N,,::~, N
(~) [01101 As is well known to a skilled person in chemistry, desired substitutions can be placed on the pyrimidinyl ring in the last steps of the synthesis. See Scheme 6 below, for example.
Scheme 6 sl~ O, S%O HN14~
N)IIN N'I" N NJ\\N H
N H202, NaWO4HZO / HZN-a / N
~} -X-Y-R2 ~ --X-Y-Rz , X-Y-R Z
R~ N HZSO4, MeOH R' N Reflux R' N
(I) (I) (I) [0111] Compounds of formula (I) wherein Rb is not hydrogen can be prepared by known methods. For example, compounds of formula (I) wherein Al is N and A2 is NH
(or vice versa) can be treated with R1(e.g., alkyl iodide) and CsCO3 to produce a compound of formula (I) wherein Rb is alkyl. See, e.g., Liverton, et al., J. Med. Chem., 42: 2180-2190 (1999).
[0112] As will be obvious to a skilled person in the art, some starting materials and intermediates may need to be protected before undergoing synthetic steps as described above.
For suitable protecting groups, see, e.g., T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, Inc., New York (1981).
Uses of Compounds of formula (I) [0113] As discussed above, hyperactivity of the TGFO family signaling pathways can result in excess deposition of extracellular matrix and increased inflammatory responses, which can then lead to fibrosis in tissues and organs (e.g., lung, kidney, and liver) and ultimately result in organ failure. See, e.g., Border, W.A. and Ruoslahti E. J. Clin. Invest. 90: 1-7 (1992) and Border, W.A. and Noble, N.A. N. Engl. J. Med. 331: 1286-1292 (1994). Studies have been shown that the expression of TGFO and/or activin mRNA and the level of TGFO and/or activin are increased in patients suffering from various fibrotic disorders, e.g., fibrotic kidney diseases, alcohol-induced and autoimmune hepatic fibrosis, myelofibrosis, bleomycin-induced pulmonary fibrosis, and idiopathic pulmonary fibrosis. Elevated TGF(3 and/or activin is has also been demonstrated in cachexia, demyelination of neurons in multiple sclerosis, Alzheimer's disease, cerebral angiopathy and hypertension.
[0114] Compounds of formula (I), which are antagonists of the TGFO family type I receptors Alk 5 and/or Alk 4, and inhibit TGFO and/or activin signaling pathway, are therefore useful for treating and/or preventing fibrotic disorders or diseases mediated by an increased level of TGFO
and/or activin activity. As used herein, a compound inhibits the TGFO family signaling pathway when it binds (e.g., with an IC50 value of less than 10 M; such as, less than 1 M; and for example, less than 5 nM) to a receptor of the pathway (e.g., Alk 5 and/or Alk 4), thereby competing with the endogenous ligand(s) or substrate(s) for binding site(s) on the receptor and reducing the ability of the receptor to transduce an intracellular signal in response to the endogenous ligand or substrate binding. The aforementioned disorders or diseases include any condition (a) marked by the presence of an abnormally high level of TGFO
and/or activin; and/or (b) an excess accumulation of extracellular matrix; and/or (c) an increased number and synthetic activity of myofibroblasts. These disorders or diseases include, but are not limited to, fibrotic conditions such as scleroderma, glomerulonephritis, diabetic nephropathy, lupus nephritis, hypertension-induced nephropathy, ocular or comeal scarring, alimentary track or gastrointestinal fibrosis, renal fibrosis, hepatic or biliary fibrosis, acute lung injury, pulmonary fibrosis (such as idiopathic pulmonary fibrosis and radiation-induced pulmonary fibrosis), post-infarction cardiac fibrosis, fibrosclerosis, fibrotic cancers, fibroids, fibroma, fibroadenomas, and fibrosarcomas. Other fibrotic conditions for which preventive treatment with compounds of formula (I) can have therapeutic utility include radiation-induced fibrosis, chemotherapy-induced fibrosis, and surgically-induced scarring including surgical adhesions, laminectomy, and coronary restenosis.
[0115] Increased TGFO activity is also found to manifest in patients with progressive cancers.
Studies have shown that in many cancers, the tumor cells, stromal cells, and/or other cells within a tumor generally overexpress TGF,6. This leads to stimulation of angiogenesis and cell motility, suppression of the immune system, and/or increased interaction of tumor cells with the extracellular matrix. See, e.g., Hojo, M. et al., Nature 397: 530-534 (1999) and Lammerts E. et al., Int. J. Cancer 102: 453-462 (2002). As a result, the tumors grow more readily, become more invasive and metastasize to distant organs. See, e.g., Maehara, Y. et al., J. Clin. Oncol.
17: 607-614 (1999) and Picon, A. et al., Cancet Epidemiol. Bi markers Prev.
7: 497-504 (1998).
Thus, compounds of formula (I), which are antagonists of the TGFO type I
receptor and inhibit TGFO signaling pathways, are also useful for treating and/or preventing various cancers which overexpress TGFO or benefit from TGFO's above-mentioned pro-tumor activities.
Such cancers include carcinomas of the lung, breast, liver, biliary tract, gastrointestinal tract, head and neck, pancreas, prostate, cervix as well as multiple myeloma, melanoma, glioma, and glioblastomas.
[0116] Importantly, it should be pointed out that because of the chronic, and in some cases localized, nature of disorders or diseases mediated by overexpression of TGFO
and/or activin (e.g., fibrosis or cancers), small molecule treatments (such as treatment disclosed in the present invention) are favored for long-term treatment.
[0117] Not only are compounds of formula (I) useful in treating disorders or diseases mediated by high levels of TGFO and/or activin activity, these compounds can also be used to prevent the same disorders or diseases. It is known that polymorphisms leading to increased TGFO and/or activin production have been associated with fibrosis and hypertension.
Indeed, high serum TGFO levels are correlated with the development of fibrosis in patients with breast cancer who have received radiation therapy, chronic graft-versus-host-disease, idiopathic interstitial pneumonitis, veno-occlusive disease in transplant recipients, and peritoneal fibrosis in patients undergoing continuous ambulatory peritoneal dialysis. Thus, the levels of TGFO
and/or activin in serum and of TGFO and/or activin mRNA in tissue can be measured and used as diagnostic or prognostic markers for disorders or diseases mediated by overexpression of TGFO and/or activin, and polymorphisms in the gene for TGFO that determine the production of TGFO and/or activin can also be used in predicting susceptibility to disorders or diseases. See, e.g., Blobe, G.C. et al., N. Engl. J. Med. 342(18): 1350-1358 (2000); Matsuse, T. et al., Am. J. Respir. Cell Mol. Biol. 13: 17-24 (1995); Inoue, S. et al., Biochem. Biophys. Res. Comm.
205: 441-448 (1994); Matsuse, T. et al, Am. J Pathol. 148: 707-713 (1996); De Bleser et al., Hepatology 26:
905-912 (1997); Pawlowski, J.E., et al., J Clin. Invest. 100: 639-648 (1997);
and Sugiyama, M.
et al., Gastroenterology 114: 550-558 (1998).
ADMINISTRATION OF COMPOUNDS OF FORMULA (I) [0118] As defined above, an effective amount is the amount required to confer a therapeutic effect on the treated patient. For a compound of formula (I), an effective amount can range, for example, from about 1 mg/kg to about 150 mg/kg (e.g., from about 1 mg/kg to about 100 mg/kg). Effective doses will also vary, as recognized by those skilled in the art, dependant on route of administration, excipient usage, and the possibility of co-usage with other therapeutic treatments including use of other therapeutic agents and/or radiation therapy.
[0119] Compounds of formula (I) can be administered in any manner suitable for the administration of pharmaceutical compounds, including, but not limited to, pills, tablets, capsules, aerosols, suppositories, liquid formulations for ingestion or injection or for use as eye or ear drops, dietary supplements, and topical preparations. The pharmaceutically acceptable compositions include aqueous solutions of the active agent, in an isotonic saline, 5% glucose or other well-known pharmaceutically acceptable excipient. Solubilizing agents such as cyclodextrins, or other solubilizing agents well-known to those familiar with the art, can be utilized as pharmaceutical excipients for delivery of the therapeutic compounds. As to route of administration, the compositions can be administered orally, intranasally, transdermally, intradermally, vaginally, intraaurally, intraocularly, buccally, rectally, transmucosally, or via inhalation, implantation (e.g., surgically), or intravenous administration.
The compositions can be administered to an animal (e.g., a mammal such as a human, non-human primate, horse, dog, cow, pig, sheep, goat, cat, mouse, rat, guinea pig, rabbit, hamster, gerbil, or ferret, or a bird, or a reptile, such as a lizard).
[0120] Optionally, compounds of formula (I) can be administered in conjunction with one or more other agents that inhibit the TGF(3 signaling pathway or treat the corresponding pathological disorders (e.g., fibrosis or progressive cancers) by way of a different mechanism of action. Examples of these agents include angiotensin converting enzyme inhibitors, nonsteroid and steroid anti-inflammatory agents, immunotherapeutics, chemotherapeutics, as well as agents that antagonize ligand binding or activation of the TGFO receptors, e.g., anti-TGFO, anti-TGF,(3 receptor antibodies, or antagonists of the TGFO type II receptors. Compounds of formula (I) can also be administered in conjunction with other treatments, e.g., radiation.
The invention will be iurther described in the following examples, which do not limit the scope of the invention described in the claims.
Example 1 4-[1-Hydroxy-4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo [1,5-a] pyridin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester Synthesis of the title compound is described in parts (a)-(b) below.
(a) 1-(2-Methyl-pyrimidin-4-yl)-2-[1,2,4]triazolo[1,5-a]pyridin-6-yl-ethane-1,2-dione 2-oxime (IVa) [0121] Sodium nitrite (1.03 g, 15 mmol) was added to a solution of 1-(2-methyl-pyrimidin-4-yl)-2-[1,2,4]triazolo[1,5-a]pyridin-6-yl-ethanone (prepared according to Scheme lb above) (2.5 g, 10 mmol) in a nzixture of HOAc/THF/HZO (6:4:1, 55 mL). The mixture was stirred at 0 C
for 1 hour and then room temperature for 1 hour. Solvent was removed under reduced pressure.
Residue was dissolved in water and NaOH (3N) was added until the pH was greater than 8. The aqueous solution was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated to give 1.8 g (64%) of the title compound as a yellow foam.
(b) 4-[1-Hydroxy-4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo[1,5-a]pyridin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester [0122] 4-Formyl-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester (0.170 g, 1.0 mmol) was added to a solution of 1-(2-methyl-pyrimidin-4-yl)-2-[1,2,4]triazolo[1,5-a]pyridin-6-yl-ethane-1,2-dione 2-oxime (0.282 g, 1 mmol) and ammonium acetate (1.54 g, 20 mmol) in acetic acid (5 mL). The mixture was refluxed for 3 hours. Solvent was removed under reduced pressure. The reaction mixture was then quenched with an ammonia/ice mixture. The aqueous solution was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated to give 0.400g (87%) of the title compound as a yellow solid.
Example 2 4-[4-(2-Methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo [1,5-a] pyridin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester [0123] Triethylphosphite (0.343 uL, 2.0 mmol) was added to a solution of 4-[1-hydroxy-4-(2-methyl-pyrimidin-4-yl)-5-[ 1,2,4]triazolo[ 1,5-a]pyridin-6-yl-1 H-irnidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester (0.40 g, 0.87 mmol; see Example 1 above) in DMF (10 mL). The mixture was heated at 110 C for 18 hours. The solvent was removed.
The residue was portioned between ethyl acetate and brine. The organic layer was dried over sodium sulfate, filtered, and concentrated to give a yellow oil. HPLC
purification gave 0.30 g (77%) of the title compound as a yellow oil. 1H NMR (300 MHz, Methanol-d4) S
9.32 (s, 1H), 8.69 (d, 1H, J = 5.7 Hz), 8.58 (s, 1H), 7.93 (m, 2H), 7.74 (d, 1H, J = 5.7 Hz), 3.68 (s, 3H), 2.65 (s, 3H), 2.15 (m, 6H), 1.99 (m, 6H). MS (ES+) m/z (M+l) 444.24.
Example 3 4-[4-(2-Methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo [1,5-a]pyridin-6-yl-lH-imidazol-2-yl]-bicyclo [2.2.2] octane-l-carboxylic acid [0124] Lithium hydroxide monohydrate (0.046 g, 1.12 mmol) was added to a solution of 4-[4-(2-methyl-pyrimidin-4-yl)-5-[ 1,2,4]triazolo[ 1,5-a]pyridin-6-yl-1 H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester (0.25 g, 0.56 mmol) in a mixture of THF/MeOH/H20 (2/1/1, 4 mL). The mixture was stirred for 3 hours, and the solvent was removed. The residue was diluted with water (30 mL). Citric acid was added to the solution to make the pH lower than 7. The aqueous solution was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated to give 0.180 g (75%) of the title compound as a yellow solid. 1H NMR (300 MHz, Methanol-d4) 6 9.29 (s, 1H), 8.65 (d, 1H, J= 5.4 Hz), 8.54 (s, 1H), 7.91 (m, 2H), 7.67 (d, 1H, J = 5.7 Hz), 2.64 (s, 3H), 2.14 (m, 6H), 2.00 (m, 6H). MS (ES+) m/z (M+1) 430.28.
Example 4 4-[4-(2-Methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo [1,5-a]pyridin-6-yl-lH-imidazol-2-yl]-bicyclo [2.2.2] octane-l-carboxylic acid amide [0125] HATU (0.265 g, 0.70 mmol) was added to a solution of 4-[4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo[1,5-a]pyridin-6-yl-lH-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid (0.150 g, 0.35 mmol) and potassium carbonate (0.1242 g, 1.75 mmol) in DMF (5 mL). The mixture was stirred for 10 minutes. NH3 was bubbled into the reaction mixture for 10 minutes.
The mixture was stirre for an additional2 hours. The mixture was filtered, and DMF was removed under reduced pressure. The residue was dissolved in DMSO and the DMSO
solution was filtered. HPLC purification of the DMSO solution gave 0.040 g (27%) of the title compound as a yellow solid. 1H NMR (300 MHz, Methanol-d4) S 9.30 (s, 1H), 8.67 (d, 1H, J
6.0 Hz), 8.56 (s, 1H), 7.92 (m, 2H), 7.69 (d, 1H, J = 6.0 Hz), 2.65 (s, 3H), 2.15 (m, 6H), 1.99 (m, 6H). MS (ES+) m/z (M+1) 429.25.
Example 5 4-[4-(2-Methyl-pyrimidin-4-y1)-5-quinoxalin-6-yl-lH-imidazol-2-yl]-bicyclo [2.2.2] octan-l-ol Synthesis of the title compound is described in parts (a)-(b) below.
(a) 1-(2-Methyl-pyrimidin-4-yl)-2-quinoxalin-6-yl-ethane-1,2-dione (IVb) [0126] To a solution of 2-(2-methyl-pyrimidin-4-yl)-1-quinoxalin-6-yl-ethanone (0.500 g, 1.9 mmol; prepared according to Scheme lb above)) in DMSO (5 mL) was added NBS
(0.337 g, 1.9 mmol) and then stirred at room temperature for 3 days. The mixture was partitioned between ether and water. Ether was washed with brine, dried over sodium sulfate, filtered and concentrated to give 0.200 g (38%) of 1-(2-methyl-pyrimidin-4-yl)-2-quinoxalin-6-yl-ethane-1,2-dione as a yellow solid.
(b) 4-[4-(2-Methyl-pyrimidin-4-y1)-5-quinoxalin-6-y1-1H-imidazol-2-y1]-bicyclo[2.2.2]octan-1-ol [0127] 4-Hydroxy-bicyclo [2.2.2] octane- 1 -carbaldehyde (0.130 g, 0.86 mmol) was added to a solution of 1-(2-methyl-pyrimidin-4-yl)-2-quinoxalin-6-yl-ethane-l,2-dione (0.200 g, 0.72 mmol) and ammonium acetate (0.554 g, 7.2 mmol) in acetic acid (10 mL). The mixture was reflux for 3 hours. Solvent was removed under reduced pressure. Reaction mixture was then quenched with ammonia/ice mixture. The aqueous solution was extracted with ethyl acetate.
Ethyl acetate was washed with brine, dried over sodium sulfate, filtered, and concentrated.
HPLC purification eluting with acetonitrile:water gave 0.06 g (20%) of the title compound as a yellow solid. 1H NMR (300 MHz, Methanol-d4) S 8.99 (m, 2H), 8.63 (d, 1H, J=
5.8 Hz), 8.43 (d, 1H, J = 1.8 Hz), 8.25 (d, 1H, J = 8.7 Hz), 8.03 (m, 1H), 7.47 (d, 1H, J =
5.7 Hz), 2.30 (m, 6H), 1.87 (m, 6H). MS (ES) m/z (M+l) 413.28.
Example 6 4-[1-Hydroxy-4-(6-methyl-pyridin-2-yl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester Synthesis of the title compound is described in parts (a)-(b) below.
(a) 1-(6-Methyl-pyridin-2-y1)-2-(4-methylsulfanyl-pyrimidin-2-y1)-ethane-1,2-dione 2-oxime (IV) [0128] Sodium nitrite (0.479 g, 6.9 mmol) was added to a solution of 1-(6-methyl-pyridin-2-yl)-2-(4-methylsulfanyl-pyrimidin-2-yl)-ethanone (1.2 g, 4.6 mmol; prepared according to Scheme 1 above) in a mixture of HOAc/THF/H20 (6:4:1, 35 mL). The mixture was stirred at 0 C for 1 hour and then at room temperature for another hour. Solvent was removed under reduced pressure. Residue was dissolved in water, to which NaOH (3N) was added until pH was larger than 8. The aqueous solution was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated to give 1.3 g (98%) of the title oxime as a yellow foam.
(b) 4-[1-Hydroxy-4-(6-methyl-pyridin-2-yl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester [0129] 4-Formyl-bicyclo[2.2.2]octane-l-earboxylic acid methyl ester (0.72 g, 2.5 mmol) was added to a solution of 1-(6-methyl-pyridin-2-yl)-2-(4-methylsulfanyl-pyrimidin-2-yl)-ethane-1,2-dione 2-oxime (0.6 g, 2.1 mmol) and ammonium acetate (3.1 g, 40 mmol) in acetic acid (30 mL). The mixture was reflux for 2 hours. Solvent was removed under reduced pressure.
Reaction mixture was then quenched with ammonia/ice mixture. The aqueous solution was extracted with ethyl acetate. Ethyl acetate was washed with brine, dried over sodium sulfate, filtered, and concentrated to 0.9 g (92%) of the title methyl ester as a yellow solid.
Example 7 4-[4-(6-Methyl-pyridin-2-yl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester [0130] Trimethylphosphite (1.0 mL, 9.7 mmol) was added to a solution of 4-[1-hydroxy-4-(6-methyl-pyridin-2-yl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1 H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester (0.9 g, 1.93 mmol; see Example 6 above) in DMF (10 mL). The mixture was stirred at 110 C for 18 hours. Solvent was removed to give a yellow oil. Column chromatography eluting with ethyl acetate:hexanes (50:50) gave 0.8 g (97%) of the title compound as a yellow solid. 1H NMR (300 MHz, DMSO-d6) S
12.25 (s, 1H), 8.51 (m, 1H), 7.71 (m, 2H), 7.59 (d, 1H, J= 6.0 Hz), 7.22 (t, 1H, J = 3.0 Hz), 3.61 (s, 3H), 3.29 (s, 3H), 2.11 (s, 3H), 1.98 (m, 6H), 1.83 (m, 6H). MS (ES+) m/z (M+l) 450.15.
Example 8 4-[5-(2-Methanesulfonyl-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1 H-imidazol-2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester [0131] Hydrogen peroxide (0.19 mL,6.68 mmol), 4N H2S04 (0.06 mL), and NaWO4HZO
(10 mg) were added to a solution of 4-[4-(6-methyl-pyridin-2-yl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester (0.60 g, 1.34 mmol;
see Example 7 above) in methonal (20 mL). The mixture was stirred at 50 C for 10 hours. The mixture was then quenched with water and stirred for 30 minutes. Saturated Na2SZO3 aqueous solution was added to neutralize the excess hydrogen peroxide. The aqueous solution was extracted with ethyl acetate. Ethyl acetate was washed with brine, dried over sodium sulfate, filtered, and concentrated. Column chromatography eluting with ethyl acetate gave 0.5 g (91%) of the title compound as a yellow solid. 1H NMR (300 MHz, Methanol-d4) 8 8.98 (m, 1H), 8.43 (m, 1H), 8.22 (m, 1H), 8.09 (m, 1H), 7.84 (m, 1H), 3.68 (s, 3H), 3.26 (s, 3H), 2.86 (s, 3H), 2.11 (m, 6h), 1.99 (m, 6H). MS (ES+) m/z (M+1) 482.02.
Example 9 4-[5-(2-Methanesulfonyl-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl] -bicyclo[2.2.2]octane-l-carboxylic acid methyl ester [0132] 4-[5-(2-Methanesulfonyl-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester (0.30 g, 0.62 mmol; see Example 8 above) was dissolved in cyclopropylamine (10 mL) and the mixture was placed in a sealed tube. The mixture was heated at 80 C for 18 hours. Solvent was removed to give 0.285 g (99%) of the title compound as a yellow solid. 1H NMR (300 MHz, Acetone-d6) 6 8.56 (m, 1H), 8.49 (m, 1H), 8.24 (m, 1H), 7.65 (m, 2H), 3.63 (s, 3H), 2.87 (m, 1H), 2.61 (s, 3H), 2.05 (m, 6H), 1.91 (m, 6H), 0.75 (m, 2H), 0.64 (m, 2H). MS (ES+) m/z (M+1) 459.17.
Example 10 4-[5-(2-Cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl] -bicyclo [2.2.2] octane-l-carboxylic acid [0133] Lithium hydroxide monohydrate (0.10 g, 2.44 mmol) was added to 4-[5-(2-Cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)- l H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester (0.28 g, 0.61 mmol) in a mixture of THF/MeOH/HZO (2/1/1, 5 mL). The mixture was stirred for 3 h. Solvent was removed.
Residue was diluted with water (30 mL). Citric acid was added to the solution to make the pH
lower than 7. The aqueous solution was extracted with ethyl acetate. Ethyl acetate was washed with brine, dried over sodium sulfate, filtered and concentrated to give 0.27 g (99%) of the title compound as a yellow solid. 'H NMR (300 MHz, Methanol-d4) 8 8.50 (m, 1H), 8.29 (m, 2H), 7.66 (m, 1H), 7.30 (m, 1H), 2.75 (m, 1H), 2.65 (s, 3H), 2.07 (m, 6H), 1.97 (m, 6H), 0.86 (m, 2H), 0.62 (m, 2H). MS (ES+) m/z (M+l) 445.10.
Example 11 4-[5-(2-Cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo [2.2.2] octane-l-carboxylic acid amide [0134] HATU (0.17 g, 0.45 mmol) was added to a solution of 4-[5-(2-Cyclopropylamino-pyrimidin-4-yl) -4-(6-methyl-pyridin-2-yl)-1 H-imidazol-2-yl] -bicyclo [2.2.2]
octanc-l-c arboxylic acid (0.10 g, 0.225 mmol; see Example 10 above) and potassium carbonate (0.155 g, 1.13 mmol) in anhydrous DMF (5 mL). The mixture was stirred for 30 minutes. Ammonia was bubbled through the mixture for 10 minutes. The mixture was continued to stir for 2 hours. The mixture was then filtered and concentrated. HPLC purification eluting with acetonitrile:water gave 0.070 g (70%) of the title compound as a yellow solid. 1H NMR (300 MHz, Methanol-d4) S
8.50 (d, 1H, J = 5.7 Hz), 8.30 (m, 2H), 7.67 (m, 1H), 7.32 (d, 1H, J= 5.7 Hz), 2.75 (m, 1H), 2.65 (s, 3H), 2.08 (m, 6H), 1.95 (m, 6H), 0.84 (m, 2H), 0.61 (m, 2H). MS (ES+) m/z (M+l) 444.21.
[0135] The compounds listed in the following Table were prepared in an analogous manner to those described in the methods and examples above.
Example Chemical Name 1H-NMR MS Method (ES+) m/z (M+l ) Ex. 12 4-[4-(2-Methyl-pyrimidin-4-yl)- (300 MHz, Methanol-d4) d 9.00 5-quinoxalin-6-yl-lH-imidazol- (m, 2H), 8.62 (d, 1H, J = 5.4 Hz), 2-yl]-cyclohexanol 8.46 (d, 1H, J = 1.2 Hz), 8.28 (d, 1H, J = 8.7 Hz), 8.06 (m, 1H), 387.1 Ex. 1 7.37 (m, 1H), 3.68 (m, 1H), 3.31 (m, 1H), 2.66 (s, 3H), 2.22 (m, 2H), 1.92 (m, 4H), 1.51 (m, 2H) Ex. 13 4-[5-Quinoxalin-6-yl-4-(2- (300 MHz, Methanol-d4) d 8.97 trifluoromethyl-pyrimidin-4-yl)- (m, 2H), 8.87 (d, 1H, J= 6.0 Hz), 1 H-imidazol-2-yl]- 8.37 (d, 1H, J = 3.0 Hz), 8.20 (d, bicyclo[2.2.2]octan-l-ol 1H, J = 9.0 Hz), 8.06 (m, 1H), 467.35 Ex. 5 7.86 (d, 1H, J = 6.0 Hz), 2.26 (m, 6H), 1.85 (m, 6H) Ex. 14 4-[4-(2-Cyclopropyl-pyrimidin- (300 MHz, Methanol-d4) d 8.99 4-yl)-5-quinoxalin-6-yl-1H- (m, 2H), 8.58 (d, 1H, J= 6.0 Hz), imidazol-2-yl]- 8.34 (d, 1H, J = 3.0 Hz), 8.25 (d, bicyclo[2.2.2]octan-l-ol 1H, J = 9.0 Hz), 7.98 (m, 1H), 439.41 Ex. 5 7.59 (d, 1H, J= 6.0 Hz), 2.25 (m, 6H), 2.14 (m, 1H), 1.85 (m, 6H), 0.94 (m, 2H), 0.76 (m, 2H) Ex. 15 6-[2-tert-Butyl-5-(2- (300 MHz, Methanol-d4) d 9.00 cyclopropyl-pyrimidin-4-yl)- (m, 2H), 8.60 (d, 1H, J = 6.0 Hz), 3H-imidazol-4-yl]-quinoxaline 8.38 (d, 1H, J = 3.0 Hz), 8.26 (d, 1H, J = 9.0 Hz), 8.00 (m, 1H), 371.35 Ex. 5 7.59 (d, 1H, J = 6.0 Hz), 2.14 (m, 1H), 1.61 (s, 9H), 0.94 (m, 2H), 0.77 (m, 2H) Ex. 16 6-[5-(2-Cyclopropyl-pyrimidin- (300 MHz, Methanol-d4) d 9.00 4-yl)-3H-imidazol-4-yl]- (m, 2H), 8.80 (s, 1H), 8.58 (d, 1H, quinoxaline J = 6.0 Hz), 8.39 (d, 1H, J = 1.5 Hz), 8.28 (d, 1H, J = 9.0 Hz), 8.05 315.18 Ex. 5 (m, 1 H), 7.5 3 (d, 1 H, J= 6.0 Hz), 2.19 (m, 1H), 1.01 (m, 2H), 0.93 (m, 2H) Ex. 17 {4-[4-(2-Cyclopropyl- (300 MHz, Methanol-d4) d 9.00 pyrimidin-4-yl)-5-quinoxalin-6- (m, 2H), 8.58 (d, 1H, J= 3.0 Hz), yl-lH-imidazol-2-yl]- 8.35 (d, 1H, J = 3.0 Hz), 8.25 (d, bicyclo[2.2.2]oct-1-yl}- 1H, J = 9.0 Hz), 7.99 (m, 1H), 453.4 Ex. 5 methanol 7.49 (d, 1H, J = 6.0 Hz), 3.59 (s, 2H), 2.13 (m, 6H), 1.69 (m, 1 H), 1.64 (m, 6H), 0.95 (m, 2H), 0.79 (m, 2H) Ex. 18 6-[5-(2-Trifluoromethyl- (300 MHz, Methanol-d4) d 8.97 pyrimidin-4-yl)-3H-imidazol-4- (m, 2H), 8.88 (d, 1H, J = 6.0 Hz), yl]-quinoxaline 8.61 (s, 1H), 8.42 (d, 1H, J= 1.5 343.15 Ex. 5 Hz), 8.23 (d, 1 H, J = 9.0 Hz), 8.13 (m, 1 H), 7.88 (d, 1 H, J = 6.0Hz), 2.65 (s, 3H) Ex. 19 6-[2-tert-Butyl-5-(2- (300 MHz, Methanol-d4) d 8.99 trifluoromethyl-pyrimidin-4-yl)- (m, 2H), 8.91 (d, 1H, J = 6.0 Hz), 3H-imidazol-4-yl]-quinoxaline 8.42 (d, 1H, J = 3.0 Hz), 8.24 (d, 399.3 Ex. 5 1H, J =9.0 Hz), 8.06 (m, 1H), 7.84 (d, 1H, J = 6.0 Hz), 1.58 (s, 9H) Ex. 20 4-[5-Quinoxalin-6-yl-4-(2- (300 MHz, Methanol-d4) d 8.98 trifluoromethyl-pyrimidin-4-yl)- (m, 2H), 8.86 (d, 1H, J = 6.0 Hz), 1H-imidazol-2-yl]-piperidine-l- 8.44 (d, 1H, J = 1.5 Hz), 8.26 (d, carboxylic acid benzyl ester 1H, J = 9.0 Hz), 8.06 (d, 1H, J = 560.26 Ex. 5 1.5 Hz), 7.84 (d, 1H, J = 6.0 Hz), 7.35 (m, 5H), 5.13 (s, 2H), 4.37 (m, 1 H), 4.05 (m, 1 H), 3.33 (m, 1H), 3.00 (m, 2H), 2.13 (m, 4H) Ex. 21 4-[4-(2-Cyclopropyl-pyrimidin- (300 MHz, Methanol-d4) d 8.81 4-yl)-5-quinoxalin-6-yl-1H- (m, 2H), 8.45 (d, 1H, J = 6.0 Hz), imidazol-2-yl]-piperidine-l- 8.25 (d, 1H, J = 1.5 Hz), 8.11 (d, carboxylic acid benzyl ester 1H, J = 9.0 Hz), 7.83 (d, 1H, J =
9.0 Hz), 7.56 (d, 1H, J= 6.0 Hz), 532.38 Ex. 5 7.20 (m, 5H), 4.96 (s, 2H), 4.19 (m, 2H), 3.3 8(m, 1H), 2.82 (m, 2H), 1.91 (m, 5H), 0.92 (m, 2H), 0.79 (m, 2H) Ex. 22 6-[5-(2-Cyclopropyl-pyrimidin- (300 MHz, Methanol-d4) d 8.99 4-yl)-2-(1-methanesulfonyl- (s, 2H), 8.57 (d, 1H, J = 5.7 Hz), piperidin-4-yl)-3H-imidazol-4- 8.37 (d, 1H, J = 1.8 Hz), 8.26 (d, yl]-quinoxaline 1H, J = 8.7 Hz), 8.03 (dd, 1H, J =
2.1 Hz, 8.7 Hz), 7.58 (d, 1H, J = 476.47 Ex. 5 5.7 Hz), 3.93 (m, 2H), 3.21 (m, 3H), 2.65 (s, 31-1), 2.10 (m, 5H), 0.98 (m, 2H), 0.86 (m, 2H) Ex. 23 4-[5-(2-Methyl-pyrimidin-4-yl)- (300 MHz, Methanol-d4) d 9.28 4-[1,2,4]triazolo[4,3-a]pyridin- (d, 1H, J = 3.0 Hz), 8.65 (d, 1H, J
6-yl-lH-imidazol-2-yl]- = 6.0 Hz), 8.54 (s, 1H), 7.92 (m, 402.46 Ex. 5 bicyclo[2.2.2]octan-l-ol 2H), 7.65 (d, 1H, J = 6.0 Hz), 2.65 (s, 3H), 2.23 (m, 6H), 1.84 (m, 6H) Ex. 24 4-[5-(2-Methoxy-pyrimidin-4- (300 MHz, Methanol-d4) 8 8.85 yl)-4-(6-methyl-pyridin-2-yl)- (d, 1H, J = 5.1 Hz), 8.61 (m, 111), 1H-imidazol-2-yl]- 8.44 (t, 1H, J = 8.1 Hz), 7.89 (m, bicyclo[2.2.2]octane-l- 1H), 7.77 (d, 1H, J = 7.5 Hz), 4.18 434.05 Ex.
carboxylic acid methyl ester (s, 3H), 3.68 (s, 3H), 3.03 (s, 3H), 9&10 2.10 (m, 6H), 1.98 (m, 6H) Ex. 25 4-[5-(2-Hydroxy-pyrimidin-4- (300 MHz, Methanol-d4) 6 8.21 yl)-4-(6-methyl-pyridin-2-yl)- (m, 3H), 7.55 (m, 1H), 7.37 (m, 1H-imidazol-2-yl]- 1H), 3.58 (s, 3H), 2.90 (s, 3H), 420.16 Ex.
bicyclo[2.2.2]octane-l- 2.00 (m, 6H), 1.87 (m, 6H) 9&10 carboxylic acid methyl ester Ex. 26 4-[5-(2-cyclopropylamino- (300 MHz, Acetone-d6) 5 8.56 (m, pyrimidin-4-yl)-4-(6-methyl- 1H), 8.49 (m, 1H), 8.24 (m, 1H), pyridin-2-yl)-1H-imidazol-2- 7.65 (m, 2H), 3.63 (s, 3H), 2.87 yl]-bicyclo[2.2.2]octane-l- (m, 1H), 2.61 (s, 3H), 2.05 (m, 459.17 Ex.
carboxylic acid methyl ester 6H), 1.91 (m, 6H), 0.75 (m, 2H), 9&10 0.64 (m, 2H).
Ex. 27 4-[5-(2-cyclopropylamino- (300 MHz, Methanol-d4) 6 8.49 pyrimidin-4-yl)-4-(6-methyl- (m, 1H), 8.30 (m, 2H), 7.66 (m, pyridin-2-yl)-1H-imidazol-2- 1H), 7.32 (m, 1H), 2.74 (m, 1H), 460.19 Ex.
yl]-bicyclo[2.2.2]octane-1- 2.65 (s, 3H), 2.07 (m, 6H), 1.93 9&10 carboxylic acid hydroxyamide (m, 6H), 0.85 (m, 2H), 0.61 (m, 2H).
Ex. 28 4-[5-(2-cyclopropylamino- (300 MHz, Methanol-d4) b 8.49 pyrimidin-4-yl)-4-(6-methyl- (m, 1H), 8.30 (m, 2H), 7.67 (m, pyridin-2-yl)-1H-imidazol-2- 1H), 7.31 (m, 1H), 3.67 (s, 3H), yl]-bicyclo[2.2.2]octane-l- 2.75 (m, 1H), 2.65 (s, 3H), 2.06 474.21 Ex.
carboxylic acid methoxy-amide (m, 6H), 1.92 (m, 6H), 0.84 (m, 9&10 2H), 0.62 (m, 2H).
Ex. 29 4-[5-(2-amino-pyrimidin-4-yl)- (300 MHz, Methanol-d4) 6 8.50 4-(6-methyl-pyridin-2-yl)-1H- (d, 1H, J = 5.4 Hz), 8.42 (d, 1H, J
imidazol-2-yl]- = 8.1 Hz), 8.34 (t, 1H, J= 7.8 Hz), bicyclo[2.2.2]octane- 1 - 7.68 (d, 1H, J = 7.5 Hz), 7.30 (d, 405.11 Ex.
carboxylic acid 1H, J = 5.4 Hz), 2.90 (s, 3H), 2.08 9&10 (m, 6H), 1.98 (m, 6H).
Ex. 30 {4-[5-(2-Cyclopropylamino- (300 MHz, Methanol-d4) 6 8.14 pyrimidin-4-yl)-4-(6-methyl- (m, 1H), 7.73 (m, 2H), 7.31 (m, pyridin-2-yl)-1H-imidazol-2- 5H), 7.06 (m, 1H), 6.70 (m, 1H), yl]-bicyclo[2.2.2]oct-1-yl}- 5.02 (s, 2H), 2.60 (m, 1H), 2.54 (s, 550.15 Ex.
carbamic acid benzyl ester 3H), 2.10 (m, 6H), 2.00 (m, 6H), 9&10 0.79 (m, 2H), 0.45 (m, 2H) Ex. 31 N-{4-[5-(2-cyclopropylamino- (300 MHz, Methanol-d4) S 8.47 pyrimidin-4-yl)-4-(6-methyl- (m, 1H), 8.29 (m, 2H), 7.69 (m, pyridin-2-yl)-1H-imidazol-2- 1H), 7.35 (m, 1H), 2.80 (s, 3H), 458.24 Ex.
yl]-bicyclo[2.2.2]oct-1-yl}- 2.65 (s, 3H), 2.10 (m, 12H), 1.36 9&10 acetamide (m, 1H), 0.85 (m, 2H), 0.62 (m, 2H).
Ex. 32 N-{4-[5-(2-cyclopropylamino- (300 MHz, Methanol-d4) 8 8.50 pyrimidin-4-yl)-4-(6-methyl- (m, 1H), 8.30 (m, 1H), 7.65 (m, pyridin-2-yl)-1H-imidazol-2- 1H), 7.49 (m, 1H), 7.29 (m, 1H), yl]-bicyclo[2.2.2]oct-1-yl}- 2.80 (s, 3H), 2.65 (s, 3H), 2.26 (m, 494.20 Ex.
methanesulfonamide 1H), 2.10 (m, 12H), 0.84 (m, 2H), 9&10 0.61 (m, 2H).
.. .... ..... ..
Ex. 33 N-{4-[5-(2-cyclopropylamino- (300 MHz, Methanol-d4) b 8.52 pyrimidin-4-yl)-4-(6-methyl- (d, 1H, J = 5.4 Hz), 8.31 (m, 1H), pyridin-2-yl)-1H-imidazol-2- 7.66 (m, 111), 7.49 (m, 1H), 7.30 yl]-bicyclo[2.2.2]oct-l-yl}- (d, 111, J = 5.4 Hz), 2.65 (s, 3H), 512.08 Ex.
2,2,2-trifluoro-acetamide 2.26 (m, 1H), 2.15 (m, 12H), 0.84 9&10 (m, 2H), 0.60 (m, 2H).
[0136] The TGF,6 inhibitory activity of compounds of formula (I) can be assessed by methods described in the following examples.
Example 34 Cell-Free Assay for Evaluating Inhibition of Autophosphorylation of TGF# Type I
Receptor [0137] The serine-threonine kinase activity of TGF(.i type I receptor was measured as the autophosphorylation activity of the cytoplasmic domain of the receptor containing an N-terminal poly histidine, TEV cleavage site-tag, e.g., His-TGF,l3RI. The His-tagged receptor cytoplasmic kinase domains were purified from infected insect cell cultures using the Gibco-BRL FastBac HTb baculovirus expression system.
[0138] To a 96-well Nickel FlashPlate (NEN Life Science, Perkin Elmer) was added 20 L of 1.25 Ci 33P-ATP/25 M ATP in assay buffer (50 mM Hepes, 60 mM NaCl, 1 mM
MgC12, 2 mM DTT, 5 mM MnC12, 2% glycerol, and 0.015% Brij 35). 10 L of each test compound of formula (I) prepared in 5% DMSO solution were added to the FlashPlate. The assay was then initiated with the addition of 20 L of assay buffer containing 12.5 pmol of His-TGFORI to each well. Plates were incubated for 30 minutes at room temperature and the reactions were then terminated by a single rinse with TBS. Radiation from each well of the plates was read on a TopCount (Packard). Total binding (no inhibition) was defined as counts measured in the presence of DMSO solution containing no test compound and non-specific binding was defined as counts measured in the presence of EDTA or no-kinase control.
[0139] Alternatively, the reaction performed using the above reagents and incubation conditions but in a microcentrifuge tube was analyzed by separation on a 4-20% SDS-PAGE
gel and the incorporation of radiolabel into the 40 kDa His-TGF[3RI SDS-PAGE band was quantitated on a Storm Phosphoimager (Molecular Dynamics).
[0140] Compounds of formula (I) typically exhibited IC5o values of less than 10 M; some exhibited IC50 values of less than 1 M; and some even exhibited IC50 values of less than 50 nM.
Example 35 Cell-Free Assay for Evaluating Inhibition of Activin Type I Receptor Kinase Activity [0141] Inhibition of the Activin type I receptor (Alk 4) kinase autophosphorylation activity by test compounds of formula (I) can be determined in a similar manner to that described above in Example 34 except that a similarly His-tagged form of Alk 4 (His-Alk 4) is used in place of the His-TGFRRI.
Example 36 TGF# Type I Receptor Ligand Displacement FlashPlate Assay [0142] 50 nM of tritiated 4-(3-pyridin-2-yl-lH-pyrazol-4-yl)-quinoline (custom-ordered from PerkinElmer Life Science, Inc., Boston, MA) in assay buffer (50 mM Hepes, 60 mM NaC12, 1 mM MgC12, 5 mM MnC12, 2 mM 1,4-dithiothreitol (DTT), 2% Brij 35; pH 7.5) was premixed with a test compound of formula (I) in 1% DMSO solution in a v-bottom plate.
Control wells containing either DMSO without any test compound or control compound in DMSO
were used.
To initiate the assay, His-TGFO Type I receptor in the same assay buffer (Hepes, NaC12, MgC12, MnC12, DTT, and 30% Brij added fresh) was added to a nickel coated FlashPlate (PE, NEN
catalog number: SMP 107), while the control wells contained only buffer (i.e., no His-TGF,(i Type I receptor). The premixed solution of tritiated 4-(3-pyridin-2-yl-lH-pyrazol-4-yl)-quinoline and test compound of formula (I) was then added to the wells. The wells were aspirated after an hour at room temperature and radioactivity in wells (emitted from the tritiated compound) was measured using TopCount (PerkinElmer Lifesciences, Inc., Boston MA).
Compounds of formula (I) typically exhibited Ki values of less than 10 M;
some exhibited Ki values of less than 1 M; and some even exhibited Ki values of less than 50 nM.
Example 37 Assay for Evaluating Cellular Inhibition of TGF# Signaling and Cytotoxicity [0143] Biological activity of the compounds of formula (I) was determined by measuring their ability to inhibit TGF(3-induced PAI-Luciferase reporter activity in HepG2 cells.
[0144] HepG2 cells were stably transfected with the PAI-luciferase reporter grown in DMEM
medium containing 10% FBS, penicillin (100 U/mL), streptomycin (100 g/mL), L-glutamine (2 mM), sodium pyruvate (1 mM), and non-essential amino acids (lx). The transfected cells were then plated at a concentration of 2.5 x 104 cells/well in 96 well plates and starved for 3-6 hours in media with 0.5% FBS at 37 C in a 5% COZ incubator. The cells were then stimulated with 2.5 ng/mL TGF(3ligand in the starvation media containing 1% DMSO either in the presence or absence of a test compound of formula (I) and incubated as described above for 24 hours. The media was washed out the following day and the luciferase reporter activity was detected using the LucLite Luciferase Reporter Gene Assay kit (Packard, cat.
no. 6016911) as recommended. The plates were read on a Wallac Microbeta plate reader, the reading of which was used to determine the IC50 values of compounds of formula (I) for inhibiting TGFO-induced PAI-Luciferase reporter activity in HepG2 cells. Compounds of formula (I) typically exhibited IC50 values of less 10 M.
[0145] Cytotoxicity was determined using the same cell culture conditions as described above.
Specifically, cell viability was determined after overnight incubation with the CytoLite cell viability kit (Packard, cat. no. 6016901). Compounds of formula (I) typically exhibited LD25 values greater than 10 M.
Example 38 Assay for Evaluating Inhibition of TGFO Type I Receptor Kinase Activity in Cells [0146] The cellular inhibition of activin signaling activity by the test compounds of formula (I) is determined in a similar manner as described above in Example 37 except that 100 ng/mL of activin is added to serum starved cells in place of the 2.5 ng/mL TGF(.3.
Example 39 Assay for TGFO-Induced Collagen Expression Preparation of Iinmortalized Collagen Promotor-Green Fluorescent Protein Cells [0147] Fibroblasts are derived from the skin of adult transgenic mice expressing Green Fluorescent Protein (GFP) under the control of the collagen 1A1 promoter (see Krempen, K. et al., Gene Exp. 8: 151-163 (1999)). Cells are immortalized with a temperature sensitive large T
antigen that is in an active stage at 33 C. Cells are expanded at 33 C and then transferred to 37 C at which temperature the large T antigen becomes inactive (see Xu, S. et al., Exp. Cell Res.
220: 407-414 (1995)). Over the course of about 4 days and one split, the cells cease proliferating. Cells are then frozen in aliquots sufficient for a single 96 well plate.
Assay of TGFO-induced Collagen-GFP Expression [0148] Cells are thawed, plated in complete DMEM (contains non-essential amino acids, 1mM
sodium pyruvate and 2mM L-glutamine) with 10 % fetal calf serum, and then incubated for overnight at 37 C, 5% CO2. The cells are trypsinized in the following day and transferred into 96 well format with 30,000 cells per well in 50 L complete DMEM containing 2 % fetal calf serum, but without phenol red. The cells are incubated at 37 C for 3 to 4 hours to allow them to adhere to the plate. Solutions containing a test compound of formula (I) are then added to wells with no TGFO (in triplicates), as well as wells with 1 ng/mL TGFO (in triplicates). DMSO is also added to all of the wells at a final concentration of 0.1%. GFP
fluorescence emission at 530 nm following excitation at 485 nm is measured at 48 hours after the addition of solutions containing a test compound on a CytoFluor microplate reader (PerSeptive Biosystems). The data are then expressed as the ratio of TGF(3-induced to non-induced for each test sample.
OTHER EMBODIMENTS
[0149] It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims.
Other aspects, advantages, and modifications are within the scope of the following claims.
Claims (53)
1. A compound of the following formula:
or an N-oxide or a pharmaceutically acceptable salt thereof, wherein R1 is heteroaryl;
each R a, independently, is alkyl, alkenyl, alkynyl, alkoxy, acyl, halo, hydroxy, amino, nitro, oxo, thioxo, cyano, guanadino, amidino, carboxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkoxycarbonyl, alkylcarbonyloxy, urea, thiourea, sulfamoyl, sulfamide, carbamoyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfanyl, cycloalkylcarbonyl, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylsulfanyl, heterocycloalkylcarbonyl, aryl, aryloxy, arylsulfanyl, aroyl, heteroaryl, heteroaryloxy, heteroarylsulfanyl, or heteroaroyl;
X is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or a bond;
Y is a bond, -C(O)-, -C(O)-O-, -O-C(O)-, -S(O)p-O-, -O-S(O)p-, -C(O)-N(R b)-, -N(R b)-C(O)-, -O-C(O)-N(R b)-, -N(R b)-C(O)-O-, -C(O)-N(R b)-O-, -O-N(R b)-C(O)-, -O-S(O)p-N(R b)-, -N(R b)- S(O)p-O-, -S(O)p-N(R b)-O-, -O-N(R b)-S(O)p-, -N(R b)-C(O)-N(R c)-, -N(R b)-S(O)p-N(R c)-, -C(O)-N(R b)-S(O)p-, -S(O)p-N(R b)-C(O)-, -C(O)-N(R b)-S(O)p-N(R c)-, -C(O)-O-S(O)p-N(R b)-, -N(R b)-S(O)p-N(R c)-C(O)-, -N(R b)-S(O)p O-C(O)-, -S(O)p-N(R b)-, -N(R b)-S(O)p , -N(R b)-, -S(O)p-, -O-, -S-, or -(C(R b)(R c))q-, wherein each of R b and R c, independently, is hydrogen, hydroxy, alkyl, alkoxy, amino, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroaralkyl;
p is 1 or 2;
and q is 1-4;
R2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, aralkyl, arylalkenyl, heterocycloalkyl, (heterocycloalkyl)alkyl, heterocycloalkenyl, (heterocycloalkenyl)alkyl, heteroaryl, heteroaralkyl, or (heteroaryl)alkenyl;
each of A1 and A2, independently, is N or NR b; and m is 0, 1, 2, or 3; provided that when m>=2, two adjacent R a groups can join together to form a 4- to 8-membered optionally substituted cyclic moiety, and further provided that if X is a bond, then Y is a bond; R2 is hydrogen or alkyl; m is 1, 2, or 3; and at least one R a is substituted at the 2-pyrimidinyl position.
or an N-oxide or a pharmaceutically acceptable salt thereof, wherein R1 is heteroaryl;
each R a, independently, is alkyl, alkenyl, alkynyl, alkoxy, acyl, halo, hydroxy, amino, nitro, oxo, thioxo, cyano, guanadino, amidino, carboxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkoxycarbonyl, alkylcarbonyloxy, urea, thiourea, sulfamoyl, sulfamide, carbamoyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfanyl, cycloalkylcarbonyl, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylsulfanyl, heterocycloalkylcarbonyl, aryl, aryloxy, arylsulfanyl, aroyl, heteroaryl, heteroaryloxy, heteroarylsulfanyl, or heteroaroyl;
X is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or a bond;
Y is a bond, -C(O)-, -C(O)-O-, -O-C(O)-, -S(O)p-O-, -O-S(O)p-, -C(O)-N(R b)-, -N(R b)-C(O)-, -O-C(O)-N(R b)-, -N(R b)-C(O)-O-, -C(O)-N(R b)-O-, -O-N(R b)-C(O)-, -O-S(O)p-N(R b)-, -N(R b)- S(O)p-O-, -S(O)p-N(R b)-O-, -O-N(R b)-S(O)p-, -N(R b)-C(O)-N(R c)-, -N(R b)-S(O)p-N(R c)-, -C(O)-N(R b)-S(O)p-, -S(O)p-N(R b)-C(O)-, -C(O)-N(R b)-S(O)p-N(R c)-, -C(O)-O-S(O)p-N(R b)-, -N(R b)-S(O)p-N(R c)-C(O)-, -N(R b)-S(O)p O-C(O)-, -S(O)p-N(R b)-, -N(R b)-S(O)p , -N(R b)-, -S(O)p-, -O-, -S-, or -(C(R b)(R c))q-, wherein each of R b and R c, independently, is hydrogen, hydroxy, alkyl, alkoxy, amino, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroaralkyl;
p is 1 or 2;
and q is 1-4;
R2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkenyl, (cycloalkenyl)alkyl, aryl, aralkyl, arylalkenyl, heterocycloalkyl, (heterocycloalkyl)alkyl, heterocycloalkenyl, (heterocycloalkenyl)alkyl, heteroaryl, heteroaralkyl, or (heteroaryl)alkenyl;
each of A1 and A2, independently, is N or NR b; and m is 0, 1, 2, or 3; provided that when m>=2, two adjacent R a groups can join together to form a 4- to 8-membered optionally substituted cyclic moiety, and further provided that if X is a bond, then Y is a bond; R2 is hydrogen or alkyl; m is 1, 2, or 3; and at least one R a is substituted at the 2-pyrimidinyl position.
2. The compound of claim 1, wherein X is aryl or heteroaryl.
3. The compound of claim 2, wherein X is an optionally substituted phenyl.
4. The compound of claim 2, wherein Y is a bond, -N(R b)-C(O)-, -N(R b)-S(O)2-, -C(O)-, -C(O)-O-, -O-C(O)-, -C(O)-N(R b)-, -S(O)p , -O-, -S(O)2-N(R b)-, - N(R b)-, -N(R b)-C(O)-O-, -N(R b)-C(O)-N(R c)-, -C(O)-N(R b)-S(O)p-N(R c)-, or -C(O)-O-S(O)p-N(R b)-.
5. The compound of claim 2, wherein R2 is hydrogen, C1-6 alkyl, aryl, heteroaryl, aryl-C1-4 alkyl, or heteroaryl-C1-4 alkyl.
6. The compound of claim 1, wherein X is a 4- to 8-membered monocyclic or bicyclic cycloalkyl or heterocycloalkyl.
7. The compound of claim 1, wherein X is piperidinyl, piperazinyl, pyrrolidinyl, tetrahydrofuran, cyclohexyl, cyclopentyl, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.1]octane, 2-oxa-bicyclo[2.2.2]octane, 2-aza-bicyclo[2.2.2]octane, 3-aza-bicyclo[3.2.1]octane, or 1-aza-bicyclo[2.2.2]octane.
8. The compound of claim 1, wherein X is piperidinyl, piperazinyl, or pyrrolidinyl.
9. The compound of claim 8, wherein the piperdinyl, piperazinyl, or pyrrolidinyl is bonded to Y via its nitrogen ring atom.
10. The compound of claim 9, wherein Y is a bond, -C(O)O-, -C(O)-N(R b)-, -S(O)2-, or -S(O)2-N(R b)-, wherein R b is hydrogen or C1-4 alkyl.
11. The compound of claim 1, wherein X is cyclohexyl, cyclopentyl, or bicyclo[2.2.2] octane.
12. The compound of claim 11, wherein Y is -N(R b)-C(O)-, -N(R b)-S(O)2-, -C(O)-, -C(O)-O-, -O-C(O)-, -C(O)-N(R b)-, -S(O)p , -O-, -S(O)2-N(R b)-, - N(R b)-, -N(R b)-C(O)-O-, -C(O)-N(R b)-O-, or -N(R b)-C(O)-N(R c)-.
13. The compound of claim 1, wherein Y is -N(R b)-C(O)-, -N(R b)-S(O)2-, -C(O)-, -C(O)-O-, -O-C(O)-, -C(O)-N(R b)-, -S(O)p-, -O-, -S(O)2-N(R b)-, - N(R b)-, -N(R b)-C(O)-O-, -C(O)-N(R b)-O-, -N(R b)-C(O)-N(R c)-, -C(O)-N(R b)-S(O)p N(R c)-, or -C(O)-O-S(O)p-N(R b)-.
14. The compound of claim 1, wherein X and Y are each a bond; R2 is hydrogen or C1-6 alkyl; m is 1 or 2; and the R a that is substituted at the 2-pyrimidinyl position is C1-4 alkyl, C3-6 cycloalkyl, or amino.
15. The compound of claim 14, wherein R2 is H or C1-4 alkyl; m is 1; and R a is -CH3, -CF3, cyclopropyl, -NH2, -NH-C1-4 alkyl, or -NH-cycloalkyl.
16. The compound of claim 1, wherein R2 is hydrogen, C1-6 alkyl, aryl, heteroaryl, aryl-C1-4 alkyl, or heteroaryl-C1-4 alkyl.
17. The compound of claim 1, wherein R2 is hydrogen, C1-4 alkyl, phenyl, pyridyl, imidazolyl, furanyl, thienyl, triazolyl, tetrazolyl, benzyl, phenylethyl, benzimidazolyl, benzothiazolyl, naphthylmethyl, naphthylethyl, or -C1-2 alkyl-pyridyl; each of which, independently, is optionally substituted with one or more substituents selected from the group consisting of fluoro, chloro, trifluoromethyl, methyl, ethyl, aminocarbonyl, alkylcarbonylamino, sulfamoyl, alkoxycarbonyl, and alkylcarbonyloxy.
18. The compound of claim 1, wherein R2 is hydrogen, methyl, ethyl, n-butyl, t-butyl, benzyl or pyridylmethyl.
19. The compound of claim 1, wherein R1 is benzo[1,3]dioxolyl, benzo[b]thiophenyl, benzo-oxadiazolyl, benzothiadiazolyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, 2-oxo-benzooxazolyl, pyridyl, pyrimidinyl, 2,3-dihydro-benzo[1,4]dioxyl, 2,3-dihydro-benzofuryl, 2,3-dihydro-benzo[b]thiophenyl, 3,4-dihydro-benzo[1,4]oxazinyl, 3-oxo-benzo[1,4]oxazinyl, 1,1-dioxo-2,3-dihydro-benzo[b]thiophenyl, [1,2,4]triazolo[1,5-a]pyridyl, [1,2,4]triazolo[4,3-a]pyridyl, quinolinyl, quinoxalinyl, quinazolinyl, isoquinolinyl, or cinnolinyl.
20. The compound of claim 1, wherein m is 0-2.
21. The compound of claim 1, wherein R a is substituted at the 2-pyrimidinyl position.
22. The compound of claim 1, wherein R a is C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, halo, amino, aminocarbonyl, or alkoxycarbonyl.
23. The compound of claim 1, wherein R b is hydrogen or C1-4 alkyl.
24. The compound of claim 1, wherein m is 0-2; R1 is heteroaryl; R2 is hydrogen, C1-6 alkyl, aryl, heteroaryl, -C1-4 alkyl-aryl, or -C1-4 alkyl-heteroaryl; X is a 4- to 8-membered monocyclic or bicyclic cycloalkyl or heterocycloalkyl; and Y is -N(R b)-C(O)-, -N(R b)-S(O)2-, -C(O)-, -C(O)-O-, -O-C(O)-, -C(O)-N(R b)-, -S(O)p-, -O-, -S(O)2-N(R b)-, -N(R b)-, -N(R b)-C(O)-O-, -N(R b)-C(O)-N(R c)-, -C(O)-N(R b)-S(O)p-N(R c)-, or -C(O)-O-S(O)p-N(R b)-.
25. The compound of claim 1, wherein m is 0-2; R1 is heteroaryl; R2 is hydrogen, C1-6 alkyl, aryl, heteroaryl, -C1-4 alkyl-aryl, or -C1-4 alkyl-heteroaryl; X is piperidinyl, piperazinyl, pyrrolidinyl, tetrahydrofuran, cyclohexyl, cyclopentyl, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.1]octane, 2-oxa-bicyclo[2.2.2]octane, 2-aza-bicyclo[2.2.2]octane, 3-aza-bicyclo[3.2.1]octane, or 1-aza-bicyclo[2.2.2]octane; and Y
is -N(R b)-C(O)-, -N(R b)-S(O)2-, -C(O)-, -C(O)-O-, -O-C(O)-, -C(O)-N(R b)-, -S(O)p-, -O-, -S(O)2-N(R b)-, -N(R b)-, -N(R b)-C(O)-O-, -N(R b)-C(O)-N(R c)-, -C(O)-N(R b)-S(O)p-N(R c)-, or -C(O)-O-S(O)p-N(R b)-.
is -N(R b)-C(O)-, -N(R b)-S(O)2-, -C(O)-, -C(O)-O-, -O-C(O)-, -C(O)-N(R b)-, -S(O)p-, -O-, -S(O)2-N(R b)-, -N(R b)-, -N(R b)-C(O)-O-, -N(R b)-C(O)-N(R c)-, -C(O)-N(R b)-S(O)p-N(R c)-, or -C(O)-O-S(O)p-N(R b)-.
26. The compound of claim 1, wherein m is 0-2; R1 is heteroaryl; R2 is hydrogen, C1-6 alkyl, aryl, heteroaryl, -C1-4 alkyl-aryl, or -C1-4 alkyl-heteroaryl; and -X-Y- is
27. The compound of claim 26, wherein A1 is N and A2 is NH, or A1 is NH and A2 is N.
28. The compound of claim 27, wherein R2 is hydrogen, C1-4 alkyl, benzyl, or pyridylmethyl.
29. The compound of claim 28, wherein m is 1 and R a is substituted at the 2-pyrimidinyl position.
30. The compound of claim 1, wherein m is 0-2; R1 is heteroaryl; R2 is hydrogen, C1-6 alkyl, aryl, heteroaryl, aryl-C1-4 alkyl, or heteroaryl-C1-4 alkyl; X is cyclohexyl, cyclopentyl, or bicyclo[2.2.2]octane; and Y is -N(R b)-C(O)-, -N(R b)-S(O)2-, -C(O)-, -C(O)-O-, -O-C(O)-, -C(O)-N(R b)-, -S(O)p-, -O-, -S(O)2-N(R b)-, -N(R b)-, -N(R b)-C(O)-O-, -N(R
b)-C(O)-N(R c)-, -C(O)-N(R b)-S(O)p-N(R c)-, or -C(O)-O-S(O)P-N(R b)-, wherein each of R b and R c, independently, is hydrogen or C1-4 alkyl.
b)-C(O)-N(R c)-, -C(O)-N(R b)-S(O)p-N(R c)-, or -C(O)-O-S(O)P-N(R b)-, wherein each of R b and R c, independently, is hydrogen or C1-4 alkyl.
31. The compound of claim 30, wherein A1 is N and A2 is NH, or A1 is NH and A2 is N.
32. The compound of claim 31, wherein R2 is hydrogen, C1-4 alkyl, benzyl, or pyridylmethyl.
33. The compound of claim 32, wherein m is 1 and R a is substituted at the 2-pyrimidinyl position.
34. The compound of claim 1, wherein X and Y are each a bond; R2 is hydrogen or C1-4 alkyl; m is 1; R a is -CH3, -CF3, cyclopropyl, -NH2, -NH-C1-4 alkyl, or -NH-cycloalkyl; and R1 is benzo[1,3]dioxolyl, benzo[b]thiophenyl, benzo-oxadiazolyl, benzothiadiazolyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, 2-oxo-benzooxazolyl, pyridyl, pyrimidinyl, 2,3-dihydro-benzo[1,4]dioxyl, 2,3-dihydro-benzofuryl, 2,3-dihydro-benzo[b]thiophenyl, 3,4-dihydro-benzo[1,4]oxazinyl, 3-oxo-benzo[1,4]oxazinyl, 1,1-dioxo-2,3-dihydro-benzo[b]thiophenyl, [1,2,4]triazolo[1,5-a]pyridyl,[1,2,4]triazolo[4,3-a]pyridyl, quinolinyl, quinoxalinyl, quinazolinyl, isoquinolinyl, or cinnolinyl.
35. The compound of claim 1, wherein the compound is selected from the group consisting of:
4-[4-benzo[1,3]dioxol-5-yl-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-benzamide;
4-[4-benzo[1,3]dioxol-5-yl-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-benzonitrile;
4-[5-(2-methanesulfonyl-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester;
4-[5-(2-methoxy-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester;
4-[5-(2-hydroxy-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo [2.2.2] octane-1-carboxylic acid;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2] octane-1-carboxylic acid amide;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo [2.2.2] octane-1-carboxylic acid hydroxyamide;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo [2.2.2] octane-1-carboxylic acid methoxy-amide;
4-[5-(2-amino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid;
{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-1-yl}-carbamic acid benzyl ester;
N-{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-1-yl}-acetamide;
N-{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-1-yl}-methanesulfonamide;
N-{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-1-yl}-2,2,2-trifluoro-acetamide;
4-[5-quinoxalin-6-yl-4-(2-trifluoromethyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octan-1-ol;
4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octan-1-ol;
6-[2-tert-butyl-5-(2-cyclopropyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
6-[5-(2-byclopropyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
{4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-1-yl}-methanol;
6-[5-(2-trifluoromethyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
6-[2-tert-butyl-5-(2-trifluoromethyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
4-[5-quinoxalin-6-yl-4-(2-trifluoromethyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-piperidine-1-carboxylic acid benzyl ester;
4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]-piperidine-1-carboxylic acid benzyl ester;
6-[5-(2-cyclopropyl-pyrimidin-4-yl)-2-(1-methanesulfonyl-piperidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
4-[5-(2-methyl-pyrimidin-4-yl)-4-[1,2,4]triazolo[4,3-a]pyridin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octan-1-ol;
4-[4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo[1,5-a]pyridin-6-yl-1H-imidazol-2-yl]-bicyclo [2.2.2] octane-1-carboxylic acid amide;
4-[4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo[1,5-a]pyridin-6-yl-1H-imidazol-2-yl]-bicyclo [2.2.2] octane-1-carboxylic acid;
4-[4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo[1,5-a]pyridin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester;
4-[4-(2-methyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]-cyclohexanol; and 4-[4-(2-methyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]-bicyclo [2.2.2] octan-1-ol.
4-[4-benzo[1,3]dioxol-5-yl-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-benzamide;
4-[4-benzo[1,3]dioxol-5-yl-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-benzonitrile;
4-[5-(2-methanesulfonyl-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester;
4-[5-(2-methoxy-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester;
4-[5-(2-hydroxy-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol2-yl]-bicyclo[2.2.2]octane-l-carboxylic acid methyl ester;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo [2.2.2] octane-1-carboxylic acid;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2] octane-1-carboxylic acid amide;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo [2.2.2] octane-1-carboxylic acid hydroxyamide;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo [2.2.2] octane-1-carboxylic acid methoxy-amide;
4-[5-(2-amino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid;
{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-1-yl}-carbamic acid benzyl ester;
N-{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-1-yl}-acetamide;
N-{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-1-yl}-methanesulfonamide;
N-{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-1-yl}-2,2,2-trifluoro-acetamide;
4-[5-quinoxalin-6-yl-4-(2-trifluoromethyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octan-1-ol;
4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octan-1-ol;
6-[2-tert-butyl-5-(2-cyclopropyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
6-[5-(2-byclopropyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
{4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-1-yl}-methanol;
6-[5-(2-trifluoromethyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
6-[2-tert-butyl-5-(2-trifluoromethyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
4-[5-quinoxalin-6-yl-4-(2-trifluoromethyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-piperidine-1-carboxylic acid benzyl ester;
4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]-piperidine-1-carboxylic acid benzyl ester;
6-[5-(2-cyclopropyl-pyrimidin-4-yl)-2-(1-methanesulfonyl-piperidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
4-[5-(2-methyl-pyrimidin-4-yl)-4-[1,2,4]triazolo[4,3-a]pyridin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octan-1-ol;
4-[4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo[1,5-a]pyridin-6-yl-1H-imidazol-2-yl]-bicyclo [2.2.2] octane-1-carboxylic acid amide;
4-[4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo[1,5-a]pyridin-6-yl-1H-imidazol-2-yl]-bicyclo [2.2.2] octane-1-carboxylic acid;
4-[4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo[1,5-a]pyridin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester;
4-[4-(2-methyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]-cyclohexanol; and 4-[4-(2-methyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]-bicyclo [2.2.2] octan-1-ol.
36. The compound of claim 1, wherein the compound is selected from the group consisting of:
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid amide;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid hydroxyamide;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo [2.2.2]octane-1-carboxylic acid methoxy-amide;
4-[5-(2-amino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid;
N-{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-1-yl}-acetamide;
N-{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-1-yl}-methanesulfonamide;
N-{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-1-yl}-2,2,2-trifluoro-acetamide;
6-[2-tert-butyl-5-(2-trifluoromethyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
6-[5-(2-byclopropyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
6-[2-tert-butyl-5-(2-cyclopropyl-pyrimidin-4-yl)-3H-imidazol-4-yl] -quinoxaline;
6-[5-(2-cyclopropyl-pyrimidin-4-yl)-2-(1-methanesulfonyl-piperidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
6-[5-(2-trifluoromethyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
{4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-1-yl}-methanol;
4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octan-1-ol;
4-[4-(2-methyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octan-1-ol;
4-[4-(2-methyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]-cyclohexanol;
4-[4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo[1,5-a]pyridin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid amide;
4-[4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo[1,5-a]pyridin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid;
4-[4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo[1,5-a]pyridin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester; and 4-[5-(2-methyl-pyrimidin-4-yl)-4-[1,2,4]triazolo[4,3-a]pyridin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octan-1-ol.
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid amide;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid hydroxyamide;
4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo [2.2.2]octane-1-carboxylic acid methoxy-amide;
4-[5-(2-amino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid;
N-{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-1-yl}-acetamide;
N-{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-1-yl}-methanesulfonamide;
N-{4-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-1-yl}-2,2,2-trifluoro-acetamide;
6-[2-tert-butyl-5-(2-trifluoromethyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
6-[5-(2-byclopropyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
6-[2-tert-butyl-5-(2-cyclopropyl-pyrimidin-4-yl)-3H-imidazol-4-yl] -quinoxaline;
6-[5-(2-cyclopropyl-pyrimidin-4-yl)-2-(1-methanesulfonyl-piperidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
6-[5-(2-trifluoromethyl-pyrimidin-4-yl)-3H-imidazol-4-yl]-quinoxaline;
{4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]oct-1-yl}-methanol;
4-[4-(2-cyclopropyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octan-1-ol;
4-[4-(2-methyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octan-1-ol;
4-[4-(2-methyl-pyrimidin-4-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]-cyclohexanol;
4-[4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo[1,5-a]pyridin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid amide;
4-[4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo[1,5-a]pyridin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid;
4-[4-(2-methyl-pyrimidin-4-yl)-5-[1,2,4]triazolo[1,5-a]pyridin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxylic acid methyl ester; and 4-[5-(2-methyl-pyrimidin-4-yl)-4-[1,2,4]triazolo[4,3-a]pyridin-6-yl-1H-imidazol-2-yl]-bicyclo[2.2.2]octan-1-ol.
37. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
38. A pharmaceutical composition comprising a compound of claim 35 and a pharmaceutically acceptable carrier.
39. A method of inhibiting the TGF.beta. signaling pathway in a subject, comprising administering to the subject an effective amount of a compound of claim 1.
40. A method of inhibiting the TGF.beta. signaling pathway in a subject, comprising administering to the subject an effective amount of a compound of claim 35.
41. A method of inhibiting the TGF.beta. type I receptor in a cell, comprising contacting the cell with an effective amount of a compound of claim 1.
42. A method of inhibiting the TGF.beta. type I receptor in a cell, comprising contacting the cell with an effective amount of a compound of claim 35.
43. A method of reducing the accumulation of excess extracellular matrix induced by TGF.beta.
in a subject, comprising administering to the subject an effective amount of a compound of claim 1.
in a subject, comprising administering to the subject an effective amount of a compound of claim 1.
44. A method of reducing the accumulation of excess extracellular matrix induced by TGF.beta.
in a subject, comprising administering to the subject an effective amount of a compound of claim 35.
in a subject, comprising administering to the subject an effective amount of a compound of claim 35.
45. A method of treating or preventing fibrotic condition in a subject, comprising administering to the subject an effective amount of a compound of claim 1.
46. A method of treating or preventing fibrotic condition in a subject, comprising administering to the subject an effective amount of a compound of claim 35.
47. The method of claim 45 or 46, wherein the fibrotic condition is induced by radiation.
48. The method of claim 45 or 46, wherein the fibrotic condition is selected from the group consisting of scleroderma, lupus nephritis, connective tissue disease, wound healing, surgical scarring, spinal cord injury, CNS scarring, acute lung injury, idiopathic pulmonary fibrosis, radiation-induced pulmonary fibrosis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, acute lung injury, drug-induced lung injury, glomerulonephritis, diabetic nephropathy, hypertension-induced nephropathy, alimentary track or gastrointestinal fibrosis, renal fibrosis, hepatic or biliary fibrosis, liver cirrhosis, primary biliary cirrhosis, fatty liver disease, primary sclerosing cholangitis, restenosis, cardiac fibrosis, opthalmic scarring, fibrosclerosis, a fibrotic cancer, a fibroid, fibroma, a fibroadenoma, a fibrosarcoma, transplant arteriopathy, and keloid.
49. A method of inhibiting growth or metastasis of tumor cells or cancer in a subject, comprising administering to the subject an effective amount of a compound of claim 1.
50. A method of inhibiting growth or metastasis of tumor cells or cancer in a subject, comprising administering to the subject an effective amount of a compound of claim 35.
51. A method of treating a disease or disorder mediated by an overexpression of TGF.beta., comprising administering to a subject in need of such treatment an effective amount of a compound of claim 1.
52. A method of treating a disease or disorder mediated by an overexpression of TGF.beta., comprising administering to a subject in need of such treatment an effective amount of a compound of claim 35.
53. The method of claim 51 or 52, wherein the disease or disorder is selected from the group consisting of demyelination of neurons in multiple sclerosis, Alzheimer's disease, cerebral angiopathy, squamous cell carcinomas, multiple myeloma, melanoma, glioma, glioblastomas, leukemia, sarcomas, leiomyomas, mesothelioma, and carcinomas of the lung, breast, ovary, cervix, liver, biliary tract, gastrointestinal tract, pancreas, prostate, and head and neck.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60604504P | 2004-08-31 | 2004-08-31 | |
US60/606,045 | 2004-08-31 | ||
PCT/US2005/030133 WO2006026306A1 (en) | 2004-08-31 | 2005-08-24 | Pyrimidinylimidazoles as tgf-beta inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2578630A1 true CA2578630A1 (en) | 2006-03-09 |
Family
ID=35431931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002578630A Abandoned CA2578630A1 (en) | 2004-08-31 | 2005-08-24 | Pyrimidinylimidazoles as tgf-beta inhibitors |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1786802A1 (en) |
JP (1) | JP2008511631A (en) |
AU (1) | AU2005280168A1 (en) |
CA (1) | CA2578630A1 (en) |
TW (1) | TW200621753A (en) |
WO (1) | WO2006026306A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005295734A1 (en) * | 2004-10-15 | 2006-04-27 | Biogen Idec Ma Inc. | Methods of treating vascular injuries |
EP2918288B1 (en) | 2006-10-03 | 2017-08-16 | Genzyme Corporation | Use of TGF beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia |
BRPI0810719A8 (en) * | 2007-04-30 | 2016-03-08 | Abbott Lab | DIACYLGLYCEROL O-ACETYLTANSFERASE TYPE 1 ENZYME INHIBITORS |
BRPI0906838A2 (en) * | 2008-01-11 | 2015-07-14 | Novartis Ag | Pyrimidines as kinase inhibitors |
US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
CA2823154A1 (en) | 2010-12-27 | 2012-07-05 | Lsip, Llc | Ips cells and method for generating same |
WO2012167261A2 (en) | 2011-06-03 | 2012-12-06 | Yale University | Compositions and methods for treating and preventing neointimal stenosis |
EP2737083A1 (en) | 2011-07-27 | 2014-06-04 | INSERM (Institut National de la Santé et de la Recherche Scientifique) | Methods for diagnosing and treating myhre syndrome |
WO2013062544A1 (en) | 2011-10-26 | 2013-05-02 | Seattle Children's Research Institute | Cysteamine in the treatment of fibrotic disease |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
DK2970205T3 (en) | 2013-03-14 | 2019-07-29 | Tolero Pharmaceuticals Inc | JAK2 and ALK2 inhibitors and methods for their use |
EP3116512B1 (en) * | 2014-03-11 | 2020-06-10 | Dai Niann-tzyy | Pharmaceutical composition and method for reducing scar formation |
UY36294A (en) | 2014-09-12 | 2016-04-29 | Novartis Ag | COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS |
WO2017100782A1 (en) | 2015-12-11 | 2017-06-15 | Research Institute At Nationwide Children's Hospital | Systems and methods for optimized patent specific tissue engineering vascular grafts |
CN109715163B (en) | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | Therapeutic combination comprising a RAF inhibitor and an ERK inhibitor |
MX2021000977A (en) | 2018-07-26 | 2021-04-12 | Sumitomo Pharma Oncology Inc | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same. |
JP2022527972A (en) | 2019-04-02 | 2022-06-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | How to predict and prevent cancer in patients with premalignant lesions |
WO2024111626A1 (en) * | 2022-11-25 | 2024-05-30 | カルナバイオサイエンス株式会社 | Novel thiazole derivative |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR039241A1 (en) * | 2002-04-04 | 2005-02-16 | Biogen Inc | HETEROARILOS TRISUSTITUIDOS AND METHODS FOR ITS PRODUCTION AND USE OF THE SAME |
UA80296C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
OA12928A (en) * | 2002-09-18 | 2006-10-13 | Pfizer Prod Inc | Novel imidazole compounds as transforming growth factor (TGF) inhibitors. |
-
2005
- 2005-08-24 WO PCT/US2005/030133 patent/WO2006026306A1/en active Application Filing
- 2005-08-24 JP JP2007530093A patent/JP2008511631A/en not_active Withdrawn
- 2005-08-24 AU AU2005280168A patent/AU2005280168A1/en not_active Abandoned
- 2005-08-24 EP EP05789340A patent/EP1786802A1/en not_active Withdrawn
- 2005-08-24 CA CA002578630A patent/CA2578630A1/en not_active Abandoned
- 2005-08-31 TW TW094129857A patent/TW200621753A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1786802A1 (en) | 2007-05-23 |
AU2005280168A1 (en) | 2006-03-09 |
WO2006026306A1 (en) | 2006-03-09 |
JP2008511631A (en) | 2008-04-17 |
TW200621753A (en) | 2006-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2578630A1 (en) | Pyrimidinylimidazoles as tgf-beta inhibitors | |
AU2003228446B2 (en) | Tri-substituted heteroaryls and methods of making and using the same | |
WO2006026305A1 (en) | Pyrimidinylpyrazoles as tgf-beta inhibitors | |
US10155763B2 (en) | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | |
US20060264440A1 (en) | Pyrazoles and methods of making and using the same | |
AU2003268447B2 (en) | Pyrazolopyridines and method of making and using the same | |
US20100035918A1 (en) | Imidazolone Compounds and Methods of Making and Using the Same | |
US20100105714A1 (en) | Furanone Compounds and Methods of Making and Using The Same | |
US8420685B2 (en) | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |